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ABSTRACT 
Plants, or cell suspension cultures derived from them, are a promising platform for the 
production of biologics and pharmaceuticals. In this work transient expression utilising 
the pEAQ vector system was deployed for the expression of virus-like particles (VLPs) in 
Nicotiana benthamiana or N. tabacum BY-2 cell suspension cultures. The results 
presented in this thesis demonstrate the potential of plant systems for the production of 
VLP-based vaccines.  
VLPs of the fish virus, Nervous necrosis virus (NNV), were successfully produced in plants 
by transient expression of the coat protein. The protein self-assembled into T = 3 
particles, which appeared to be morphologically identical to the wild-type NNV when 
analysed by high resolution microscopy but were devoid of nucleic acid. In addition, 
transgenic BY-2 cell suspension lines were generated expressing correctly assembled 
NNV VLPs.  
Poliovirus (PV)-like particles from all three PV serotypes, containing either the wt coat 
protein or coat proteins with stabilising mutations, were successfully expressed in 
plants. These were generated by co-expression of the structural polyprotein P1 and the 
proteinase 3CD. Sufficient quantities of purified particles could be obtained for 
structural and immunological analysis. Mice carrying the gene for the human PV 
receptor were protected from wild-type PV when immunised with the plant-made 
stabilised PV VLPs. Structural analysis of the stabilised mutant of PV3 at 3.6 Å resolution 
revealed a structure almost indistinguishable from wild-type PV3, with the stabilising 
mutations having no effective on the antigenic surface of the particle.  
To make the product more attractive to the vaccine industry, tobacco BY-2 cells have 
been successfully tested for the transient expression of the above-mentioned PV mutant 
VLPs using the cell-pack method.  
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Chapter 1: GENERAL INTRODUCTION 
 MOLECULAR PHARMING 
Molecular pharming is a modern buzzword that refers to the recombinant expression of 
pharmaceutically useful proteins in plants. It started with the production of chimaeric 
human growth hormone in 1986 via transgenic tobacco and sunflower (Barta et al., 
1986), followed by the synthesis of monoclonal antibodies in transgenic tobacco in 1989 
(Hiatt et al., 1989) and human serum albumin in transgenic tobacco and cell cultures 
(Sijmons et al., 1990). Protein-based pharmaceuticals are big business with a potential 
market of $US 278.2 billion by 2020 (PMR, 2015). In recent years plants have become an 
attractive alternative to more conventional cell-culture based approaches (see below 
section 1.1.1) for the production of a wide array of pharmaceutical components as many 
researchers have discovered the advantages of plants as bioreactors. One of the reasons 
for the renewed interest in plants as bioreactors is the development of methods for the 
rapid production of candidate proteins via transient expression, obviating the 
requirement for lengthy transformation and regeneration procedures.  
 PLANTS AS EXPRESSION SYSTEM 
In the last 20 years plants have become serious competitors to other production 
systems for pharmaceuticals, such as bacteria, yeast or mammalian cells. They offer a 
safe, inexpensive and potentially limitless way to produce therapeutics in a quick and 
flexible manner. Plants require only simple inorganic nutrients, water, carbon-dioxide 
and sunlight for efficient growth. Furthermore, they bring a low risk of contamination 
with endotoxins or mammalian pathogens (Lico et al., 2008; Ma et al., 2003; Twyman et 
al., 2003) which can be an issue with mammalian cell cultures. Unlike prokaryotic 
expression systems, plants are able to introduce post-translational modifications such as 
glycosylation (Ma et al., 2005). In insect and yeast cells glycosylation is limited to very 
simple and inconsistent high mannose glycoforms (Chen and Lai, 2013). It is of 
advantage if a production system for pharmaceutical components, especially vaccines, is 
quick in the response to a sudden increase in demand. Transient expression in plants can 
be adjusted rapidly with low manufacturing costs (Giddings, 2001; Twyman et al., 2003). 
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Nicotiana benthamiana (N. benthamiana) has long been the favourite host when it 
comes to the production of recombinant proteins since it is well studied and agro-
infiltration is easy without causing great damage to the tissue (Goodin et al., 2008). 
Additionally, it allows a wide number of plant viruses to replicate which makes it a 
versatile host for virus-derived expression vectors. However, protein production is not 
limited to N. benthamiana. Several types of plants and plant tissues have been used for 
the production of protein such as potatoes, alfalfa and Arabidopsis thaliana but lettuce 
stands out as a VLP production host that combines all the benefits from N. benthamiana 
but furthermore contains fewer phenolics and alkaloids which can be difficult to remove 
(Lai and Chen, 2012; Platis and Labrou, 2008; Rybicki, 2009). A decade or two ago the 
idea of edible vaccines, in which plant tissue expressing the recombinant protein would 
be directly consumed, sparked a lot of interest, but has now lost its popularity due to 
problems of dose and quality control which is difficult to guarantee without purification 
(Rybicki, 2014; Sala et al., 2003).  
Despite the major risks and flaws, mammalian cells dominate the biopharmaceutical 
industry because they can produce high titres (1-5g/L) of complex proteins with 
mammalian glycan structures (Chu and Robinson, 2001); with Chinese hamster ovary 
cells culture being the most successful manufacturing platform for biologics. In direct 
comparison, plants produce at least 10-fold less recombinant protein and it can take up 
to 18 months to create a stable transgenic plant line. This means so far plants produce 
less of the desired product than the other platforms and it takes longer to do so 
(Thomas et al., 2011). However, this can be overcome with the development of transient 
expression system in plants. Large amounts (50 mg/kg fresh weight) protective antigens 
of influenza were transiently produced in plants within less than three weeks from the 
release of the viral sequence to the end product (D'Aoust et al., 2010; D'Aoust et al., 
2008).  
In 1982 the first commercially produced therapeutic recombinant protein was insulin 
made in Escherichia coli (E. coli). Its success is down to the simplicity and low costs of the 
product (Santos et al., 2016). The first plant-made therapeutic (PMT) protein approved 
by the US Food and Drug Administration (FDA) for human use was Protalix’s Elelyso 
(taliglucerase alfa) in 2012 and the first plant-made vaccine got approval in 2006 by the 
US Department of Agriculture for the use in chicken against Newcastle disease virus 
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(NDV) (FDA, 2012; Sparrow et al., 2007). However, both pharmaceuticals were not 
produced in whole plants but in plant cell suspension cultures.  
Plant suspension cultures are a potentially great alternative to whole plants for 
recombinant production of pharmaceuticals. I will introduce their characteristics, 
benefits and flaws in the next section.  
 PLANT SUSPENSION CULTURES 
Despite the breakthrough of Protalix’s Elelyso- the first licensed PMT, plant suspension 
cultures are still very much neglected and their capability not fully exhausted. Even 
though plant suspension cultures are around for over four decades, with the first 
reported recombinant protein made in 1990 by Sijmons and colleagues (Sijmons et al., 
1990), efforts have lagged to exploit their potential. Companies and investors are wary 
of this unfamiliar production method (Maxmen, 2012).  
Plant suspension cultures combine the advantages of whole plants with those of 
traditional fermenter systems. They grow in contained, controlled and sterile 
environment with almost no limitation for mass culture and are capable of high quality 
protein production with complex glycosylation. The growth media is inexpensive, lacking 
animal components but unlike whole plants, suspension cultures are not phototrophic 
and therefore need a carbon source. The cultivation strategies are versatile and range 
from shake flasks, stirred tank reactors (Doran, 1999), wave reactors (Eibl et al., 2010) to 
bubble columns (Terrier et al., 2007). Most commonly used is the batch fermentation 
where the medium is inoculated and after inoculation the reactor is a closed system 
except for added oxygen (Santos et al., 2016). All this makes production of therapeutics 
in plant suspension cultures compatible with pharmaceutical good manufacturing 
practice (GMP).  
Plant suspension cultures are not limited to one plant species; the most commonly used 
ones derived from tobacco (Nicotiana tabacum), rice (Oryza sativa) and carrot (Daucus 
carota).  Bright Yellow-2 (BY-2) is a widely used tobacco cultivar which can multiply up to 
100-fold within 7 days with a doubling time of 16-24 h under ideal conditions (Santos et 
al., 2016) (Figure 1.1-1). Developed in 1968 in the Japan Tobacco Company (Kato, 1972) 
transformation with Agrobacterium tumefaciens (A. tumefaciens) has proven to be 
highly efficient (Nagata et al., 1992) in this cultivar; allowing the synthesis of several 
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biopharmaceuticals like Hepatitis B surface antigen (Smith et al., 2002) or the Norwalk 
virus capsid protein (Zhang and Mason, 2006).  
 
Figure 1.1-1: BY-2 cells under the light microscope. 
 STABLE- VS. TRANSIENT-EXPRESSION  
There are two different ways to express pharmaceuticals, including VLPs, in plants and 
suspension cultures: (i) stable transformation of either the nuclear or plasmid genome 
or (ii) transient expression. Though used for seminal studies in the early days of 
molecular pharming, the use of stable transformation has declined as the process is 
time-consuming and therefore not suitable for rapid screening of a wide variety of 
different constructs or a quick response to emerging epidemics (Kusnadi et al., 1997). 
Transient expression uses the soil bacterium A. tumefaciens which causes crown gall 
disease, to deliver foreign sequences to plants. Since the 1970`s it has been known that 
this gram-negative bacterium can transfer a part of its special Ti (tumor-inducing) 
plasmid into the plant cell where it then integrates into the host genome (Chilton et al., 
1977). The gene of interest is inserted into the T-DNA region of a binary plasmid which 
will then be expressed in the plant cell. This allows screening and production in a matter 
of days. However, expression is limited to the infiltrated tissue but large-scale 
production and processing has been developed (D'Aoust et al., 2010). This is in contrast 
to stable transformation where the foreign gene becomes part of the genome and 
making the transgene heritable through succeeding generations.  
All three platforms have advantages and disadvantages—despite their great scalability, 
transgenic plants have a slow development cycle due to the need to regenerate plants 
and produce homozygous true-breeding lines. Also regulations of transgenic plants 
handicap the possibilities of this system. However, a great example for a successful 
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therapeutic made in transgenic plants is the HIV-neutralizing human monoclonal 
antibody 2G12 which is currently undergoing phase I clinical trials (Ma et al., 2015). 
Transient expression is not as tightly regulated as transgenic plants; mainly because the 
gene of interest is not introduced into the germline and hence not heritable and also 
transmission through pollen is impossible. Transient expression is more established and 
accepted with Medicago`s influenza vaccine currently undergoing phase 3 clinical trials 
(D'Aoust et al., 2010). It allows the rapid production of high protein yields ideal for 
emergencies such as vaccines and prophylactic antibodies, as seen in the recent 
outbreak of Ebola virus disease in West Africa (Arntzen, 2015). Although scalability has 
shown to be possible it is still a very niche production system. In contrast plant cell 
suspension cultures allow contained production very similar to the commonly used 
prokaryotic or mammalian cell based expression systems. Plant cells have been 
overshadowed by whole-plant platforms but the approval of taliglucerase alfa for use in 
human adults in 2012 and then for paediatric use in 2014 (Tekoah et al., 2015) has 
opened the way to the full acceptance of this technology and all plant-based 
pharmaceuticals in general.  
 VIRAL VECTORS USED FOR VLP PRODUCTION 
A number of plant virus-derived systems have been employed for transient expression 
of VLPs. These range from vectors based on the complete viral genome to which a 
foreign gene has been added, through deconstructed vectors in which non-essential 
viral functions have been deleted, to non-replicating virus-based systems. Full viral 
vectors behave like wild type virus by moving within their host and producing infectious 
virus particles but are also able to express heterologous proteins. Their ability to 
replicate and move from cell to cell and systemically results in extremely high levels of 
protein expression. However, during replication the gene insert can undergo mutation 
or deletion and it is difficult to express several genes in the same cell. Two full virus 
vectors, the potato virus X (PVX) and the cowpea mosaic virus (CPMV) have mostly been 
used for epitope display (Canizares et al., 2006; Marusic et al., 2001) but also for the 
plant-based expression of hepatitis core-like particles (Mechtcheriakova et al., 2006). 
The use of full virus vectors has been reviewed by Porta and Lomonossoff (Porta and 
Lomonossoff, 1996, 2002). 
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The creation of deconstructed viral vectors involves the removal of viral genes which are 
not essential for the production of the target protein, for example the viral coat protein, 
and may be replication-competent or replication-deficient. They are designed for rapid, 
high level production of recombinant proteins in plants, without the problems of 
biocontainment. The history and use of deconstructed viral vectors has recently been 
reviewed (Peyret and Lomonossoff, 2015) and the pEAQ and magnICON®- systems have, 
in particular, been used to produce VLPs in plants (Matic et al., 2012; Thuenemann et al., 
2013b).  
The pEAQ vectors are based on CMPV; a bipartite virus whose genome consists of two 
separately-encapsidated RNA molecules: RNA-1 (6.0 kb) and RNA-2 (3.5 kb). Each RNA 
molecule has a single open reading frame encoding one polyprotein. RNA-1 carries the 
sequence for the viral replication machinery and the 24K protease, which is responsible 
for processing of the polyproteins. RNA-2 encodes the coat proteins plus the movement 
protein but depends entirely on RNA-1 for its replication. The first major step towards 
the development of the pEAQ vectors was the finding that most of the RNA-2 
polyprotein can be deleted and replaced with a sequence of choice without impairing its 
replication by RNA-1 (Canizares et al., 2006; Rohll et al., 1993). This so called delRNA-2 
construct had to be introduced into leaves by agro-infiltration (Liu and Lomonossoff, 
2002) together with RNA-1 (Canizares et al., 2006). It was found that keeping the first 
512 nucleotides at the 5`end of RNA-2, including two in-frame AUGs at positions 161 
and 512 (the main translation initiation site), as well as the entire RNA2 3`UTR  is 
necessary to sustain the ability of the delRNA-2 construct to be replicated by RNA-1 
(Rohll et al., 1993). However, this required the precise in-frame positioning of the 
foreign sequence between AUG 512 and the 3`UTR which made insertion of 
heterologous sequences into the delRNA-2 construct a troublesome two-step process 
(Sainsbury et al., 2009). Another important finding was that co-infiltration of the 
delRNA-2 construct with P19, the suppressor of gene silencing from Tomato bushy stunt 
virus, stabilised the mRNA transcribed from the T-DNA. The effect is so powerful that 
replication by RNA-1 could be suspended. Studies originally intended to simplify cloning, 
revealed that removal of AUG 161 caused a 10-fold increase in yield of an inserted GFP 
gene through increased translational efficiency of the mRNA (Peyret and Lomonossoff, 
2013; Sainsbury and Lomonossoff, 2008). Further improvement was gained when 
another out-of-frame upstream AUG at 115 was removed, even though removing only 
AUG 115 weakened translation compared to the wildtype. The explanation behind these 
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results could be that AUG 161 inhibits translation initiation at AUG 512. This also 
supports the finding that removing AUG 115 initiates an open reading frame that 
extends past AUG 161: AUG 115 might allow ribosomes to bypass AUG 161 and re-
initiate at AUG 512 (Sainsbury and Lomonossoff, 2008). This new and improved 
expression system showed to enhance expression of GFP, DsRed, the Hepatitis B virus 
core antigen (HBcAg), and human anti-HIV antibody 2G12 (Peyret and Lomonossoff, 
2013; Sainsbury and Lomonossoff, 2008; Sainsbury et al., 2010b). For the reason that the 
high yields were due to increased translation the system was named CPMV-hypertrans 
(CPMV-HT). This early HT expression system, based on a shortened version of CPMV 
RNA-2 with a mutated 5`UTR, is the direct precursor to the pEAQ vector series.  
In order to make cloning and expression with CPMV-HT easier the plasmid backbone, 
originally derived from pBINPLUS, had been reduced to less than half its original size 
without compromising transient expression levels; resulting in a 5.2 kilobase backbone. 
The reduction in size resulted in greatly improved yields during cloning procedures. To 
ease addition of further expression cassettes into the T-DNA, three restriction sites 
(AsiSI, MluI and FseI) adjacent to the original AscI site of pBINPLUS were added. The 
resulting vector pEAQbeta was the starting point in the Lomonossoff lab for the design 
of a series of vectors, including pEAQ-HT (Sainsbury and Lomonossoff, 2008; Sainsbury 
et al., 2009).  
The pEAQ-HT expression vector (published on GenBank under accession number 
GQ497234.1) was used for the work described in this thesis. It carries the P19 
suppressor of gene silencing, NPTII eukaryotic kanamycin resistance gene and a multiple 
cloning site within the CPMV-HT cassette; which allows replication of the plasmid in 
E. coli and A. tumefaciens along with high levels of expression in plants (see Figure 
1.2-1). The pEAQ vectors have been deployed in the production of a number of different 
proteins through several different approaches. A variety of enveloped and non-
enveloped VLPs have been expressed in plants using the pEAQ vectors. These include 
hepatitis B virus (HBV), papillomaviruses and porcine respiratory and reproductive 
syndrome virus (PRRSV) (Thuenemann et al., 2013a). Furthermore, active enzymes have 
been synthesised through agroinfiltration of pEAQ, like human gastric lipase (hGL) 
(Vardakou et al., 2012). Even entire synthetic pathways have been manipulated using 
pEAQ through co-expression of multiple enzymes which showed full functionality in 
planta (Kanagarajan et al., 2012). This allows the analysis of their modes of action in the 
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biosynthetic pathway, as well as potentially allowing metabolic engineering. The pEAQ 
vectors have proven to not only work in whole plants but also in a variety of transgenic 
cell suspension cultures (Larsen and Curtis, 2012; Sun et al., 2011).  
 
 
Figure 1.2-1: Diagram of the pEAQ-HT expression vector. The vector backbone harbours 
essential elements for plasmid replication in E. coli and A. tumefaciens and the T-DNA carries the 
NPTII kanamycin resistance gene and the P19 suppressor of gene silencing. The gene of interest is 
inserted in the multiple cloning site (MCS) between the modified CPMV RNA-2 5’UTR containing 
the HT mutations, and the native CPMV RNA-2 3’UTR. These UTRs are themselves flanked by the 
CaMV 35S promoter and the nos terminator.  
Behind the high expression potential of the pEAQ vectors lays a modification of the 
5`UTR in the CPMV cassette. It was found that removal of AUG 161 caused a 10-fold 
increase in yield of an inserted GFP gene through increased translational efficiency of 
the mRNA transcribed from the T-DNA. A further enhancement was obtained when an 
additional out-of-frame upstream AUG at 115 was also removed (Sainsbury and 
Lomonossoff, 2008).  
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 VIRUS-LIKE PARTICLES AS VACCINES  
VLPs are convincing look-alikes of viruses but are lacking infectious genomic material. 
However, VLPs retain the native antigenic conformation of the immunogenic proteins 
and the repetitive structure of the original virus particle. They thus combine both safety 
and the potency to elicit a strong immune response (Grgacic and Anderson, 2006; 
Kushnir et al., 2012) due to their size, shape and surface where they display epitopes in a 
dense repetitive array (Bachmann and Jennings, 2010; Chen and Lai, 2013). Following 
the recombinant expression of the viral proteins many self-assemble spontaneously into 
VLPs, though some require a maturation step. Currently used non-recombinant vaccines 
against viral diseases are made from lab-cultured pathogens which have to be 
attenuated or inactivated. This comes with bio-containment concerns because of the 
risk of residual pathogenic activity due to incomplete attenuation or inactivation. It is of 
fundamental importance for a vaccine to be unable to cause disease without 
compromising immunogenicity. A potentially safer approach is therefore the synthesis 
of vaccines based on the expression of specific components of pathogens which can 
mimic the immunological properties of the original virus without its pathogenic 
properties and VLPs are excellent candidates for such synthetic vaccines. In addition, 
certain VLPs have also been investigated as potential drug-delivery vehicles and as 
imaging agents for biomedical purposes.  
The concept of using plants for the synthesis of pharmaceuticals is more than two 
decades old and several different VLP based vaccine candidates have been produced:  
Bluetongue virus (BTV) is a non-enveloped, insect-transmitted virus causing the 
Bluetongue disease in ruminants. Its complex, multi-layered capsid is built out of four 
structural proteins arranged in three concentric shells; each protein is present in a 
different stoichiometry. Despite this complex setup, Thuenemann et al. successfully 
produced BTV-8 VLPs in N. benthamiana which effectively protected sheep from 
challenge. The approach to their production involved the co-expression of the four 
different viral structural proteins using pEAQ-HT with carefully adjusted ratios in order 
to obtain large quantities of correctly-assembled VLPs (Thuenemann et al., 2013b).  
Human Papillomavirus (HPVs) is a non-enveloped tumour-inducing DNA virus that 
accounts for approximately 5% of all human cancers (Munger et al., 2004; Parkin and 
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Bray, 2006). The capsid is about 55 nm in diameter formed by the major (L1) and minor 
(L2) capsid protein. The L1 protein self-assembles into highly immunogenic VLPs or into 
capsomers made of five L1 monomers (Kirnbauer et al., 1992). Three VLP based vaccines 
against HPV are already on the market (Gardasil, Gardasil-9 (Merck) and Cervarix 
(GSK)) based on the expression of L1 in insect or yeast cells (Harper et al., 2004; Villa et 
al., 2006). However, high production costs hinder their use in developing countries as 
most people at risk cannot afford them. Matić et al. aimed to develop an alternative, 
less expensive vaccine made in plants using the pEAQ system (Matic et al., 2012). They 
expressed full-length HPV-8 L1 and a truncated version, produced by deleting the C-
terminal nuclear localization signal. Electron microscopy proved that assembly of the 
expressed HPV-8 L1 into VLPs of T = 1 or T = 7 symmetry had occurred (Matic et al., 
2012) and thus represents another candidate vaccine.   
Norwalk virus (NV) causes acute gastroenteritis in humans. The major problem for 
developing a viable vaccine against NV is that there is currently no method of 
propagating the virus in cell culture and hence traditional killed or live-attenuated 
vaccines have not been developed. Most recently, Mathew et al. confirmed the 
production of Narita 104 virus capsid protein VLPs in N. benthamiana which generate a 
significant mucosal and serum antibody response when inoculated into mice 
demonstrating that the authors had made a potential plant-derived vaccine candidate 
against NV (Mathew et al., 2014). 
Probably the most successful plant-produced vaccine candidate, currently undergoing 
phase III clinical trials, is against influenza virus. D’Aoust et al. showed that plants are 
capable of producing enveloped influenza VLPs which elicit a protective immune 
response in mice (D'Aoust et al., 2008; Landry et al., 2010). Recently Medicago USA Inc. 
adapted the plant-based influenza VLP expression to large-scale production allowing the 
purified end product to be obtained only 3 weeks after receiving the sequence (D'Aoust 
et al., 2010).  
The fact that complex particles such as multishelled orbivirus capsids, as well as 
enveloped influenza VLPs can be synthesized in plants shows that plant-based 
expression of such therapeutics can deliver to at least the same level as conventional 
systems.  
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Table 1.3.1: Transiently expressed VLP-based vaccine candidates made in plants. 
Virus Summary Reference 
Influenza 
Influenza virus-like particles induce a 
protective immune response against a lethal 
viral challenge in mice, produced for H7N9 
outbreak virus. 
D`Aoust et al., 
2010 
Papillomavirus 
HPV-16 L1 VLPs via agroinfiltration-mediated 
transient expression or via transplastomic 
expression. 
Maclean et 
al., 2007  
Fernandez-
San Millan et 
al., 2008 
Papillomavirus Expression of HPV-8 L1 VLPs. 
Matić et al., 
2012 
Papillomavirus 
Transient expression of chimaeric L1::L2 VLPs 
and proof of increased breadth of immune 
response. 
Pineo et al., 
2013 
Bovine 
papillomavirus 
Transient expression of BPV L1 VLPs. 
Love et al., 
2012 
Human norovirus 
NaVCP VLPs which generate a mucosal and 
serum antibody response. 
Mathew et 
al., 2014 
Bluetongue virus Protective bluetongue virus-like particles. 
Thuenemann 
et al., 2013b 
Table 1.3.1 summarises the potential lying within the transient expression of VLPs in 
plants. In this work two very different viruses were chosen in order to explore the 
possibilities of plant-based vaccine production. The rather simple nervous necrosis virus 
and the more complex poliovirus will be further described in the following chapters of 
this thesis.  
 NERVOUS NECROSIS VIRUS 
Nervous necrosis virus (NNV) infection is a serious disease known to affect over 40 
cultured marine fish species worldwide (Tan et al., 2001; Walker and Winton, 2010), 
causing extensive economic losses to the aquaculture industry each year (Lin, 2007). The 
disease caused by NNV is commonly known as viral nervous necrosis (VNN). Infected fish 
display extensive cellular vacuolation and neuronal degeneration in the central nervous 
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system and the retina, due to NNV induced apoptosis (Figure 1.4-1) (Chen et al., 2006; 
Wang et al., 2010). Symptoms of VNN are abnormal swimming behaviour and muscle 
tremors (Roy, 2010). 
 
Figure 1.4-1: Histopathology of Mandarin fish infected with NNV. A) Brain tissue of NNV-
infected Mandarin fish. Black arrows point to numerous vacuoles caused by NNV infection. B) 
Brain tissue of mock-infected Mandarin fish. (Tu et al., 2016).  
NNV is member of the genus Betanodavirus and can be classified into five genotypes: 
striped jack NNV (SJNNV), tiger puffer NNV (TPNNV), barfin flounder NNV (BFNNV), red-
sprotted grouper NNV (RGNNV) (Nishizawa et al., 1997) and turbot NNV (TNNV) 
(Johansen et al., 2004). Each of these five genotypes infects a number of different fish 
but all of them share the same features (Roy, 2010). They are small (25-30 nm in 
diameter), non-enveloped, spherical viruses with two single-stand positive-sense RNA 
molecules (Lin et al., 2001); a RNA-dependent RNA polymerase is encoded by RNA1 and 
RNA2 contains the information for the coat protein (Mori et al., 1992). 180 copies of the 
coat protein self-assemble into a T = 3 capsid (Cheng et al., 1994).  
NNV infects larvae and juvenile stages with lethality up to 99% but full-grown fish are 
susceptible as well (Lin, 2007). Though, the infection rate of NNV is temperature 
dependent. Chi and colleagues found that between 24-32 °C virus titre increased in fish 
with an increase of the temperature. However, the virus replication rate was down 
regulated at 20 °C although infections still took place (Chi et al., 1999). The outbreak of 
the disease depends on the temperature which again is depending upon the virus strain 
and the fish species (Chi et al., 1999). Studies showed that NNV is spread horizontally 
and also vertically (Nishizawa et al., 2012).  
Several kinds of NNV vaccines candidates have been developed including recombinant 
capsid protein (Husgag et al., 2001; Lin, 2007; Sommerset et al., 2005), synthetic 
peptides (Coeurdacier et al., 2003), virus-like particle (Liu et al., 2006; Thiery et al., 2006) 
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and inactivated virions (Kai and Chi, 2008; Yamashita et al., 2005). However, the biggest 
problem so far is that no effective vaccine has been developed that does not need to be 
injected into each fish separately. The final aim of this work is to design a vaccine which 
protects all developmental stages of the fish against NNV and that can be administered 
orally. 
 POLIOVIRUS 
Poliovirus (PV) is the causative agent of poliomyelitis, a crippling disease known to 
humankind since antiquity (Landsteiner and Popper, 1909). Children with a naïve 
immune system are more susceptible to the disease but polio can strike at any age. It 
infects primarily via the faecal-oral route and poor hygienic conditions facilitate the 
spread. Once PV is ingested it multiplies in the oropharyngeal and intestinal mucosa 
(Sabin, 1956), from there it enters the lymph nodes and then causes blood viremia 
(Racaniello, 2006). Most PV infections cause asymptomatic viral replication that is 
limited to the gut and only about 24% of those infected develop minor symptoms such 
as fever, headache and sore throat. In even rarer instances, (only 1-2%) the virus enters 
the central nervous system (CNS) where it destroys motor neurons causing paralysis of 
extremities or even death (Racaniello, 2006). The spinal cord is a thick bundle of nerve 
fibres that emerges from the brain and runs downwards with the function to connect 
the body with the brain. Grey matter occupies the centre of the spinal cord and has the 
shape of a butterfly with outstretched wings. The anterior horns represent the 
forewings of the butterfly and their role is the coordination of limb movement. If PV 
enters the CNS it replicates in the anterior horns of the grey matter causing lesions and 
therefore the affected muscles lose their function due to a lack of nervous activation, 
resulting in irreversible paralysis. The condition is known as acute flaccid paralysis (AFP). 
In the most severe cases PV attacks the motor neurons of the brain stem, reducing 
breathing capacity and causing difficulty in swallowing and speaking. Without 
respiratory support, bulbar polio can result in death (WHO, 2015). PVs invasion of the 
CNS is accidental as it does not present a benefit for its normal life cycle. Polio arrives at 
the CNS via retrograde axonal transport with a pace of up to 12 cm/day (Ohka et al., 
1998); PV containing vesicles are brought to the spinal cord by CD155 dependent axonal 
transport (Mueller et al., 2002; Ohka et al., 2004). It is known that physical trauma like 
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hard exercise stimulates retrograde axonal transport of PV and therefore facilitates viral 
invasion of the CNS (Gromeier and Wimmer, 1998).  
Poliovirus occurs in three serotypes (PV1, PV2 and PV3) and is classified as a member of 
the Picornaviridae, a large family of small RNA viruses which includes foot and mouth 
disease virus, hepatitis A virus, rhinovirus and coxsackie virus. Its single stranded 
(+)-sense RNA genome (~7500 nucleotides) contains a single large open reading frame 
encoding one 220 kDa polyprotein which is subsequently processed by a series of 
proteolytic cleavages to generate the viral proteins (Kitamura et al., 1981). One of the 
processing intermediates, P1, is a ~100 kDa protein containing the sequences of all 
capsid proteins. P1 is subsequently processed by the viral proteinase 3Cpro/3CD to 
produce the mature capsid proteins (Ypma-Wong et al., 1988). Poliovirus is composed of 
60 copies each of four proteins: VP1, VP3 and an immature precursor, VP0 which gets 
further processed into VP2 and VP4 during RNA uptake (Basavappa et al., 1998; Holland 
and Kiehn, 1968; Jacobson et al., 1970). Finally, all 4 proteins form an icosahedral capsid 
27-30 nm in diameter (see Figure 1.5-1) (Hogle et al., 1985).  
 
Figure 1.5-1: Poliovirus capsid structure. The figure in the left panel is a full-atomic model of the 
structure of the Mahoney strain of type 1 poliovirus. The figure has been radially-depth cued with 
atoms colour coded according to their radius in the virus particle. Features that are closer to the 
centre appear dark; features furthest from the centre appear white. In the right panel, VP1 is 
blue, VP2 is yellow, VP3 is red, and VP4 is green. Note the star-shaped mesas at the fivefold axes, 
the three-bladed propellers at the threefold axes, and the deep canyon that separates the star-
shaped mesas from the nearest blades of the propellers. Figure courtesy of Jim Hogle and Mike 
Strauss, Harvard Medical School.  
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Two distinct antigenic forms of poliovirus exist, named D and C antigen (Mayer et al., 
1957) or also referred to as N (native) and H (heated) (Hummeler and Hamparian, 1958) 
because D/N can be converted to C/H by heating (Le Bouvier, 1955). The D antigen is 
found on infectious virus whereas the C antigen is expressed on non-infectious empty 
particles (Le Bouvier, 1955; Schwerdt and Fogh, 1957). C particles do not display the 
antigens responsible for eliciting protective immune responses and are ineffective as 
vaccines.  
Empty particles, such as VLPs, do not undergo the final maturation cleavage of VP0 into 
VP2 and VP4, which reorders the proteins on the inside of the virus capsid with a 
concomitant increase in particle stability (Basavappa et al., 1994). The cleavage occurs 
simultaneously with RNA insertion which, of course, does not occur in VLPs.  
Consequently, although empty capsids are initially in the desirable D conformation they 
can be easily converted to the C form during extraction and purification (Marongiu et al., 
1981). Therefore, to produce an effective vaccine from recombinantly expressed empty 
particles, it will be necessary to stabilise the particles to reduce/eliminate conversion 
form D to C form while maintaining the desired antigenic phenotype.  
 200 YEARS OF POLIO HISTORY 
The crippling disease of poliomyelitis is known to humanity since ancient times. An 
Egyptian carving dated back to 1403-1365 BC is displayed in the Ny Carlsberg 
Glyptoteket Copenhagen depicting Ruma, guardian priest of the Temple of Astarte in 
Memphis (Figure 1.5-2). His weak and deformed leg is believed to be the result of polio 
(Williams, 2013). However, the roots of the disease stayed a mystery for a long time, 
even though severe outbreaks in the 19th century in Europe and America sparked 
increased scientific interest. Polio first appeared in the literature in 1789 (Underwood, 
1789) describing the disease to be only affecting children, which led German doctors 
and researchers to name it “Kinderlähmung” which translates to infantile paralysis. 
Kinderlähmung is a term which is still used Germany even though since 1858 it is known 
that polio also attacks adults when the first recorded case of polio in an adult man was 
published in Switzerland (Vogt, 1859). Poliomyelitis had many titles one of which was 
Heine-Medin disease, named after two influential European researchers. Jacob von 
Heine (1800-1879) wrote the first coherent description of the disease in 1840, however 
mistaking teething to be the reason for the paralysis that he observed in his young 
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patients. Karl Oscar Medin (1847-1927) was a Professor of paediatrics in Stockholm and 
the first who called polio a systemic illness that did not paralyse every sick person. His 
assistant Ivar Wickmann (1872-1914) also played an important role in the understanding 
of the polio spread. His thorough investigations of polio cases in Sweden in the early 
1900 lead him to the conclusion that polio was contagious and can spread from person 
to person and he was the first to have the idea of asymptomatic carriers; an idea that 
has been highly controversial so far (Wickmann, 1911; Williams, 2013).  
 
Figure 1.5-2: Carving dated 1403-1365 BC showing an Egyptian man with a withered leg.  
(Reproduced with kind permission of Glyptoteket. Man with a Crippled Leg. Digital image. 
Glyptoteket, n.d. Web. 10.09.2016 <http://www.glyptoteket.com/>).   
Researchers devoted their lives to discover the reason behind the paralysis but the 
advances in science did not allow the researchers to come up with an explanation to the 
emerging disease. Until in 1870 Jean-Martin Charcot and Alfred Vulpian analysed 
samples of polio victims discovering lesions in the grey matter of the anterior horns of 
the spinal cord (Charcot, 1870; Vulpian, 1870). A few years later the German physician 
Adolph Kussmaul (1822–1902) first used the term poliomyelitis which translates to 
inflammation of the spinal cord (Compston, 2016). A name that stuck with the disease 
ever since.  
Discovering the lesions in the anterior horns was a great leap forwards in the 
understanding of the disease but the cause of poliomyelitis was still a big point of 
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discussion and disagreement between scientists. Until 1908 at the meeting of the Royal 
and Imperial Society of Physicians in Vienna Karl Landsteiner (1868-1943) reported the 
successful experimental transmission of poliomyelitis from a 9-year old boy who had 
died of polio to monkeys. Until then most people believed that a bacterium is the 
causative agent of the disease and the idea of an even smaller organism, like a virus, was 
still very new. Landsteiner had filtered the dead boy`s homogenised spinal cord through 
a Berkefeld candle which is a hollow cylinder filled with silica clay, but the holes are too 
small to let bacteria through. He injected the filtrate into two Old world monkeys which 
developed paralytic symptoms a couple of days later and under the microscope the 
spinal cord of the monkeys showed the typical lesions of poliomyelitis (Eggers, 1999). 
Therewith he proved that the disease causing agent cannot be a bacterium but it was 
not until the 1952 when the microscopy caught up and for the first time PV particles 
could be seen under the electron microscope that the voices of sceptics were silenced 
(Goldsmith and Miller, 2009; Reagan and Brueckner, 1952).   
Meanwhile poliomyelitis went on a rampage through the world with a peak in 1952 with 
58, 000 cases of paralytic poliomyelitis and 9, 000 deaths in America (Williams, 2013), 
leaving the hospitals unable to cope without a cure or treatment. Severe cases of 
poliomyelitis, where the brain stem got infected and breathing became immobilised, 
had to stay in respirators that mimicked the breathing movement for the paralysed 
patient. The first iron lung was developed 1929 by Phillip Drinker, proving to be a life 
saver for thousands of polio patients (Drinker and Shaw, 1929). Some patients never 
recovered and their life relied on the iron lung, like June Middleton who died at the age 
of 83 having spent 60 years connected to the respiratory device (DailyMail, 2009).   
The next big milestone for poliovirus research was the design by Enders and Weller 1949 
of a method to cultivate poliovirus in vitro (Enders et al., 1949). Based on this progress 
the first vaccine was developed by Jonas Salk and introduced in 1955 (Salk et al., 1954). 
The vaccine consists of all three serotypes which are inactivated (killed) with 
formaldehyde. IPV is given by intramuscular injection and needs to be administered by a 
trained health worker. In 1954 the Cutter incident shattered the trust of the population 
in vaccination when 200 000 children in the USA received incompletely inactivated polio 
vaccine and a high frequency of initial paralysis was observed in the inoculated limb 
(Nathanson and Langmuir, 1963). However, improvements of the production reinstalled 
IPV and in the second year of routine IPV vaccination the numbers of paralytic cases had 
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fallen to 5, 500 and only 220 deaths in America (Williams, 2013). In parallel Salk`s biggest 
rival Albert Sabin was working on a less expensive, orally administered vaccine (OPV) 
which got released 1961 and became the most successful tool in the fight against 
poliovirus (Sabin, 1957). OPV is a live attenuated virus which carries point mutations 
causing lower neurovirulence and reduced transmissibility but the ability to replicate 
allows high immune responses.  
The fast improvement of molecular biology enabled deeper insights into the 
composition and life cycle of viruses. The big interest in poliovirus made it the first 
animal virus to have its genome sequenced in 1981 (Kitamura et al., 1981), revealing a 
RNA genome with only 7440 nucleotides encoding 11 genes. Only a couple of years later 
the crystal structure was solved by Hogle and his colleagues in 1985 (Hogle et al., 1985) 
depicting a detailed image of the capsid. In 1989 the human poliovirus receptor (CD155) 
that interacts with poliovirus during infection was discovered by Mendelsohn and 
further characterized by Koike (Koike et al., 1990; Mendelsohn et al., 1989). Discovering 
the PV receptor was an integral part of poliovirus research because this knowledge 
allowed the engineering of transgenic mice carrying the receptor: an inexpensive model 
to study poliovirus infection (Ren et al., 1990).   
Despite over 200 years of research the story of polio has not come to an end. Work on 
poliovirus is ongoing (Chan et al., 2016) as the virus is still a thread and there is plenty 
more to reveal and discover.  
 NEED FOR NEW VACCINES 
The development of the first polio vaccine was down to the support by the March of 
Dimes, a non-profit organisation funded 1938 by President Franklin D. Roosevelt. 
Roosevelt himself was a polio victim; he contracted the disease as an adult and was 
never able to use his legs again. His personal commitment for this fundraising campaign 
with the aim to fight the disease and to support its victims made it a massive success. In 
the first year $1.8 million was raised most of which was dimes directly sent to the White 
House in envelopes (Williams, 2013). However, the biggest success of the campaign was 
the development and release of IPV. From this point, polio declined rapidly from tens of 
thousands of new cases per year to a mere handful in America (March of Dimes, 2007) . 
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However, failure to implement strategic approaches led to ongoing spread of polio 
paralysing more than 350 000 people in 125 endemic countries (WHO, 2015). To set an 
end to the dilemma the Global Polio Eradication Initiative (GPEI) was created. Their aim 
is to completely eradicate and contain all wild, vaccine-related and Sabin polioviruses 
worldwide, such that no child ever again suffers paralytic poliomyelitis (GPEI, 
2010). GPEI is a public-private partnership led by national governments and 
spearheaded by the World Health Organization (WHO), Rotary International, the US 
Centers for Disease Control and Prevention (CDC), and the United Nations Children’s 
Fund (UNICEF). Their efforts payed off, decreasing the cases by over 99% since the 
initiative’s foundation in 1988 and eradicating it from 123 countries down to only two 
remaining countries with endemic polio: Afghanistan and Pakistan. The GPEI estimates 
having saved about 10 million people from paralysis (GPEI, 2010).  
OPV has been the instrument of choice in the Global Polio Eradication Initiative, 
especially in developing countries because it is relatively inexpensive and easy to 
administer, and it induces gastrointestinal mucosal immunity which prevents virus 
transmission as well as protecting recipients from disease. However, OPV has flaws: one 
of them is its genetic instability through which it can regain neurovirulence by reversion 
mutations. This can cause vaccine-associated paralytic poliomyelitis (VAPP) in the 
vaccine recipient, albeit at very low frequency (Burns et al., 2013; Henderson et al., 
1964; Kew et al., 2002; Kew et al., 1998). Clinical signs and severity of paralysis 
associated with VDPV and wild-type (wt) PV are indistinguishable and they pose the 
same risk on the population: VDPV associated outbreaks happen all over the world 
(Burns et al., 2013; Gumede et al., 2013; Kew et al., 2002; Kew et al., 2005). In addition, 
these attenuated strains may undergo genetic recombination during replication with 
other polio or non-polio human enteroviruses, resulting in circulating vaccine-derived 
polioviruses (cVDPVs) that display neurovirulent phenotypes similar to wild-type 
polioviruses (Minor, 2009). Usually people stop shedding vaccine virus 2-4 weeks after 
vaccination, yet vaccinees with the immunodeficiency disorder are known to shed the 
virus for much longer without getting sick from it which makes them very hard to find 
(Alexander et al., 2009; Bellmunt et al., 1999; Kew et al., 1998); there is currently a man 
living in the UK who has shed type 2 vaccine derived PV for 28 years (Dunn et al., 2015). 
He is excreting highly virulent and antigenically drifted virus and there is no strategy to 
deal with this problem which raises questions about the safety of the population 
especially after the recent changes in vaccine production.   
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Furthermore, OPV also lacks thermostability and requires the utilisation and 
maintenance of a cold chain. The Salk inactivated vaccine (IPV) induces effective 
humoral immunity which protects against disease in the vaccinee but does not prevent 
replication of the wt virus encountered subsequently, thus allowing continued 
transmission within a population.  Importantly, the IPV Salk vaccine is significantly more 
expensive than the Sabin vaccine. Production of both vaccines requires propagation of 
large amounts of infectious poliovirus which carries the risk of an accidental 
reintroduction. Failure to implement strategic approaches has led to ongoing 
transmission of the virus.  
Global eradication of PV is close, with no recorded wt cases of type 2 since 1999 and no 
case of type 3 since November 2012 but several cases of type 1 in this year (2016) 
already (GPEI, 2016) (Table 1.5.1). After more than two years without wild poliovirus in 
Nigeria, the Government reported in August 2016 two children paralysed by the disease. 
This leaves Pakistan, Afghanistan and Nigeria as the last reservoirs of wt PV. Until 
poliovirus transmission is interrupted in these countries, all countries remain at risk of 
importation of polio, especially vulnerable countries with weak public health and 
immunisation services. Re-introduction of these wild polio strains continues to occur in 
countries that have previously eliminated wild virus circulation via world travellers, and 
VDPVs may continue to evolve from the cryptic replication of attenuated OPV strains. 
The WHO is therefore seeking novel polio vaccines with the overall objective of 
developing genetically stabilised poliovirus virus-like particles as a cheap and viable 
source of vaccine to replace current IPVs. Such virus-free vaccines will become 
increasingly relevant as wt polio is eradicated also in order to eliminate the risk of 
misusing polio as a bioweapon. 
Table 1.5.1: Wild type 1 and cVDPV cases, September 2016 (GPEI, 2016). 
 Total cases 
Year-to-date 2015 Year-to-date 2016 Total 2015 
Wt PV cVDPV Wt PV cVDPV Wt PV cVDPV 
Globally 26 3 41 14 74 32 
In endemic countries 26 0 41 3 74 3 
In non-endemic 
countries 
3 3 0 9 0 29 
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 AIMS OF THIS THESIS 
The overall aim of this project was to explore the capabilities of plants to express VLPs as 
vaccines and to investigate the efficacy and properties of the plant-made product with 
the focus on potential industrial application. In particular, I started off with the 
expression of a rather simple virus: Nervous necrosis virus (NNV) which builds itself out 
of 180 copies of one single protein. NNV infects over 40 marine fish species world-wide 
and is a major problem for the fish farm industry. The objective was to develop an 
inexpensive vaccine against NNV using a plant expression platform, which would 
possibly allow oral vaccination of the fish. Once the general techniques were established 
and the production of pure and structurally sound VLPs in plants were proven I moved 
onto a more complex task: the development of a synthetic plant-produced vaccine 
against poliovirus. This requires the expression of not only the structural proteins but 
also the protease needed for their correct processing. The goal was the generation of 
non-infectious poliovirus-like particles (PV VLPs) that have the capability of eliciting a 
protective immune response against polio. Together with the WHO-funded consortium 
we developed stabilised mutant versions of the poliovirus gene P1, which keep the 
correct antigenicity during expression and purification.  
In order to make the product more attractive to the vaccine industry, I adopted tobacco 
BY-2 cells for the transient expression of the above-mentioned PV mutant VLPs using the 
cell-pack method. BY-2 cells grow in suspension culture and have no limit for mass 
production which is a potential advantage over whole plants.  
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Chapter 2: MATERIALS AND METHODS 
 MEDIA, BUFFERS AND SOLUTIONS 
The recipes for bacterial growth media, buffers and solutions are summarised in Table 
2.1.1.  
Table 2.1.1: Recipes of media, buffers and solutions. 
Name Recipe 
Antibiotics 
100 μg/ml kanamycin (in water) 
50 μg /ml rifampicin (in methanol) 
500 μg/ml carbenicillin (in water) 
5 x Formaldehyde gel 
running buffer (FGRB)  
100 mM MOPS, 40 mM sodium acetate, 5 mM EDTA, 
adjust to pH 7  
1 x HEPES buffer 
238.3 g/l HEPES, add solid NaOH until the pH is ~6.8, 
adjust pH to 7.0 with 5N NaOH, sterile filter and store at 
4 °C 
Luria Bertani (LB) media 
10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, adjust to 
pH 7.0 
LB agar as LB, plus 10 g/l agar 
MMA 
10 mM MES buffer, pH 5.6; 10 mM MgCl2, 100 μM 
acetosyringone, pH 7.5 
Murashige and Skoog 
(MS)- media 
4.6 g/l Murashige and Skoog Plant Salt Mixture, 30 g/l 
sucrose, 100 mg/l Inositol, 1 mg/l Thiamine, 0.2 mg/l 
2.4-dichlorophenoxyacetic acid, 200 mg/l KH2PO4, adjust 
pH to 5.8 with 1N NaOH, autoclave 
Orange-G loading buffer 
(for agarose gels) 
0.025 g orange-G dissolved in 25 ml 60% (v/v) glycerol in 
1x TBE 
Phosphate buffered 
saline (PBS) 
140 mM NaCl, 15 mM KH2PO4, 80 mM Na2HPO4, 27 mM 
KCl, pH 7.2 
PBS + EDTA buffer (10L) 
13.7 mM NaCl, 2.685 mM, KCl 0.885 mM, CaCl2 •2H2O, 
0.495 mM MgCl2 •6H2O, 1.685 mM Na2HPO4•12 H2O, 
2.27mM KH2PO, 20 mM EDTA 
10 x PIPES buffer 
0.58 g/l NaCl, 3 g/l PIPES (piperazine-N,N′bis[2-
ethanesulfonic acid]), 0.2 g/l MgCl2•6H2O, adjust pH to 6.5 
with 1N NaOH, sterile filter and store at 4 °C 
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Protein extraction 
buffer (P-buffer) 
305 ml of 0.2 M Na2HPO4, 195 ml of 0.2 M NaH2PO4, 
500 ml of Milli–Q water, Complete Inhibitor Cocktail tablet 
(Roche), pH 7 
Protein loading buffer 
(for SDS gels) 
750 μl 4x LDS sample buffer (Invitrogen), 250 μl β-
mercaptoethanol  
SOC (Life technologies) 
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM 
glucose 
TBE buffer 10.8 g/l Tris-HCl, 5.5 g/l Boric, 2 mM EDTA, pH 7.6 
10 x TBS buffer 0.5 M Tris, 3 M NaCl, 10 mM EDTA, adjust pH to 8.5 
TEN/NET buffer 100 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 7.5 
Western blot block 
buffer 
5% (w/v) dry milk, 0.1% (v/v) Tween-20, in PBS  
Western blot transfer 
buffer 
3.03 g/l Tris-HCl, 14.4 g/l glycine, 20% (v/v) methanol  
Western blot wash 
buffer 
0.1% (v/v) Tween-20 in PBS  
 MOLECULAR CLONING TECHNIQUES 
Standard molecular biology procedures were performed as described by Sambrook et al. 
(Sambrook, 1989) and the manufacturers instructions were followed when specific 
reagents were used.  
 PLASMID CONSTRUCTION 
Sequences were obtained from collaborators in the WHO consortium, codon-optimised 
for Nicotiana benthamiana and ordered for synthesis from GeneArt (Life Technologies) 
with flanking AgeI and XhoI sites. The genes were inserted into pEAQ plasmids for 
expression.  
 DNA/PLASMID ISOLATION AND PURIFICATION 
Plasmid DNA was isolated from bacteria using the QIAprep Spin Miniprep Kit (Qiagen). 
DNA fragments from PCR reactions were prepared with the QIAquick PCR Purification Kit 
Materials and methods 
37 
 
(Qiagen) and from agarose gels using QIAquick Gel Extraction Kit (Qiagen). Purified DNA 
was stored at -20 °C.  
 RESTRICTION DIGEST 
Digestions of DNA fragments and plasmids was performed using restriction enzymes 
supplied by NEB (New England Biolabs) and were carried out as per manufacturer`s 
instructions.  
 DNA LIGATION 
Purified DNA fragments were quantified using a NanoDrop spectrophotometer and an 
insert: vector molar ratio of 3:1 was calculated. Ligation was carried out using T4 ligase 
(NEB) either at room temperature for 30 minutes or at 16 °C overnight.  
 POLYMERASE CHAIN REACTION (PCR) 
DNA fragments for subsequent cloning were amplified using high-fidelity polymerase 
Phusion (NEB) with primers listed in the Appendix 1. The reactions were set up as 
follows:  
Phusion HF buffer (5x) 10 µl 
dNTPs (10 nM) 1.0 µl 
Forward primer (10 µM) 2.5 µl 
Reverse primer (10 µM) 2.5 µl 
DNA template (20-25 ng) 1.0 µl 
Phusion polymerase 0.5 µl 
dH2O 32.5 µl 
                                                      50.0 µl 
The following program was run to amplify DNA using a variable annealing temperature 
(XY):  
1 98 °C 2 mins 
2 98 °C 10 sec 
3 XY °C 20 sec 
4 72 °C 15-30 sec/kb 
 
5 Go to step 2 25 x 
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6 72 °C 5 min 
7 4 °C ∞ 
DNA fragments for subsequent analysis by agarose gel electrophoresis were amplified 
using GoTaq Green Master Mix (Promega) with primers listed in Appendix 1. When 
colony PCR was performed a small amount of bacterial culture replaced the template 
DNA.  
GoTag Green MM 10 µl 
Forward primer (10 µM) 0.5 µl 
Reverse primer (10 µM) 0.5 µl 
Reverse primer (10 µM) 2.5 µl 
DNA template (20-25 ng) 1.0 µl 
dH2O 8.0 µl 
                                                     20.0 µl 
The program was run as follows with a variable annealing temperature (XY):  
1 95 °C 5 mins 
2 95 °C 1 min 
3 XY °C 45 sec 
4 72 °C 1 min/kb 
 
5 Go to step 2 31 x 
6 72 °C 5 min 
7 4 °C ∞ 
 AGAROSE GEL ELECTROPHORESIS 
For analysis and purification of PCR products or plasmid digests, agarose gel 
electrophoresis was conducted. Generally, 0.8% (w/v) agarose was dissolved in TBE 
buffer and HyperLadder I (Bioline) used as a standard DNA marker. Samples were mixed 
with 5x loading buffer and migrated on gels for 45 minutes at 100 V.  
 DNA SEQUENCING 
Sequencing reactions were prepared according to Eurofins Genomics (Wolverhampton, 
UK) requirements. Sequencing was carried out by Eurofins Genomics.  
 
Materials and methods 
39 
 
 SITE-DIRECTED MUTAGENESIS (SDM) 
Point mutations were introduced into plasmids using specifically designed primers in 
order to change individual nucleotides. The GeneArt Site-directed mutagenesis system 
(Invitrogen) was used and instructions were followed closely. After verification of the 
mutation by sequencing the construct was transformed into agrobacteria for expression 
in plants. 
 GROWTH, STORAGE AND TRANSFORMATION OF COMPETENT CELLS 
One Shot® Top10 chemically competent E. coli (Life Technologies) was used for 
propagation of plasmids. They were grown at 37 °C in LB media with respective 
antibiotic selection. E. coli was transformed using heat-shock. It was allowed to recover 
in SOC in a shaking incubator at 37 °C before being plated on LB agar plates with 
appropriate antibiotics.  
A. tumefaciens LBA4404 (Hoekema et al., 1983) was propagated at 28 °C in LB media 
containing 50 µg/ml kanamycin and 50 µg/ml rifampicin. Transformation of 
A. tumefaciens LBA4404 was carried out by electroporation at 2.5 kV; recovered in SOC 
at 28 °C for an hour before being plated on LB agar plates with the respective antibiotic 
selection.  
After colony PCR and sequencing, Glycerol stocks of positive colonies of E. coli and 
A. tumefaciens were prepared by mixing an aliquot of the culture in the stationary phase 
with glycerol for a final concentration of 25%. They were snap-frozen in liquid nitrogen 
and stored at -80 °C.  
 PLASMIDS USED 
Genes synthesized by GeneArt (Life Technologies) were sent to us in the small and 
simple pMA plasmid, carrying ampicillin resistance.  
Rapid and high level production of recombinant protein in plants was achieved using the 
deconstructed viral vector pEAQ-HT which contains a polylinker for simple insertion of 
the gene of interest, P19 to supress gene silencing and nptII that enables kanamycin 
resistance. At least 10-fold reduction in expression of the gene of interest was achieved 
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by removing the HT-mutation AUG161 using site directed mutagenesis (see 2.2.8). This 
pEAQ vector was utilized for the expression of toxic genes to keep their negative impact 
on the plant down (Thuenemann et al., 2013b).  
 TRANSIENT EXPRESSION OF PROTEINS IN NICOTIANA BETHAMIANA 
 PLANT GROWTH CONDITIONS 
N. benthamiana plants were grown in glasshouses maintained at 25 °C with 
supplemental lighting to guarantee 16 hours of daylight and watered daily.  
 AGROINFILTRATION 
A. tumefaciens containing the respective constructs were grown to stable phase in LB 
medium supplemented with the appropriate antibodies. The culture was pelleted by 
centrifugation at 2000 x g for 10 minutes and re-suspended in MMA buffer to the 
desired optical density at 600 nm (OD600). Routinely, an OD600 of 0.4 was used unless 
several constructs were co-expressed. For co-expression the constructs were mixed in a 
1:1 ratio. The agro-suspension was left at room temperature for 0.5–3 hours prior to 
pressure infiltration into the extracellular space of 3-4 week old N. benthamina leaves 
(as described in Thuenemann et al., 2013b).  
 PROTEIN EXTRACTION 
Small-scale extractions were done to test protein expression or for time-course 
purposes. Four leaf discs (approximately 100 mg) were sampled and placed into a 2 ml 
screw-cap microcentrifuge tube together with a ¼-inch ceramic bead (MP Biomedicals). 
The leaf tissue was homogenised in an Omni Bead Ruptor 24 (Camlab) at speed setting 4 
for 30 sec with 3 x the volume of protein extraction buffer. A clarification spin (16, 00 x g 
for 10 minutes) followed to separate the soluble protein from the plant cell debris.  
For the purpose of VLP preparation, large-scale extraction was carried out using 
infiltrated leaf material 4-7 dpi. It was weighed and homogenised in a Waring blender 
with 3 x the volume of extraction buffer. The crude extract was filtered over 2 layers of 
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Miracloth (Calbiochem) followed by a clarification spin at 9,500 x g for 15 minutes at 
4 °C. Afterwards, the supernatant was further purified with density gradients.   
 TRANSIENT EXPRESSION IN TOBACCO BY-2 CELLS 
 GROWTH CONDITIONS 
BY-2 cells were grown in Erlenmeyer flasks at 28 °C in the darkness whilst shaking at 
170-190 rpm. In order to maintain a healthy BY-2 suspension culture every 7 days 1 ml 
of culture was transferred into 50 ml fresh MS media.    
 CELL-PACK FORMATION AND TRANSIENT EXPRESSION 
For the purpose of transient expression of recombinant proteins in BY-2 cells, larger 
suspension cultures had to be set up. MS media was inoculated with 1/10 of its volume 
of 4-7 days old BY-2 suspension culture. After 72–144 h the cells were harvested using a 
Büchner funnel lined with filter paper and a vacuum pump to remove the media and 
form a tight cell pack which was consequently transferred into a petri dish. 
A. tumefaciens were prepared as described in 2.3.2 and dropped onto the cell-pack 
making sure to fully saturate it. Together with a water container, for stable humidity 
levels, the cell-packs were incubated in a lightproof box for 8-10 days at 28 °C.  
 PROTEIN EXTRACTION  
Small-scale extractions were carried out to test expression of recombinant proteins or 
for time-course experiments as described in Section 1.13 using a cork borer (11 mm in 
diameter) to sample 4 discs of infiltrated cell-packs. For VLP preparations infiltrated cell-
packs were spread out thinly on aluminium foil and dipped in liquid nitrogen until 
frozen. Extraction buffer was added and the cells ground to a smooth paste. The crude 
extract was filtered over 2 layers of Miracloth (Calbiochem) followed by a clarification 
spin at 9,500 x g for 15 minutes at 4 °C. Afterwards, the supernatant was further purified 
with density gradients. 
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 PROTEIN ANALYSIS 
 POLYACRYLAMIDE GEL ELECTROPHORESIS 
Protein samples were boiled 5-10 minutes in protein loading buffer before being loaded 
onto NuPAGE Bis-Tris pre-cast gels, of 4% (w/v) or 4-12% (w/v) acrylamide. As protein 
standard SeeBlue Plus 2 (Invitrogen) was used. Gels were run in NuPAGE MOPS or MES 
buffer at 200 V for 47 minutes. After electrophoresis the gels were either used for 
Western blotting (see below) or stained with InstantBlue (Expedeon) for one hour. The 
gels were destained in water for at least one hour before imaging. Protein bands of 
interest were cut out from stained PAGE-gels and identified by Mass Spectrometry by 
Dr. Gerhard Saalbach (John Innes Centre Proteomics facility).  
 WESTERN BLOTTING AND IMMUNODETECTION 
Western blotting was performed using Western blot transfer buffer to transfer the 
proteins from the gels to Amersham Hybond-ECL nitrocellulose membranes (GE 
Healthcare) for one hour at 100 V whilst maintaining a constant cooling by ice bath. 
Later on the BioRad Trans-Blot® TurboTM Transfer System was adopted for faster 
transfer times.  
Membranes were blocked in Western blot block buffer for 30-60 minutes at room 
temperature followed by adding the appropriate primary antibody for one hour. The 
membranes were washed three times for 5 minutes in wash buffer before being blotted 
in the appropriate HRP-conjugated secondary antibody for 30-60 minutes, followed by 
another three washes. Antibodies used in this study are listed below in Table 2.5.1. 
Immobilon Chemiluminescent HRP substrate (Millipore) was used to detect bound 
secondary HRP-conjugated antibody. The emitted luminescence was detected digitally 
on an ImageQuant LAS 500 (GE Healthcare). 
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Table 2.5.1: Antibodies used in Western blots. 
Name Target Species HRP Supplier 
ab26812 NNV rabbit no Abcam 
Sh16 PV VP1 sheep no NIBSC 
MAB8566 PV VP1 mouse no Millipore 
Anti-mouse Mouse IgG goat yes Life Technologies 
ab97125 Sheep IgG donkey yes Abcam 
Anti-rabbit Rabbit IgG goat yes Promega 
 VLP PURIFICATION 
 POLYETHYLENE GLYCOL (PEG) PRECIPITATION 
After the clarification spin, the crude plant extract was transferred to a glass beaker and 
particles were precipitated at 4 °C overnight by adding a solution of PEG 6000 (to the 
desired final concentration) and NaCl (final concentration of 0.2 M). The PEG precipitate 
was obtained by centrifugation for 20 min at 13,000 x g and resuspended thoroughly in 
the respective buffer.  
 DENSITY GRADIENTS 
 Sucrose cushion 
In Ultra-Clear 25x89 mm ultracentrifuge tubes (Beckman Coulter) the clarified extracts 
were underlain with sucrose solutions prepared in the appropriate buffer. The bottom 
fraction was 1 ml of 70% (w/v) sucrose solution and topped with 5 ml of 25% (w/v) or 
35% (w/v) sucrose solution depending on the VLP density. Centrifugation was carried 
out in a SureSpin 630/36 ultracentrifuge swing-out rotor (Sorvall) at 167,000 x g for 3 
hours at 4 °C. The fractions were retrieved by piercing the bottom of the tube with a 
needle.  
 Sucrose gradient 
The extracts were underlain with sucrose solutions prepared in the corresponding buffer 
in either Ultra-Clear 25x89 mm or 14x89 mm ultracentrifugation tubes, depending on 
the sample volume. The gradient was made out of sucrose solutions increasing in 
concentration (20%-60% w/v) from top to bottom. The volume of each layer was 
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adjusted according to the tube size. Centrifugation was carried out in a SureSpin 630/36 
ultracentrifuge swing-out rotor (Sorvall) at 167,000 x g for 3 hours at 4 °C or for smaller 
sample volumes in a TH641 ultracentrifuge swing-out rotor (Sorvall) for 2, 5 hours at 
4 °C. The bottom of the tube was pierced with a needle to retrieve the fractions and the 
material was collected as it dripped out.  
 NYCODENZ GRADIENT 
Further purification of VLP samples was achieved by Nycodenz gradient 
ultracentrifugation. Nycodenz solutions of 20% to 60% (w/v) concentrations were 
prepared in the appropriate buffer and used to underlay the samples in Ultra-Clear 
14x89 mm ultracentrifugation tubes. Centrifugation was carried out in a TH641 
ultracentrifuge swing-out rotor (Sorvall) for 22-24 hours at 247,103 x g at 4 °C enabling 
separation of VLPs from persistent plant contaminants. Desired fractions were collected 
either by piercing the sides of the tubes and sucking out the material or by piercing a 
hole in the bottom and collecting the sample as it dripped out.  
 DIALYSIS  
Dialysis was used as a method to remove the density gradient medium from samples 
and for buffer exchange. Two different methods of dialysis were used depending on the 
sample. SnakeSkin dialysis tubing (Thermo Scientific) with 10 kDa molecular weight cut-
off (MWCO) was used as per manufacturer`s instructions. Buffer was exchanged twice 
within at least 24 hours of dialysis. Also PD10 columns (GE healthcare) were used and 
the manufacturer`s spin protocol was followed.  
 PROTEIN CONCENTRATION 
For small amounts of temperature-insensitive samples the SpeedVac (Savant) was used 
to reduce the sample volume by vacuum evaporation. Larger volumes of durable 
material were pelleted using a TH641 ultracentrifuge swing-out rotor (Sorvall) for 1, 5 
hours at 197,819 x g at 4 °C, followed by resuspension in a small volume of buffer. 
Temperature sensitive and fragile samples were concentrated using the Amicon Ultra-15 
Centrifugal Filter Units (Millipore) with a 100 kDa MWCO. This method allows buffer and 
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small solutes to pass through the membrane while gently concentrating the VLPs at a 
controlled temperature.   
 VLP ANALYSIS 
 TRANSMISSION ELECTRON MICROSCOPY 
TEM was routinely used to assess the integrity of VLPs. Samples were adsorbed onto 
plastic and carbon-coated copper 400 mesh grids, washed with several drops of water 
and then stained with 2% (w/v) uranyl acetate for 15-30 seconds. Grids were imaged 
using a FEI Tecnai G2 20 Twin TEM with bottom-mounted digital camera. 
 NATIVE AGAROSE GEL ELECTROPHORESIS 
For the detection of encapsidated nucleic acid, purified VLPs were mixed with Orange-G 
loading dye and run in duplicate on native agarose gels (1% w/v in TBE) for 2 hours at 
60 V. One gel was stained in a 0.5 µg/ml ethidium bromide bath for 20 minutes and to 
detect nucleic acid bands it was visualised under UV light. The other gel was stained in 
InstantBlue (Expedeon) to visualize protein.  
 LOWRY ASSAY 
In order to determine protein concentration of purified VLP samples the Modified Lowry 
Assay Kit (Thermo Fischer Scientific) was applied, closely following the manufacturer’s 
microplate procedures. The OD750 of the wells was read on a POLARstar Omega plate 
reader (BMG Labtech). A standard curve was created in Microsoft Excel by plotting the 
average blank-corrected 750 nm values for each BSA standard against its concentration 
in µg/ml. This standard curve was employed to determine the protein concentration of 
the samples.  
 FURTHER ANALYSIS 
For experiments that could not be carried out at the John Innes Centre samples were 
sent to collaborators. Immunological tests in animals were conducted at The National 
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Institute for Biological Standards and Control (NIBSC) and for cryo-electron microscopy 
(Cryo-EM) particles were sent to the University of Oxford (polio) or the University of 
Leeds (NNV).  
 EXTRACTION AND ANALYSIS OF RNA 
 RNA EXTRACTION FROM VIRUS PARTICLES 
Purified virus particles and virus-like particles were incubated in TEN/NET buffer at 60 °C 
for 5 minutes together with 2% (w/v) SDS to denature the coat proteins. The same 
volume of a 1:1 mixture of phenol and chloroform was added and mixed amply by 
vortex. The mixture was centrifuged at 16,000 x g for 10 minutes and afterwards the 
aqueous layer was transferred into a fresh tube. To precipitate RNA from the aqueous 
fraction, 0.2 volumes of 3 M sodium acetate at pH 5.5 and 2.5 volumes of ice-cold 100% 
ethanol were added and the sample was kept at -20 °C overnight. The sample was 
centrifuged at 16,000 x g for 15 minutes at 4 °C to recover the RNA pellet. The pellet was 
washed with 70% (v/v) ethanol, air-dried and resuspended in a small volume (5-10 μl) of 
DEPC-treated sterile water. The concentration of extracted RNA was measured using a 
NanoDrop spectrophotometer and the samples were stored at -80 °C. 
 ELECTROPHORESIS OF ENCAPSIDATED RNA 
Extracted RNA was analysed by agarose gel electrophoresis under denaturing 
conditions. Samples were prepared as follows: 
Extracted RNA 4.5 µl 
5 x FGRB 2.0 µl 
Deionised formamide 10.0 µl 
12.3 M Formaldehyde 3.5 µl 
 20.0 µl 
The samples were heated at 65 °C for 10 minutes to denature RNA and placed on ice 
immediately. 0.5 μl ethidium bromide (10 mg/ml) and 2 μl Orange-G loading dye were 
mixed into the samples and loaded on a 1.2% agarose gel prepared in 1x FGRB and 
2.2 M formaldehyde. Additionally, 5 μl of Transcript RNA marker from Sigma was 
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prepared as above and run as a standard. Samples were electrophoresed at 60 V for 
1.5–2 hours and RNA bands visualised under UV light (wavelength = 302 nm) and imaged 
using Gene Snap (Syngene). 
 PHOTOGRAPHY 
Photography was used to document detrimental effects on leaf tissue of certain 
constructs, to visualize density gradients and to display proteins bands on stained SDS-
PAGE gels. Excitation of fluorescent proteins was achieved using Blak-Ray lamps (Ultra-
Violet Product Ltd). Unless otherwise specified, I took the photographs. 
 SOFTWARE 
Vector NTI Advance 11.5 (Invitrogen) was used for vector design, in silico cloning 
strategies, sequence analyses and alignments, as well as predictions of protein 
sequences, sizes and attributes.  
The BLAST function of the National Center for Biotechnology Information website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used both for nucleotide and protein 
sequence alignments.  
The GenBank database of the National Center for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/genbank/) was used to find sequences of interest.  
Microsoft Office software suite was used for data analysis and making figures.   
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Chapter 3: PRODUCTION AND CHARACTERISATION OF NNV VLPS 
 INTRODUCTION 
Nervous necrosis virus (NNV) is a member of the family Nodaviridae that consists of two 
genera: Alphanodavirus, which usually infects insects, and Betanodavirus, also known as 
piscine nodavirus (Mori et al., 1992). NNV infects over 40 marine fish species and is a 
massive threat for the fish industry as it causes mass mortality in many economically 
important fish species worldwide (Tan et al., 2001; Walker and Winton, 2010), such as 
the Japanese parrotfish (Oplegnathus fasciatus) (Yoshikoshi and Inoue, 1990), 
barramundi (Lates calcarifer) (Glazebrook, 1990), European sea bass (Dicentrarchus 
labrax) (Breuil et al., 2001), turbot (Scophthalmus maximus) (Bloch, 1991), redspotted 
grouper, (Epinephelus akaara) (Mori et al., 1991) and Atlantic halibut (Hippoglossus 
hippoglossus) (Grotmol et al., 1997). The annual market of for example grouper larvae is 
worth more than 300 million US dollars (Kai and Chi, 2008).  
Wild-type NNV is a small, spherical, nonenveloped virus carrying a bipartite positive-
sense RNA genome. RNA1 (3.1 kb) encodes two proteins: the RNA-dependent RNA 
polymerase (102 kDa), important for RNA transcription and replication and also protein 
B (10 kDA) which is expressed from a subgenomic RNA3 (0.4 kDa) (Friesen and Rueckert, 
1982; Guarino et al., 1984; Saunders and Kaesberg, 1985). Protein B is a non-structural 
protein involved in inhibition of host RNA interference (Chao et al., 2005; Guo et al., 
2003; Mori et al., 1992). RNA2 (1.4 kb) encodes the coat protein precursor alpha 
(43 kDa) and has additional function in regulating the synthesis of RNA3 (Dasgupta et al., 
1984; Friesen and Rueckert, 1984; Mori et al., 1992). The major protein produced during 
viral infection is coat precursor protein alpha which rapidly self-assembles into 
provirions (Friesen and Rueckert, 1981; Gallagher and Rueckert, 1988). Provirions 
mature by spontaneous autocatalytic cleavage of the coat protein alpha post assembly; 
producing proteins beta (38 kDa) and gamma (5 kDa) which remain part of the mature 
virion (schematic representation Figure 3.1-1) (Hosur et al., 1987). It is assumed that 
maturation cleavage plays a role in infection when the RNA gets delivered into the host 
cell, a model that is similar to that proposed for poliovirus where VPO gets cleaved into 
VP2 and VP4 during RNA uptake (Cheng et al., 1994; Schneemann et al., 1992). 
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Figure 3.1-1: Genome organisation of NNV. RNA1 encodes two proteins: the RNA-dependent 
RNA polymerase and also protein B, which is expressed from a subgenomic RNA3. RNA2 encodes 
the coat protein precursor alpha and has additional function in regulating the synthesis of RNA3. 
The major protein produced during viral infection is coat precursor protein alpha which rapidly 
self-assembles into provirions. Provirions mature by spontaneous autocatalytic cleavage of the 
coat protein alpha post assembly; producing proteins beta and gamma.  
NNV infection causes viral nervous necrosis (VNN) due to NNV-induced lesions in the 
central nervous system and in the retina. The results are abnormal swimming behaviour, 
dark colouring and massive mortality (Bovo et al., 1999; Grotmol et al., 1997; Thiery et 
al., 1999). VNN often causes mortality rates higher than 99% in larvae and early juvenile 
stages and can result in rapid loss of the hatchery; hence the development of an 
effective and viable vaccine is of great interest of the aquaculture industry. Adult fish are 
susceptible as well but mortality rates are lower (Lin, 2007).  
In general, NNV can be transmitted in two ways: vertically and horizontally. In vertical 
transmission the broodfish transfers the virus to their offspring by shedding viruses 
through gonadal fluids whereas the transmission between individual fish of the same 
generation is called horizontal transmission. Vertical transmission of the virus from the 
broodfish to the eggs has been reported in several fish species like, striped jack 
(Pseudocaranx dentex), sea bass (Dicentrarchus labrax), and barfin flounder (Verasper 
moseri) (Grotmol and Totland, 2000; Mushiake et al., 1994; Peducasse et al., 1999). The 
only available control strategies are segregation or elimination of NNV carrier-spawners 
(Mushiake et al., 1994; Watanabe et al., 2000). Furthermore, sterilisation of the eggs has 
been tested using several techniques, including washing the eggs with ozonated sea-
water, which efficiently inactivated NNV. None of the larvae from virus-exposed eggs 
washed with ozonated sea-water developed VNN (Arimoto et al., 1996; Grotmol and 
Totland, 2000). However, such harsh treatment may enhance the risk of causing 
abnormal fry, delay of hatching and reduced hatching rate (Arimoto et al., 1996) and the 
safe dosage of ozone or chemicals differs between species. Horizontal transmission has 
been demonstrated experimentally within the same species (Glazebrook, 1990; 
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Peducasse et al., 1999) but also between species by using filtered homogenates from 
diseased redspotted grouper juveniles to transfer NNV to striped jack larvae (Arimoto et 
al., 1996; Mori et al., 1991). These experimental results strongly support the assumption 
that horizontal transmission of NNV takes place under natural conditions where healthy 
fish cohabitate with carriers. Their cannibalistic behaviour facilitates the horizontal 
spread of the virus.  
All jawed vertebrates share the same fundamental parts of host defence. There are two 
main layers of immune responses: innate immune responses and adaptive immune 
responses. The innate immune system creates a fast, non-specific reaction to the 
pathogen infecting the host organism. If the pathogen cannot be defeated with innate 
defences, the adaptive immune system will attack the pathogen with specificity and 
memory (Rauta et al., 2012). The adaptive (or acquired) immune system employs two 
types of lymphocytes: T cells are major components of cell-mediated immunity whereas 
B cells produce immunoglobulins (Ig) that are key elements of humoral immune 
responses (Mashoof and Criscitiello, 2016). T cell receptors and B cell receptors (plasma 
membrane anchored Ig, as opposed to secreted Ig that is also known as antibody) are 
extremely diverse molecules at their antigen binding tips.  
In principle the immune system of the teleost fish is very similar to that of higher 
vertebrates. However, their immune system is conditioned by their aquatic habitat and 
also by their poikilothermic condition (Tort et al., 2003). Fish are free living organisms 
from early embryonic stages of live. Thus, compared to terrestrial animals, fish have a 
greater challenge coping with high microbial loads, which bombard their mucosal 
barriers. Consequently, innate immunity is their fundamental defence mechanism and 
the skin, gills and the gut are the first line of defence against pathogens (Hitzfeld, 2016; 
Uribe et al., 2011). They are covered in mucus, which contains antibodies as well as 
antimicrobial proteins, like lysozyme, phosphatases and trypsin (Fast et al., 2002). In 
addition, the epidermis carries defending cells like lymphocytes and macrophages (Uribe 
et al., 2011). In mammals, nonspecific cellular immune responses are executed by 
cytotoxic cells, known as natural killer cells. The nonspecific cytotoxic cells of fish are 
morphologically distinct from the large granular lymphocytes of mammals but they are 
suggested to be functionally similar (Evans and Jaso-Friedmann, 1992). The complement 
system in higher vertebrates can be activated in three ways: via the classical, the 
alternative and the lectin pathway. All three pathways have also been described in 
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several teleost groups and it appears to be one of the central immune responses in fish 
(Endo et al., 1998; Nonaka et al., 1984). However, the main difference in fish is that they 
possess multiple isoforms of the key activation molecule C3, whereas mammals carry 
only one isoform (Gongora et al., 1998; Kuroda et al., 2000). The biological meaning of 
the variability may be the specialisation to bind specific surfaces and to increase 
efficiency in eliminating immunogens (Tort et al., 2003).  
Same as other vertebrates, fish have organs whose main function is immune defence. 
Most of the lymphoid organs present in mammals are also found in fish, expect for the 
lymphatic nodules and the bone marrow (Tort et al., 2003). The immune organs in 
teleost fish comprise the thymus, kidney, spleen, and liver. The thymus is responsible for 
the production of T lymphocytes which are involved in macrophage function and B-cell 
stimulation (Hitzfeld, 2016; Uribe et al., 2011). The functional equivalent of the bone 
marrow in vertebrates is the kidney of teleost fish. It mostly contains antibody-
producing B lymphocytes, which are important in the development of humoral immunity 
and immunological memory. The spleen is the major site of macrophage phagocytosis of 
blood-borne antigens and the liver of teleost fish is involved in presentation of 
particulate antigens (Hitzfeld, 2016).  
As in mammals, teleost ﬁsh possess adaptive immune systems based on antigen 
recognition by Igs, T cell receptors (TCR), and major histocompatibility complex 
molecules (MHC) I and MHC II molecules. The basic structure of Ig consists of two 
identical heavy (H) chains and two identical light (L) chains (exceptions in shark and 
camelids). Both heavy and light chains contain one N-terminal variable domain and one 
or more C-terminal constant domains. Variable domains participate in antigen 
recognition and the domains that comprise the constant regions mediate effector 
functions of the antibody molecule. Such humoral immunity mediated by Ig includes 
tagging of pathogens for destruction by phagocytes, neutralization of toxins and viruses, 
and activation of the complement cascade (Mashoof and Criscitiello, 2016). Three Ig 
heavy chain isotypes have been described in teleosts: IgM, IgD, and IgT. While IgM 
constitutes the main systemic immunoglobulin, the role of IgD is unknown. IgT functions 
analogously to mammalian IgA by protecting mucosal surfaces (Sunyer, 2013). Both IgM 
and IgD are expressed in B cells found both in systemic and mucosal lymphoid areas, 
whereas IgT is uniquely expressed by a B cell subset devoid of IgM and IgD (Magadan et 
al., 2015; Rombout et al., 2014). Ig of teleost fish is found in the skin, gut, gill mucus, 
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bile, and systemically in the plasma (Lobb and Clem, 1981; Rombout et al., 1986). Most 
fish respond to primary antigenic challenges by producing specific antibodies, whereas 
the response to secondary challenge is generally faster and of greater magnitude. This 
makes vaccination an attractive strategy for control of infectious disease in the 
aquaculture industry (Mashoof and Criscitiello, 2016; Morrison and Nowak, 2002). 
Studies indicate that a transfer of maternal antibody takes place in many fish species. 
The finding raises the possibility that female fish could be vaccinated to provide their 
offspring with protection against various pathogens. However, it is still questionable 
whether transfer of maternal antibody confers protection against specific infection 
(Castillo et al., 1993; Lillehaug et al., 1996; Sin et al., 1994). 
Adaptive immunity based on B and T cells is present in both systemic and mucosal 
immune systems in teleost fish. At the mucosal barriers, e.g. the skin,  gills and the gut, 
the B and T lymphocytes induce and regulate the secretion of antibodies (Kunisawa and 
Kiyono, 2005). Biochemical analyses showed differences in mucosal and serum Igs of 
fish, revealing the presence of a specialised mucosal antibody: IgT (Lobb, 1987; Zhang et 
al., 2011). However, the story of how mucosal immune systems defend teleosts is far 
from understood, especially the mechanisms by which memory is established and 
maintained at the mucosa (Salinas, 2015). Peyer's patches, antigen transporting M cells, 
IgA- and the IgM joining J chain, which are essential components of the mammalian 
mucosal immune system, are not yet reported in teleost fish (Rombout et al., 2011; 
Rombout et al., 2014). Novel tools will hopefully lead to conclusions in this area of 
research, thus benefit the use of oral vaccines in fish (Salinas, 2015).  
The most common vaccination methods in fish are injection and immersion. Vaccines 
that have been administered via injection, elicit mostly an internal immune response 
and can therefore be considered as systemic vaccines. However, in fish intramuscular 
injection can also induce a certain degree of mucosal responses (Rombout et al., 2014; 
Valdenegro-Vega et al., 2013). Immersion vaccination of fish leads to uptake by the skin, 
the gills and the gut, subsequently inducing local responses (Wendelaar Bonga, 1997). 
Oral vaccines however, can only be effective if the antigens reach the correct inductive 
sites. If an adequate amount of antigen reaches the end gut, local as well as systemic 
antibody responses can be induced in fish (Rombout et al., 1986). This can be achieved 
with the support of adjuvants. 
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Adjuvants can be classified into two groups: group 1 adjuvants influence the fate of the 
vaccine antigen in time, place, and concentration, ultimately improving its immune-
availability. Group 2 adjuvants co-stimulate signals during antigen recognition that will 
provide an environment for the most favourable antigen-specific immune response 
(Schijns, 2001; Tafalla et al., 2013). Despite severe side effects, traditional adjuvants 
such as mineral oils are routinely used in different vaccines for fish. Particularly 
interesting for the work presented in this thesis is the use of adjuvants in orally 
administered vaccines. Microparticles belong to group 1 adjuvants and offer a promising 
alternative to oil emulsions (Sinyakov et al., 2006). Biodegradable Poly-(lactide-co-
glycolide) (PLGA) polymers have successfully been deployed in oral fish vaccines (Lavelle 
et al., 1997; Tian and Yu, 2011). PGLA microparticles enclose the antigen and protect it 
against destruction in the stomach. The antigen is then released by diffusion through 
pores and by matrix degradation. Adjuvants of the second group, which have 
successfully been used in oral administration of vaccines are β-Glucans. They are known 
to stimulate the non-specific immune response of both mammals and fish (Tafalla et al., 
2013).  
In order to control the spread of NNV and to protect fish farms from the virus a vaccine 
has to be developed which is inexpensive and potent but, most importantly, easy to 
administer. Several vaccine candidates have been engineered but they need to be 
injected into each fish separately. One example is the VLP-based vaccine of Liu and 
colleagues who expressed NNV VLPs in E. coli for intramuscular immunisation of 
grouper. The results reveal that 1 µg VLPs/g of fish body weight is enough to stimulate a 
full-scale immune response and the antibody titre was detected at 1 week and 
increased thereafter (Liu et al., 2006). The VLPs induced a rapid and specific humoral 
immune response that protected grouper against virus infection. This demonstrated the 
potency of NNV VLPs as candidate vaccines  
Besides the fact that injecting individual fish is usually not feasible, the highest mortality 
occurs in larvae and the size of most fish species at the larval stage is too small to be 
immunised by injection (Lin, 2007). One alternative is the bath immunisation with 
inactivated virus. Kai and colleagues investigated the potential of bath immunisation of 
grouper larvae against VNN disease with inactivated NNV (Kai and Chi, 2008). After 
inactivation the virus particles were mixed with melted hydrogenated plant oil to form 
solid lipid nanoparticles which encapsulates and stabilises the particles; making it more 
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resistant to stomach acids. The encapsulated vaccine was able to enter the fish through 
its body surface or via the digestive tract. The results showed effective protection of the 
fish when bath immunised with nano-encapsulated inactivated betanodavirus (Kai and 
Chi, 2008). The biggest enemy of oral vaccines is the gastrointestinal tract. The success 
of an oral vaccine depends on a method that protects the antigen from gastrointestinal 
digestion and effectively delivers antigen to the hindgut of fish. Lin and colleagues came 
up with a very clever technique to protect their recombinant subunit vaccine from the 
stomach acids of the fish. They expressed the capsid protein in E. coli, killed the bacteria 
and then fed it to Artemia nauplii; a shrimp which naturally feds on bacteria and is a 
common starter feed for fish larvae. The Artemia containing the bacteria were used 
alive for oral vaccination or were frozen at −20 °C for later use (Lin, 2007). In this case 
two biolayers, the E. coli cell wall and the Artemia cuticle, protected the antigen from 
gastrointestinal degradation and enabled delivery of sufficient antigen to the hindgut 
resulting in protection of grouper larvae from VNN (Lin, 2007). Another hands-off 
vaccination technique has been tried where fish were reared at 17 °C and challenged 
with live NNV. Even though the virus successfully infected the fish, no mortality was 
observed. This finding is based on the temperature-dependent multiplication rate of 
NNV, because of the low temperature its virulence was reduced (Nishizawa et al., 2012). 
However, this depends upon the virus strain and the fish species (Chi et al., 1999) and is 
therefore not totally reliable.  
Overall it becomes clear that several potential vaccines have been developed but none 
has been marketed yet. The reasons are many-sided but mostly feasibility of 
administration, costs and effectiveness are the factors that stop those vaccine 
candidates from making it to industrial production. The aim of this project was to 
express NNV VLPs in plants which can function as a vaccine protecting all developmental 
stages of fish against NNV. Recombinant expression of NNV VLPs has already been 
achieved by Lin et al. in 2001. Using Sf21 insect cells and a recombinant baculovirus 
vector, they expressed the NNV capsid protein which assembled into VLPs. However, 
they recognized differences in the density of the VLPs and later found out that their 
insect cell-produced VLPs encapsidate random RNA of different sizes (Lin et al., 2001). 
This result is consistent with the results obtained with insect nodavirus VLPs which are 
known to package random cellular RNAs when recombinantly expressed (Schneemann 
et al., 1993). Lin and colleagues used the VLPs for cryo-EM and generated a ~23 Å 
reconstruction. Though by modern standards this is a rather low resolution structure, it 
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was sufficient for the authors to state that their VLPs closely resemble the native virus in 
size and geometry (Lin et al., 2001).  
This chapter describes recombinant expression of NNV coat protein in plants with the 
aim of generating properly assembled NNV VLPs which might subsequently be used as a 
vaccine against VNN. It also describes the development of optimal extraction and 
purification methods for the plant-expressed NNV VLPs as well as the characterisation of 
their properties.   
 FIRST EXPRESSION OF NNV COAT PROTEIN IN PLANTS 
In order to express NNV VLPs in plants the region of RNA2 encoding the capsid protein 
(GeneBank accession number EF617326.1) was codon optimised for the expression in 
N. benthamiana and ordered from GeneArt (Life Technologies) with flanking Agel and 
Xhol restriction sites allowing cloning via restriction digest into our expression vector of 
choice forming pEAQ-HT-NNV. The construct was transformed into E. coli for 
propagation and then into agrobacteria. Before agroinfiltration the sequence was 
confirmed by sequencing (see section 2.2.7). Infiltrated leaves were harvested 6 dpi 
when they started to show signs of yellowing (Figure 3.2-1). Out of experience yellowing 
(not to be mistaken for necrosis) is a positive sign for high expression levels. After 
homogenisation and crude purification, the plant extract (see section 2.6) was run 
through a sucrose gradient with fractions ranging from 20% (w/v) to 60% (w/v) as shown 
in Figure 3.2-1 B.  
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Figure 3.2-1: Overview of the workflow. A) Leaf infiltrated with pEAQ-HT-NNV 6 dpi. B) Clarified 
plant extract was underlain with a discontinuous sucrose gradient. C) After ultracentrifugation 
the sucrose gradient was fractioned by piercing the bottom of the tube.  
After ultracentrifugation the sucrose gradient was fractionated from the bottom and 
each fraction was run on a SDS-PAGE gel, which was stained with InstantBlue and also 
transferred onto a membrane for Western blotting to analyse the protein expression 
(Figure 3.2-2). 
 
Figure 3.2-2: Analysis of NNV coat protein expression. Clarified leaf extract was separated on a 
discontinuous 20%-60% (w/v) sucrose gradient and after ultracentrifugation fractionated from 
the bottom. A) Sucrose fractions were run on SDS-PAGE and the protein stained with InstantBlue. 
B) A duplicate of the SDS-PAGE was transferred on a nitrocellulose membrane for 
immunodetection. The Western blot was probed with anti-NNV (ab26812) antibody. M = SeeBlue 
Plus 2 with molecular weights indicated. SN = Supernatant. The red box and arrow indicate 
position of NNV coat protein.  
Production and characterisation of NNV VLPs 
57 
 
Detecting expression of a particular protein in a crude plant extract on a SDS-PAGE gel 
can be difficult because of the large background of endogenous plant proteins which are 
still in the sample. It is particularly difficult when the desired protein is not well 
expressed. However, faint bands of roughly the right size for the NNV coat protein alpha 
of 43 kDa can be detected in the 30% and 40% sucrose fraction on the SDS-PAGE gel 
shown in Figure 3.2-2 A. These bands were excised from the stained gel, sent for mass 
spectrometry analysis and the protein was identified as nodavirus coat protein. A more 
precise method is Western blotting, where specific antibodies are used for protein 
detection. Therefore, a duplicate of the SDS-PAGE gel was transferred onto a membrane 
and blotted with anti-NNV antibody Figure 3.2-2 B. It shows signals in the 50%, 40% and 
30% (w/v) fraction and the strongest band is in the 40% (w/v) fraction, which confirms 
the results collected so far.  
The above results confirm expression of the NNV coat protein in plants. The coat protein 
was detected in a region of the gradient with higher sucrose concentrations which 
implies that the protein has been incorporated into structures of significant size; 
however, it does not automatically confirm VLP assembly. This can only be verified by 
TEM which is presented later in this chapter. 
It is significant that the protein detected after plant-based expression has an apparent 
size of 43 kDa. During NNV infection the major protein produced is the precursor protein 
alpha (43 kDa) which self-assembles into provirions (Friesen and Rueckert, 1981; 
Gallagher and Rueckert, 1988). Provirions mature by spontaneous autocatalytic cleavage 
of the coat protein alpha; producing proteins beta (38 kDa) and gamma (5 kDa) which 
remain part of the mature virion (Hosur et al., 1987). VLPs are non-infectious, as they do 
not contain genomic material, and therefore do not undergo maturation cleavage. This 
explains the larger molecular mass of the coat protein observed in the plant made VLPs 
compared to the coat protein isolated from infectious virus where it gets cleaved into 
proteins beta and gamma.  
Summary of section 3.2: NNV coat protein is expressed in plants and when run through 
a discontinuous sucrose gradient it collects in the 30% and 40% (w/v) fraction. An 
indication towards assembled particles but this has to be confirmed by TEM.  
 
Production and characterisation of NNV VLPs 
58 
 
 OPTIMISATION OF PROTEIN YIELD 
 TIME COURSE EXPERIMENT 
In the previous section expression of the NNV coat protein was confirmed (Figure 3.2-2). 
In order to determine the day with the highest level of desired protein a time course 
analysis was conducted. For this purpose, a plant was infiltrated with pEAQ-HT-NNV and 
leaf discs were sampled 1 to 10 dpi. Protein was extracted and expression analysed on a 
Western blot (Figure 3.3-1).  
 
Figure 3.3-1: Expression of NNV coat protein over time. Exactly the same amount of infiltrated 
leaf material was sampled from a plant expressing NNV coat protein 1 to 10 dpi. The protein was 
extracted and analysed on a Western blot which was probed with anti-NNV (ab26812) antibody. 
M = SeeBlue Plus 2 with molecular weights indicated. C- = leaf material infiltrated with 
pEAQ-HT-EV (empty vector control). Red arrow indicates position of coat protein (43 kDa).  
The above Western blot demonstrates accumulation of NNV coat protein already 2 dpi 
with a steady level until 5-6 dpi after which it decreases and completely disappears at 
9 dpi. One can also observe bands of 70-75 kDa appearing already 1 dpi and slowly 
decreasing whilst the amount of coat protein rises. These bands could be dimers of the 
coat protein but this would need to be confirmed. Similar  experiments using the same 
vector but expressing GFP instead of the NNV coat protein revealed that the highest 
levels of expression on day 6 (Saxena, 2010). Combining this knowledge with the result 
of the time course analysis (Figure 3.3-1) results in 4-6 dpi for maximum NNV coat 
protein yield. It also suggests that accumulation of NNV coat protein occurs more quickly 
than GFP and shows the value of time courses. 
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 OPTIMISATION OF THE AGROBACTERIUM SOLUTION 
Another factor that might influence protein expression is the OD600 of agrobacterium 
suspensions used for infiltration. As default we use an OD600 of 0.4 in the lab which has 
proven to work best when expressing GFP (Saxena, 2010). However, I was curious to 
know if a lower or higher OD has an impact on the expression level of the NNV coat 
protein. For that reason, A. tumefaciens harbouring pEAQ-HT-NNV were resuspended in 
MMA buffer to an OD600 of 0.2, 0.4, 0.6 or 0.8 and infiltrated into separate plants. Leaf 
discs were sampled 5, 6 and 7 dpi and protein was extracted.  
 
Figure 3.3-2: Finding the most efficient OD600 for agro-infiltration and expression of NNV coat 
protein.  A. tumefaciens carrying pEAQ-HT-NNV was resuspended in MMA buffer to an OD600 of 
0.2, 0.4, 0.6 or 0.8 and infiltrated into separate plants. Leaf discs were sampled 5, 6 and 7 dpi and 
protein was extracted. Western blot was probed with anti-NNV (ab26812) antibody. M = SeeBlue 
Plus 2 with molecular weights indicated.  
The protein samples were run on a SDS-PAGE and transferred on a membrane for 
immunodetection using anti-NNV antibody. The blot is depicted in Figure 3.3-2 but no 
striking differences between the samples are apparent. Though especially on 5 dpi and 
7 dpi there is a slightly increased amount of protein detected in the sample of OD600 0.4. 
Overall the lowest (0.2) and highest (0.8) OD600 appear least beneficial which confirms 
that an OD600 of 0.4 is the best concentration of agrobacteria for expressing NNV coat 
protein in plants.  
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Summary of section 3.3: Using an A. tumefaciens solution with an OD600 of 0.4 achieves 
highest yields of NNV coat protein 4-6 days after infiltration.  
 OPTIMIZATION OF PARTICLE PURIFICATION 
Precipitation with polyethylene glycol is a standard method used for the concentration 
of virus particles when handling large volumes of liquids (Leberman, 1966). Therefore, I 
wanted to test if it would also work with the NNV VLPs and tried different PEG 
concentrations. Crude plant extracts were mixed with 2%, 4% and 6% (w/v) PEG 
overnight at 4 °C, centrifuged and the pellets resuspended in TBS buffer followed by 
standard sucrose gradient ultracentrifugation. As a control one sample was not treated 
with PEG. The sucrose fractions were run on SDS-PAGE gels and shown in Figure 3.4-1.    
 
Figure 3.4-1: Trying PEG for NNV VLP concentration. Crude plant extracts containing NNV VLPs 
were mixed with 2%, 4% and 6% (w/v) PEG following the standard PEG precipitation protocol. 
Afterwards the resuspended samples were separated on a standard sucrose gradient. As a 
control one sample was not treated with PEG. After ultracentrifugation each fraction was 
retrieved by piercing the bottom of the tube and run on SDS-PAGE. Red arrows indicate the NNV 
coat protein. M = SeeBlue Plus 2 with molecular weights indicated. SN = Supernatant.  
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Even though precipitation with 4% (w/v) PEG works well with many viruses the result 
shown in Figure 3.4-1 indicate a problem with NNV VLPs using this method. When 
applying the lowest concentration of only 2% (w/v) PEG, bands of the expected size are 
detected in the 30% and 40% (w/v) sucrose fraction; an outcome which is in accord with 
the untreated control sample. However, there is also a ~43 kDa band in the 20% (w/v) 
sucrose visible which suggests non assembled coat protein or broken particles (see red 
arrows in Figure 3.4-1). Samples that were treated with higher PEG concentrations are 
completely free of coat protein. No bands of the correct size are apparent on the SDS-
PAGE gels. One can conclude that PEG precipitation does not benefit purification or 
concentration of NNV VLP samples; it rather seems to have a destabilising effect on the 
particles. In the 2% (w/v) PEG treated sample coat protein appears in the 20% (w/v) 
sucrose fraction which can be a result of broken VLPs. Even more evident becomes the 
negative effect in the 4% and 6% (w/v) PEG treated samples, where NNV coat protein 
cannot be seen at all. It is likely that the PEG destroyed the VLPs and the unassembled 
coat protein remained in the SN but is too dilute to be detectable on the SDS-PAGE gel. 
Another possible explanation is failure to resuspend the pellets after PEG precipitation.  
Because PEG precipitation did not help concentrating the sample another approach was 
tried. Clarified plant extract was centrifuged through a sucrose gradient and the 30% 
and 40% (w/v) sucrose fractions containing the NNV VLPs (see SDS-PAGE and Western 
blot Figure 3.4-2) were combined and dialysed. After dialysis the large sample volume 
was subject to ultracentrifugation in order to pellet and simultaneously concentrate the 
VLPs.  
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Figure 3.4-2: Pelleting NNV VLPs for concentration and purification. Clarified plant extract 
containing NNV VLPs was run through a sucrose gradient. The 30% and 40% (w/v) sucrose 
fraction harbouring the NNV VLPs were combined, dialysed and then pelleted. Two different 
buffers were used for resuspension. Lane 1 = PBS buffer. Lane 2 = TBS buffer. Western blot was 
probed with anti-NNV (ab26812) antibody. M = SeeBlue Plus 2 with molecular weights indicated. 
Red boxes and arrow indicate NNV coat protein alpha. Black arrow indicates mature NNV coat 
protein beta.  
Pelleting is only successful when the particles are very stable, otherwise they can break 
under the strong forces applied in the ultracentrifuge. Here, after ultracentrifugation the 
pellet was thoroughly resuspended in either PBS buffer or TBS buffer in order to test 
which buffer stabilises the VLPs best. The samples were run on a SDS-PAGE and also a 
Western blot was conducted to analyse the purity of the sample and also the stability of 
the NNV VLPs. In Figure 3.4-2 A the pelleted samples are very clean and no obvious 
contamination is detectable. When comparing the pelleted samples to the original 30% 
and 40% (w/v) fraction it becomes apparent how well the pelleting step improved 
purity. However, there are no apparent differences between the results obtained with 
the two buffers as determined by the SDS-PAGE. Looking at the Western blot (Figure 
3.4-2 B) in lane 1 the NNV VLP pellet which was resuspended in PBS-buffer not only has 
a strong band of the correct size for the coat protein but also a slightly less distinct band 
of lower molecular mass. This band is not present in lane 2 where TBS buffer was used 
for resuspension. Most likely this lower molecular mass protein which was detected by 
the anti-NNV antibody is degraded coat protein or even the mature coat protein beta. 
Nodavirus provirions are known to be less stable until they undergo maturation, where 
the coat protein gets cleaved into two smaller proteins of 37 kDa and 5 kDa (see 3.1) 
(Hosur et al., 1987; Schneemann et al., 1992). As there is no such band in lane 2 one can 
conclude the reason for the degradation is the PBS buffer and not the pelleting. The 
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biggest difference between PBS and TBS buffer is their pH value. TBS is with a pH of 8.5 
closer to the natural pH of ocean water (pH 8.2-8.4) than PBS buffer with pH 7.2.  It 
seems like the TBS buffer stabilises the VLPs or hinders maturation.     
Summary of section 3.4: In summary the results of this chapter taught me that the NNV 
VLPs survive pelleting which is an easy way to concentrate them when dealing with 
larger sample volumes; whereas PEG precipitation seems to destabilise the VLPs or 
render them insoluble. Most comfortable are NNV VLPs in a buffer with a rather alkaline 
pH like TBS. The preference for an alkaline pH may reflect the adaptation of the particles 
to the pH of ocean water, which is 8.2 to 8.4.  
 CHARACTERISATION OF NNV VLPS 
 TRANSMISSION-ELECTRON MICROSCOPY (TEM) 
Until now the focus was on characterising the NNV coat protein and the results 
presented so far strongly indicate VLP assembly, but correct assembly of the protein and 
finally formation of NNV VLPs still had to be confirmed via TEM. The following drawing 
(Figure 3.5-1) explains the process adopted for NNV VLP purification in order to produce 
a concentrated sample which could be further analysed with the electron microscope.  
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Figure 3.5-1: Sketch of NNV VLP purification. Clarified plant extract containing NNV VLPs was 
underlain with 5 ml of 25% (w/v) sucrose and 1 ml 70% (w/v) sucrose and ultracentrifuged. The 
bottom fraction was retrieved and after dialysis run through a discontinuous sucrose gradient of 
20%-60%. Routinely NNV VLPs were located by immunodetection and the respective fractions 
pooled and dialysed. The VLPs were concentrated by pelleting and resuspended in a small 
volume of TBS to obtain a pure sample of NNV VLPs.  
The NNV VLPs shown in Figure 3.5-2 came from clarified plant extract derived from 60 g 
infiltrated leaf material. It was centrifuged through a sucrose cushion as a first clean up 
step, followed by a sucrose gradient centrifugation. Localisation of the VLPs in the 30% 
and 40% (w/v) fraction was confirmed via Western blot (see Figure 3.4-2). After dialysis 
the sample was pelleted and resuspended in 500 µl of TBS buffer and visualised under 
the TEM to assess the integrity, appearance and approximate size of the NNV VLPs. 
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Figure 3.5-2: Electron micrographs of NNV VLPs. Plant extract containing NNV VLPs was purified 
through two sucrose gradients and concentrated by pelleting. NNV VLPs are visualised by 
negative staining and transmission electron microscopy.  
The TEM images show properly assembled NNV VLPs of correct size (25-30 nm) and 
form. They are evenly shaped and of great abundance. Wild type NNV forms a T = 3 
icosahedral capsid made out of 180 identical subunits (Cheng et al., 1994) and the plant 
produced NNV VLPs are indistinguishable from the native particles by electron 
microscopy. Interestingly the NNV VLPs appear full on the electron micrographs; no dark 
spot can be seen in their centre. Often the stain penetrates and accumulates inside of 
empty particles, whereas in viruses containing nucleic acid this does not occur. Even 
though stain penetration can be influenced by the buffer used, it is an indication that 
the plant-made NNV VLPs encapsidate nucleic acid during particle assembly. To 
quantitate the amount of VLPs produced and to avoid possible effect of nucleic acid in 
the sample, modified Lowry protein assay has been carried out using this sample. A yield 
of 10 mg/kg fresh weight of the highly purified VLPs was calculated.   
Summary of section 3.5.1: NNV coat protein expressed in plants spontaneously 
assembles into evenly shaped and correctly sized VLPs. Plant produced NNV VLPs are 
indistinguishable from wild type NNV particles by electron microscopy.   
 NATIVE GEL ELECTROPHORESIS 
In 2003 Lu and colleagues expressed NNV VLPs in E. coli and found that their VLPs 
encapsidated various sizes of host RNA (Lu et al., 2003). As discussed above, the TEM 
images in Figure 3.5-2 indicated that the plant-produced NNV VLPs may also contain 
nucleic acid. To confirm this, two NNV VLPs samples were run on native agarose gels 
together with approximately 10 μg each of CPMV and empty VLPs of CPMV (eVLPs) as 
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controls. One gel was stained with Coomassie blue protein stain, while a duplicate gel 
was stained with ethidium bromide to visualize nucleic acid (Figure 3.5-3).  
 
Figure 3.5-3: Native gel electrophoresis of NNV VLPs to analyse encapsidation of nucleic acid. A) 
Native gel electrophoresis of NNV VLPs, CPMV and eVLPs. Approximately 10 µg of CPMV and 
eVLPs and 3-5 µg purified NNV VLPs were loaded per lane. B) Native gel electrophoresis of NNV 
VLPs and CPMV. Approximately 10 µg of CPMV 6 µg purified NNV VLPs were loaded per lane. The 
particles were separated on 1% agarose gels and stained with Coomassie blue or ethidium 
bromide.  
Gel electrophoresis of VLPs on agarose gels is an effective method for analysing the 
nucleic acid content of particles. RNA-containing CMPV particles can be stained with 
both ethidium bromide and Coomassie blue, whereas CPMV eVLPs, which do not 
contain any nucleic acid are only be stained with Coomassie blue. Because the 
concentration of NNV VLPs was too low in Figure 3.5-3 A to obtain a definitive result, the 
experiment was repeated, but this time using a more concentrated NNV VLP sample 
(Figure 3.5-3 B). Even though the concentration of the NNV VLPs is still low compared 
with CPMV controls, and thus the Coomassie blue stain relatively faint, Figure 3.5-3 
shows that the plant-produced NNV VLPs do not appear to encapsidate significant 
nucleic acid. However, for a more accurate result the nucleic acid extraction could be 
conducted using purified NNV VLPs and analysed for RNA/DNA content.  
Summary of section 3.5.2: Plant produced NNV VLPs are free of nucleic acid.  
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 CRYO-ELECTRON-MICROSCOPY (CRYO-EM) 
In the family Nodaviridae 180 coat proteins assemble and form a T = 3 capsid with a 
diameter of ~25-35 nm. For more detailed structural analysis, cryo-EM was performed 
by Daniel Hurdiss at the University of Leeds, UK on NNV VLPs prepared as described in 
Figure 3.5-1. This technique allows the determination of 3D structure of a particle to 
close to atomic resolution through computational averaging of multiple particle images. 
The results obtained using this technique are summarised in Figure 3.5-4.  
 
Figure 3.5-4: Cryo-EM analysis of NNV VLPs. NNV VLPs were loaded on copper grids, frozen 
rapidly by plunging into liquid ethane and imaged. A) NNV VLPs unstained in vitreous ice. B) 
Reference free, 2D class averages of NNV VLP generated in Relion. C) 3D map of NNV with a 
global resolution of 3.8 Å. D) Density for a single asymmetric unit of the T = 3 NNV-VLP with fitted 
atomic model (4WIZ). E) Representative alpha-helical density with a local resolution of ~3.4 Å 
showing clear side chain density.   
Images of unstained, frozen-hydrated NNV-VLPs were imaged using an electron 
microscope fitted with a direct electron detecting camera (Figure 3.5-4 A). Single-
particle image processing was carried out in Relion (Figure 3.5-4 B), which allowed us to 
determine the solution structure of the NNV-VLP to a global resolution of 3.8 Å (Figure 
3.5-4 C). This revealed that the NNV-VLP is an isometric particle with T = 3 symmetry 
(Figure 3.5-4 D), consistent with previously reported structures (Chen et al., 2015; Cheng 
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et al., 1994). Three P-domains of the capsid protein interact and form spikes on the 
particle surface. They are attached to the rest of the capsid protein but the linkers are 
unstructured. The shell domain displayed a higher local resolution of 3.4 Å, with well-
resolved side-chain density (Figure 3.5-4 E).  
Summary of section 3.5.3: The above cryo-EM studies represent the first time plant-
produced NNV VLPs have been visualised in such high resolution. It revealed a 3.8 Å 
structure of authentic looking NNV VLPs.  
 TOWARDS TRANSGENIC EXPRESSION OF NNV VLPS 
The aim is to generate a transgenic line of N. benthamiana for NNV VLPs. Stable 
transformation can be done using the same pEAQ-HT-NNV construct that was used for 
transient expression, however it carries the suppressor of silencing P19 which derives 
from the tomato bushy stunt virus (TBSV) (Voinnet et al., 2003). P19 is one of the 
reasons behind the high expression levels obtainable with the pEAQ-HT vectors. It is a 
19 kDa protein that specifically sequesters siRNAs and thereby blocks post-
transcriptional gene silencing and leads to up-regulation of protein expression (Omarov 
et al., 2006; Ye et al., 2003). However, when trying to regenerate plants from 
transformed leaf discs, P19 interferes with miRNA pathways involved in growth and 
development causing severe developmental defects (Chapman et al., 2004; Dunoyer et 
al., 2004; Saxena et al., 2011). Thus, wild-type P19 cannot be deployed when generating 
stably transformed plants.  
The mutation R43W in P19 was first identified in an attenuated strain of TBSV in 
N. benthamiana (Chu et al., 2000). A single amino acid substitution of arginine at 
position 43 with tryptophan still allows P19 to bind siRNA duplexes but the binding is 
unstable, resulting in reduced suppression of RNA silencing (Omarov et al., 2006). This 
mutant form of P19 has been shown to be tolerated in homozygous transgenic 
N. benthamiana plants and has been deployed to make the pEAQ vectors suitable for 
the creation of lines of transgenic plants (Saxena et al., 2011).  
In order to create the point mutant R43W/P19, primers P19-R43W-SDM-F and P19-
R43W-SDM-R (listed in Appendix 1) were used to change ‘CGG’ (encoding arginine) to 
‘TGG’ (encoding tryptophan) generating pEAQ-HT-NNV-P19m via site-directed 
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mutagenesis (SDM). After verification of the mutation by sequencing, 
pEAQ-HT-NNV-P19m was transformed into agrobacteria for transient expression in 
plants.  
 
Figure 3.6-1: Transient expression of NNV VLPs in presence of wt P19 and P19m. A) Comparison 
of protein expression using either pEAQ-HT-NNV or pEAQ-HT-NNV-P19m on a Western blot. 
Western blot was probed with anti-NNV antibody. M = SeeBlue Plus 2 with molecular weights 
indicated. Red arrow indicates position of NNV coat protein. B, C) Verifying correct assembly of 
NNV VLPs under the TEM when using pEAQ-HT-NNV-P19m. NNV VLPs are visualised by negative 
staining and transmission electron microscopy. White arrows indicate NNV VLPs. 
In order to verify if NNV VLPs are still expressed and assemble correctly when using the 
construct pEAQ-HT-NNV-P19m and to compare the protein expression level to the 
original pEAQ-HT-NNV, separate plants were infiltrated with the constructs and protein 
was extracted. In Figure 3.6-1 A the amount of NNV coat protein that accumulated in 
the presence of wt P19 and the R43W P19m was compared. The levels of NNV coat 
protein detected in the presence of R43W P19m were noticeably lower than was found 
with wt P19, a result consisted with that obtained with transient GFP expression by 
Saxena et al. (2011). The lower levels of coat protein accumulation is likely to mean that 
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fewer NNV VLPs will form and this was apparent when visualizing VLPs in samples 
obtained using the two different version of P19 under the electron microscope (Figure 
3.6-1 B, C).  
Summary of section 3.6: The suppressor of silencing P19 cannot be deployed when 
generating stably transformed plants as it interferes with miRNA pathways involved in 
growth and development causing severe developmental defects. Therefore, a point 
mutation (R43W) was inserted into wt P19 generating pEAQ-HT-NNV-P19m. Expression 
of the coat protein is reduced but correct assembly of VLPs was confirmed.   
 FUTURE WORK  
Due to time limitations the aim of creating a stable transgenic N. benthamiana line 
expressing NNV VLP has not been reached. However, the first step towards this goal has 
been made (see section 3.6) by generating pEAQ-HT-NNV-P19m which can directly be 
used for stable integration of the NNV coat protein sequence into the N. benthamiana 
genome. For this purpose, the “leaf disc method” first described by Horsch and Klee in 
1986 will be followed.  
 DISCUSSION 
Several vaccine candidates against NNV have been developed but none has been 
commercialised yet. However, the expanding world population and over-fishing of the 
oceans has led to a growing demand for farmed fish, making it a very high value 
industry. NNV causes mortality rates with up to 99% turning it into an enemy for the fish 
industry and the interest in a prophylactic treatment such as a vaccine, is high (Lin, 
2007). In order to produce a practical fish vaccine, feasible administration and cost 
efficiency of production, as well as immunological efficacy have to be prioritised. 
Intramuscular injection of single fish is laborious and costly. Therefore, alternative 
vaccination techniques, like oral vaccination through feeding the fish with the vaccine or 
bath immunisation should be explored. 
The aim of this project was to investigate the feasibility of producing a plant-produced 
NNV VLP vaccine. This involved characterising plant-produced NNV VLPs and optimising 
their expression level, purification and stability. Transiently expressed NNV VLPs 
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accumulate to relatively high levels in plants within 4-6 dpi. Their relatively simple set-up 
of only one protein that self-assembles into an icosahedral structure of 180 copies 
makes them an attractive model for studies of VLP production in plants.  
The absence of genomic material in VLPs can make them less stable than their parent 
virus and therefore delicate to purify (see instability of wt PV VLPs in section 4.6.4). The 
NNV VLPs, however, proved to be stable and survived pelleting in the ultracentrifuge 
which simplified their concentration and purification when handling large sample 
volumes. Though, the adopted purification technique described in Figure 3.5-1 does not 
succeed in totally removing contamination with plant-derived proteins. Other 
purification techniques, like Nycodenz gradient ultracentrifugation, were tried but 
without success. More work has to be put into optimising the purification in order to 
obtain a cleaner result without compromising on the concentration. The plant-produced 
NNV VLPs showed no evidence of the encapsidation of nucleic acid, unlike their 
counterpart produced in E. coli (Lu et al., 2003). Absolute purity and no residue of the 
expression host are features to aim for when developing a vaccine where 
contaminations could potentially tamper the immune response of the recipient or cause 
a health risk. Though the recombinant subunit vaccine developed by Lin and colleagues 
provided complete protection from VNN, when fish were fed the oral vaccine without it 
ever having been extracted or purified from the expression host (Lin, 2007). An 
advantage of plants over other conventional expression systems is that they bring a low 
risk of contamination with endotoxins or mammalian pathogens (Lico et al., 2008; Ma et 
al., 2003; Twyman et al., 2003), unlike the above-mentioned E. coli. Therefore, absolute 
purity might not be necessary for a plant-produced fish vaccine especially when it keeps 
the costs low but still elicits a protective immune response.  
The high-resolution structural studies (carried out by Daniel Hurdiss at the University of 
Leeds, UK) revealed that the plant-made NNV-VLPs are of isometric shape with T = 3 
symmetry, consistent with previously reported structures and authentic looking when 
compared to the wild-type NNV (Chen et al., 2015; Cheng et al., 1994). To date, animal 
studies have not been carried out using this plant-produced vaccine candidate but it is of 
very high priority and the requirements for testing have been discussed with Dr. Richard 
Paley at CEFAS, Weymouth, UK. It is important to test if the VLPs do elicit an immune 
answer when administered to fish. Oral vaccination seems to be the easiest when 
working with a large number of fish. Possibilities like pressing plant material harbouring 
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NNV VLPs into pellets and feeding it to the animals should be investigated. It would be 
very simple, inexpensive and quick to do as it does not require any purification of the 
VLPs. If this is applicable depends on the concentration needed for complete protection 
and whether the plant-produced amounts are sufficient. 
Generating transgenic N. benthamiana lines expressing NNV VLPs was an idea that was 
considered late in the project. The first step of the procedure, preparing and testing an 
expression construct that can directly be used to transform the plants, has been 
completed; however, generating stable transgenics is a lengthy process and could not be 
undertaken during this study. Nonetheless, the creation of stably transformed lines of 
plants would make the idea of fabricating pellets for oral vaccination against NNV easier 
because once a stable transgenic plant for NNV VLPs has been developed agro-
infiltration is unnecessary. The disadvantage of transgenic plants is the strict regulation 
that comes with this technique, which modifies the germline of plants, which is likely to 
hinder the commercial development of such a product. The possibility of generating 
stable transgenics for NNV VLPs with an inducible promotor has been considered. The 
heat inducible promotor (EC71016) which can be activated with a single, short heat 
shock treatment of 37° C, a temperature which is totally acceptable for the Australian 
plant N. benthamiana, appears to be particularly attractive. The advantage of an 
inducible promotor is that protein expression can be controlled externally by simple 
methods. One could either place the NNV coat protein under the control of an inducible 
promotor or the wild-type suppressor of silencing, P19. As discussed above, P19 cannot 
be deployed when generating stably transformed plants but under the control of an 
inducible promoter its expression could be switched on after the critical stages of plant 
development. This would most likely have a positive impact in the expression of the 
desired protein rather than using the mutated version P19m which leads to a significant 
decrease in expression level (Figure 3.6-1).  
NNV is a relatively simple virus which is composed out of 180 copies of the same protein 
(Cheng et al., 1994). Its simplicity made it a great tool for me to study general 
techniques of VLP production in plants which I could apply to my main project: the 
development of a synthetic, plant produced VLP vaccine against poliovirus which is 
described in the following chapters.     
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Chapter 4: EXPRESSION OF POLIO VLPS IN PLANTS 
 INTRODUCTION 
Poliovirus contains a single stranded (+)-sense RNA molecule of 7410 nucleotides 
containing a large open reading frame (Kitamura et al., 1981; Racaniello and Baltimore, 
1981). Once the RNA enters the host cell it is translated into a single and highly 
autocatalytic 220 kDa polyprotein. Translation is initiated at the internal ribosome entry 
site (IRES), a structured RNA cis-acting element within the 5` UTR (Wimmer et al., 1993). 
The polyprotein can be sectioned into two parts: the structural and non-structural 
region. The structural region includes the proteins that form the capsid, whereas the 
non-structural region contains proteinases and polymerases important for replication 
and infection. Processing of the polyprotein takes place in several steps which are 
sketched in Figure 4.1-1. First the proteinase 2A cuts and therewith separates the 
structural from the non-structural region, releasing P1 (Kitamura et al., 1981; Toyoda et 
al., 1986). Then P3 gets released through cis-cleavage by the proteinase 3Cpro/3CD 
(Lawson and Semler, 1992) which is also responsible for the processing of P1 into VP0, 
VP1 and VP3 (Hellen et al., 1989; Ypma-Wong et al., 1988).  
Particularly important for the work described in this chapter is the proteinase 3CD which 
actually is a precursor molecule of the proteinase 3Cpro and the polymerase 3Dpol. 
Interestingly 3CD does not possess any polymerase activity, but it cleaves sites in the 
structural region more efficiently in vitro than 3Cpro (Jore et al., 1988; Ypma-Wong et al., 
1988). Additionally 3Cpro is known to be involved in apoptosis of the host cell (Barco et 
al., 2000), an important process during infection as it facilitates the exit of virus progeny 
from cells (Tolskaya et al., 1995). It also may protect progeny viruses from host immune 
defences and supresses inflammatory responses (Teodoro and Branton, 1997; Tolskaya 
et al., 1995). However, the activity of 3Cpro is not limited to apoptosis; it cleaves a variety 
of host proteins such as different transcription factors and inhibits host cell RNA and 
protein synthesis (Baltimore and Franklin, 1962; Clark et al., 1991; Kaariainen and Ranki, 
1984; Yalamanchili et al., 1996). In order to reduce the toxic effect of 3Cpro its precursor 
3CD was deployed in this project for the processing of P1.  
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Figure 4.1-1: Schematic representation of the PV polyprotein processing and maturation. First 
the proteinase 2A cuts and therewith separates the structural from the non-structural region, 
releasing P1. Then P3 gets released and cleaved by the proteinase 3Cpro/3CD which is also 
responsible for the processing of P1 into VP0, VP1 and VP3. During RNA uptake VP0 undergoes a 
maturation step to yield VP4 and VP2.  
Studies suggest that the formation of PV capsids proceeds through several 
intermediates: first a 5S promoter subunit with one copy of VP0, VP1 and VP3 assembles 
and then 5 of those come together and form a 14S pentamer (Phillips and Fennell, 
1973). These pentamers are the main building blocks of the empty 75S PV procapsid 
consisting of 60 copies each of VP0, VP1 and VP3 (Bruneau et al., 1983; Jacobson and 
Baltimore, 1968; Putnak and Phillips, 1981). The last stage in the formation of infectious 
particles is the autocatalytic cleavage of the immature precursor VP0 to yield VP4 and 
VP2, also referred to as the final maturation step during RNA uptake (Basavappa et al., 
1998; Basavappa et al., 1994; Hogle et al., 1985; Holland and Kiehn, 1968; Jacobson et 
al., 1970). This processing step reorders the proteins on the inside of the virus capsid 
with a concomitant increase in particle stability (Basavappa et al., 1994). Finally, all 4 
proteins form an icosahedral capsid of 27-30 nm in diameter (Hogle et al., 1985). 
However, poliovirus assembly is not that straightforward. A number of intermediates 
accumulate including the empty capsid, consisting of 60 copies of each of VP0, VP1 and 
VP3, and the provirion consisting of VP0, VP1, VP3 plus the viral RNA (Fernandez-Tomas 
and Baltimore, 1973; Guttman and Baltimore, 1977a). Empty particles, such as VLPs, do 
not undergo the final maturation event and therefore consist only of VP0, VP1 and VP3. 
Particles with uncleaved V0 are less stable than mature virions (Guttman and Baltimore, 
1977a) but the outside architecture of empty particles is virtually indistinguishable from 
the mature virus (Basavappa et al., 1994; Jiang et al., 2014).    
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Poliovirus occurs in three serotypes (PV1, PV2 and PV3) which share 71% identical 
nucleotides in the RNA genome. Most of the nucleotide differences occur in the third 
position of codons, resulting in low frequency of amino acid differences (Toyoda et al., 
1984). The highest amino acid variations can be detected in the P1 region whereas non-
structural proteins are more highly conserved (Toyoda et al., 1984). The three main coat 
proteins (VP1, VP2 and VP3) form structurally similar 8-stranded β-barrels decorated 
with loops connecting the beta-strands (Hogle, 2002). Structural differences among the 
serotypes can primarily be found in the loop regions of VP1 that cluster near the fivefold 
axes of the capsid (Lentz et al., 1997). All three poliovirus serotypes recognise a common 
cellular receptor: CD155 (also known as poliovirus receptor PVR). The human poliovirus 
receptor CD155 was first identified by Mendelsohn in 1989 as an integral membrane 
protein of the immunoglobulin superfamily (Mendelsohn et al., 1989). It is expressed in 
a wide range of tissues and usually works as a cell-cell adhesion molecule through 
interaction with nectin-3 (Koike et al., 1990; Mendelsohn et al., 1989; Mueller and 
Wimmer, 2003).  
 
Figure 4.1-2: Schematic representation of the PV cell entry with conformational transition from 
D to C antigenicity. Infection is initiated by attachment to the PV receptor (CD 155), which 
induces the conformational transition from D to C antigenicity in the virus. Also vesicle formation 
is initiated upon receptor binding which internalises the PV particle. The N-terminus of VP1 and 
VP4 are externalised to anchor the particle in the membrane. The viral RNA gets translocated into 
the cytoplasm where it is replicated to yield progeny RNAs and translated to yield viral proteins. 
When poliovirus binds the receptor it triggers irreversible conformational changes 
resulting in the formation of the so called A particle or 135S particle (versus 160S for the 
native virion) (De Sena and Mandel, 1977). In the A particle the capsid protein VP4 and 
the N-terminus of VP1 are externalised (Chow et al., 1987; De Sena and Mandel, 1977). 
Both externalised peptides allow the particle to anchor in the membrane independently 
of the receptor (Danthi et al., 2003; Fricks and Hogle, 1990; Tosteson and Chow, 1997; 
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Tosteson et al., 2004). After binding to the cell the PV particles are internalised in 
vesicles and the genome is released leading to the formation of empty particles that 
sediment at 80S (Belnap et al., 2000a; Brandenburg et al., 2007).  
The outer shell of poliovirus is dominated by star-shaped mesas along the fivefold axis 
and by three-bladed propeller-like structures at the threefold axes (see Figure 1.5-1). 
Between these features lies a surface depression known as the “canyon” which 
surrounds each of the twelve fivefold axes of the capsid and is the site of receptor 
attachment (Bernhardt et al., 1994; Colston and Racaniello, 1994; Colston and 
Racaniello, 1995). At the base of the canyon is a hydrophobic pocket which is occupied 
in wt virus by a fatty acid-like ligand or “pocket factor”. It has been suggested that the 
pocket factor plays a role in the thermal stability of the virion for transport from host to 
host but as soon as CD155 binds, the pocket factor gets dislodged and uncoating can 
proceed (Filman et al., 1989; Grant et al., 1994; Rossmann et al., 2002).  
PV VLPs have been produced in various recombinant expression systems (e.g. vaccinia 
virus, baculovirus, Saccharomyces cerevisiae) (Ansardi, 1991; Brautigam et al., 1993; Jore 
et al., 1994), but this is the first time recombinant expression of PV VLPs has been 
attempted in plants. However, the observation that it is possible to produce VLPs of a 
plant-infecting member of the order Picornavirales, CPMV, by transient expression of 
the capsid protein precursor (VP60) and the CPMV equivalent of 3Cpro, the 24K protease 
(Saunders et al., 2009), suggested that a similar approach could be viable for poliovirus. 
This chapter is about the expression of wt PV 1, 2 and 3 VLPs in N. benthamiana aimed 
at defining the optimal conditions for expression and purification. The focus of this 
chapter is on balancing the toxic effect of 3Cpro/3CD in plants without compromising VLP 
yield and on increasing the purity of the sample. Furthermore, the plant produced PV 
VLPs will be described and examined for stability and use as potential vaccines.  
 VERIFY EXPRESSION OF POLIO CAPSID PROTEINS 
For the recombinant production of poliovirus particles two components are required: 
the P1 region which encodes the capsid proteins and the poliovirus proteinase that 
processes P1 into VP0, VP1 and VP3. Without the cleavage of P1 particles cannot form 
(Jiang et al., 2014). However, as mentioned above, the proteinase 3Cpro responsible for 
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these cleavages has toxic side effects when expressed in a wide variety of different cells; 
therefore, the more efficient and less harmful precursor 3CD was chosen in this work. 
The sequence information for wt PV1-P1 and 3CD were provided from our collaborators 
from the University of Leeds. The wt PV1-P1 is highly similar to the Mahoney strain. The 
sequences for wt PV2-P1 (MEF-1/Lansing) and wt PV3-P1 (Saukett) were received from 
our collaborators at the National Institute for Biological Standards and Control (NIBCS) 
(listed in Appendix 2: Sequences). All sequences were codon-optimised for the 
expression in N. benthamiana and cloned into pEAQ-HT via restriction digest.  
In order to test P1 expression, plants were infiltrated with agrobacterium suspensions 
harbouring pEAQ-HT-wt-PV1-P1. Leaf discs were sampled 3 to 7 dpi and protein 
extracted. As a positive control leaves were co-infiltrated with pEAQ-HT-wt-PV1-P1 and 
pEAQ-HT-3CD and sampled 6 dpi. The negative control is plant leaf material infiltrated 
with pEAQ-HT-EV (empty vector); this was also sampled on day 6 after infiltration. The 
protein was transferred on a nitrocellulose membrane for immunodetection using the 
anti-VP1 MAB8566 antibody (Figure 4.2-1).   
 
Figure 4.2-1: Verifying expression of P1 and demonstrating the necessity of 3CD for correct 
processing of the polyprotein. Samples were taken 3-7 dpi from leaves expressing 
pEAQ-HT-wt-PV1-P1 and the protein extracted. As a positive control (C+) leaves were co-
infiltrated with pEAQ-HT-wt-PV1-P1 and pEAQ-HT-3CD and sampled 6 dpi. The negative control 
(C-) is plant leaf material infiltrated with pEAQ-HT-EV (empty vector); also sampled on day 6 after 
infiltration. The protein was transferred onto a nitrocellulose membrane for immunodetection 
using the anti-VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights indicated.  
Plants agroinfiltrated with only pEAQ-HT-wt-PV1-P1 produced a high molecular band of 
approximately 96 kDa when protein extracts were analysed by Western blotting (Figure 
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4.2-1). This is consistent with the size of unprocessed P1. When pEAQ-HT-3CD was co-
inoculated with pEAQ-HT-wt-PV1-P1, the band corresponding to P1 disappeared and a 
band corresponding in size to VP1 with a molecular mass of 37 kDa can be detected on 
the blot (C+). This indicates that that processing of P1 occurs in of co-expressed 3CD. 
Summary of section 4.2: PV P1 can be transiently expressed in plants and processing can 
be achieved by co-expression of the proteinase 3CD.   
 OPTIMISING CO-EXPRESSION OF P1 AND 3CD 
 THE TOXICITY OF 3CD 
The toxic effect of the proteinase 3CD became apparent in the infiltrated tissue with 
severe necrosis occurring; however, the results above demonstrate that the use of 3CD 
is indispensable (Figure 4.2-1). In order to reduce the negative impact of 3CD on the leaf 
without losing its proteinase activity for the correct processing of P1, the AUG 161 
mutation on the pEAQ-HT-3CD plasmid was reversed to decrease 3CD expression 10-fold 
(Sainsbury and Lomonossoff, 2008). This approach had previously used successfully to 
downregulate expression of a Bluetongue virus (BTV) protein (Thuenemann et al., 
2013b). Using agrobacterium suspensions with a high OD600 for P1 and a lower one for 
3CD should also help to balance out the impact of 3CD`s toxicity. Reverting AUG 161 was 
achieved with SDM using the primer pair: Rev AUG161_F and Rev AUG161_R (listed in 
Appendix 1). In Figure 4.3-1 the accumulation of wt PV1 VP1 is shown when using 3CD in 
either a HT or non-HT construct. Here, equal amounts of agrobacterium suspensions 
harbouring pEAQ-HT-wt-PV1-P1 (OD600 = 0.8) or pEAQ-HT-3CD/ pEAQ-3CD (OD600 = 0.4) 
were mixed and infiltrated into leaves. Samples were taken over a period of time of 10 
days and the protein analysed on a Western blot using anti-VP1 MAB8566 antibody. 
Also, a picture was taken 6 dpi to compare the effect of HT 3CD with non-HT 3CD on the 
infiltrated leaves.  
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Figure 4.3-1: Comparison of HT 3CD with non-HT 3CD when co-infiltrated with wt PV1 P1. A) 
Equal amounts of agrobacteria solutions harbouring pEAQ-HT-wt-PV1-P1 (OD600 = 0.8) or 
pEAQ-HT-3CD (OD600 = 0.4) were mixed and infiltrated into leaves and a picture was taken 6 dpi 
(C). The Western blots were probed with anti-VP1 MAB8566 antibody. M = SeeBlue Plus 2 with 
molecular weights indicated. C+ = PV1. Red arrows indicate location of VP1. B) Equal amounts of 
agrobacteria solutions harbouring pEAQ-HT-wt-PV1-P1 (OD600 = 0.8) or pEAQ-3CD (OD600 = 0.4) 
were mixed an infiltrated into leaves and a picture was taken 6 dpi (D). Samples were taken for 
10 days and the protein analysed.  
When co-expressing pEAQ-HT-wt-PV1-P1 and pEAQ-HT-3CD correct processing took 
place and VP1 accumulated (Figure 4.3-1 A). However, severe necrosis killed the 
infiltrated tissue within 4-6 days (Figure 4.3-1 C). This limits the expression of the PV 
capsid protein to the early days post-infiltration, a fact which becomes particularly 
obvious when comparing the expression time-course to the experiment where non-HT 
3CD was used (Figure 4.3-1 B, D). Lowering the amount of proteinase available did not 
appear to affect P1 processing but increased the yield of VP1; extended the duration 
VP1 is expressed and decreased the necrosis in the infiltrated tissue. The time course 
experiment in Figure 4.3-1 B demonstrated that expression of PV capsid protein VP1 
took place over the entire time of the experiment with highest levels of the protein 
being observed 5-6 dpi when non-HT 3CD was utilised. In all future experiments the 
non-HT 3CD was used and infiltrated plants harvested on 5 or 6 dpi for optimal yield of 
wt PV1.  
Summary of section 4.3.1: The proteinase 3CD causes severe necrosis in the plant tissue 
when expressed at high levels. Reducing the amount of 3CD by reversing the HT-
mutation increases the yield of VP1 and extends the time over which it is expressed. 
Given the fact that both P1 and 3CD are expressed from separate vectors and no 
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unprocessed P1 is detected, suggests a high degree of specificity between P1 and the 
proteinase.  
 PROOF OF VLP ASSEMBLY AND COMPARISON OF YIELD DIFFERENCE 
Most obvious becomes the positive impact the non-HT 3CD has on expression and yield 
of VLPs when comparing two wt PV1 VLP samples under the TEM. In the following TEM 
images the first plant-made PV VLPs are presented and I compare the difference in yield 
between either wt PV1 VLPs produced with HT 3CD (Figure 4.3-2 A, B) or non-HT 3CD 
(Figure 4.3-2 C, D). The same number of plants was agroinfiltrated with either 
pEAQ-HT-wt-PV1-P1 and pEAQ-HT-3CD or pEAQ-3CD and crude VLP extraction was 
conducted 6 dpi. The samples were visualised by TEM.  
 
Figure 4.3-2: Comparing VLP yield when either HT to non-HT 3CD was applied. A, B) The same 
number of plants was agroinfiltrated with either pEAQ-HT-wt-PV1-P1 and pEAQ-HT-3CD (white 
arrows indicate PV VLPs) or pEAQ-3CD (C, D). The samples were visualised by TEM.  
The TEM images above prove successful assembly of PV VLPs, the first report of such 
produced in plants. The wt PV1 VLPs are of authentic icosahedral shape and correct size 
(27-30 nm). Even though this is not a quantitative comparison, the TEM images show a 
striking difference in yield when 3CD is less abundant. The proteinase causes severe 
necrosis in the infiltrated leaf tissue which restricts productivity. When damage caused 
by 3CD is limited, the productivity of the plant cells is enhanced and therefore more wt 
PV1 VLPs are produced.   
Summary of section 4.3.2: Expression and assembly of PV VLPs is successful in plants, 
properly shaped VLPs were visualised by TEM. Reducing the expression of 3CD in the 
experiment increases the yield of PV VLPs.  
 
Expression of polio VLPs in plants 
81 
 
 OPTIMISATION OF EXTRACTION AND PURIFICATION 
 SUCROSE CUSHION 
Wt PV1 VLPs were purified by centrifuging clarified plant extract through a sucrose 
cushion constructed of 5 ml 25% (w/v) sucrose and a 1 ml 70% (w/v) sucrose bottom 
fraction. After ultracentrifugation the bottom of the tube was pierced and the fractions 
collected. The samples were analysed by SDS-PAGE followed by staining with 
InstantBlue and Western blotting using anti-VP1 Sh16 antibody.  
 
Figure 4.4-1: First step in the purification process of PV VLPs. A) Clarified plant extract was run 
through a sucrose cushion made out of 5 ml 25% (w/v) sucrose and a 1 ml 70% (w/v) sucrose 
bottom fraction. The 70% (w/v) bottom fraction, the interface (IF), the 25% (w/v) fraction and the 
supernatant (SN) were retrieved by piercing the bottom of the tube with a needle. B) For the 
detection of the PV capsid protein the fractions were run on a SDS-PAGE. C) A duplicate was 
transferred on nitrocellulose membrane for immunodetection using anti-VP1 Sh16 antibody. 
M = SeeBlue Plus 2 with molecular weights indicated. Red arrow indicates position of VP1. D) 
TEM images of wt PV1 VLPs after sucrose cushion purification in negative stain. White arrows 
indicate VLPs and black arrows indicate contamination. 
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The Western blot shows that the VP1 sediments to a position that is consistent with the 
coat proteins assembling into higher order structures, such as VLPs. The VLPs sediment 
mainly in the 70% (w/v) sucrose fraction but also in the interface (IF) between the 70% 
and 25% (w/v) sucrose fractions which also contains plant cell-derived protein (Figure 
4.4-1 B). Even though the IF contains many host proteins, it still carries large amounts of 
valuable PV VLPs and was therefore combined with the bottom fraction. A small signal 
of VP1 is detected in the 25% (w/v) sucrose fraction which could represent non-
assembled PV capsid protein, incorrectly assembled or broken PV particles. After dialysis 
the combined sample was visualised by TEM (Figure 4.4-1 D). In the TEM image evenly 
sized wt PV1 VLPs of 27-30 nm in diameter can be seen with a dark centre where the 
stain has penetrated the capsid. This is an indicator for truly empty VLPs not carrying 
plant RNA or DNA. Though, also visible are smaller particle-like structures of 
approximately 10-20 nm and uneven shape (see black arrows in Figure 4.4-1 D). This is 
thought to be RuBisCo (Ribulose-1,5-bisphosphate carboxylase/oxygenase) which can 
assemble into octameric structures and therefore pass through the 25% (w/v) sucrose 
fraction.  
Summary of section 4.4.1: Though a sucrose step gradient is a valuable first measure for 
concentrating VLPs, it fails to clearly separate the VLPs from plant contaminants.   
 NYCODENZ GRADIENT 
In order to remove the contamination and further concentrate the sample it was run 
through a discontinuous gradient of 20% to 60% (w/v) Nycodenz. Three bands formed 
during ultracentrifugation, whereof two were grey and the top one green. Each band 
was removed by piercing the side of the tube with a needle (as shown in Figure 4.4-2 A) 
and analysed via immunodetection on a Western blot using anti-VP1 MAB8566 
antibody.  
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Figure 4.4-2: Second step in the purification process of PV VLPs. A) For further purification the 
sample was run through a discontinuous Nycodenz gradient and the fractions of interest 
retrieved by piercing the side of the tube with a needle. B) PV VP1 was detected on a Western 
blot by using anti-VP1 Sh16 antibody. M = SeeBlue Plus 2 with molecular weights indicated. Red 
arrow indicates position of VP1. D) TEM images of wt PV1 VLPs after sucrose cushion and 
Nycodenz gradient purification. White arrows indicate PV VLPs. 
After several attempts the optimal duration of the ultracentrifugation step was found to 
be 22-24 h at 247,103 x g in a TH641 swing out rotor after which three bands formed 
within the gradient. Analysis of the content of each band by Western blotting revealed 
that the middle band contains concentrated VP1 (Figure 4.4-2 B). A small signal of VP1 
can also be detected in band 2 and 3; however, this is down to cross-contamination 
when retrieving the fractions and/or incorrectly assembled particles. Centrifugation of 
the samples for 22-24 h allows separation of the VLPs from contamination, like RuBisCo. 
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When visualising band 1, which was tested positive for containing VP1, the TEM image 
illustrates a very clean sample of plant produced wt PV1 VLPs (Figure 4.4-2 C).   
The following illustration (Figure 4.4-3) explains the process adopted to gently purify and 
concentrate PV VLPs from crude plant extract.   
 
Figure 4.4-3: Diagram of PV VLP purification. Clarified plant extract containing PV VLPs was 
underlain with 5 ml of 25% (w/v) sucrose and 1 ml 70% (w/v) and spun in the ultracentrifuge. The 
bottom fraction was retrieved and after dialysis run through a discontinuous Nycodenz gradient 
of 20%-60% (w/v). Routinely PV VLPs were localised with immunodetection on a Western blot 
and the respective fractions dialysed. The sample volume was reduced with centrifugal filter units 
to increase VLP concentration.  
Clarified plant extract containing PV VLPs was routinely run through a sucrose cushion as 
the first step in the purification protocol. The bottom fraction was retrieved and the 
sucrose removed using PD10 desalting columns (GE Healthcare). For further purification 
and concentration, the sample was centrifuged through a discontinuous Nycodenz 
gradient which allowed the separation of VLPs from particulate plant contaminants. 
Again PD10 desalting columns were utilised for the removal of Nycodenz and the sample 
volume was reduced to the desired concentration using Amicon centrifugal filter units 
(Millipore).  
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Summary of section 4.4.2: Sequential centrifugation through a sucrose cushion and a 
Nycodenz gradient allows the removal of particulate plant contaminants when the 
duration of the ultracentrifugation exceeded 22 h at 247,103 x g in a TH641 swing out 
rotor.   
 FINDING THE BEST BUFFER 
To further optimise sample purity and also to improve long term stability of the PV VLPs, 
various buffers were tested. Three buffers were chosen on the basis of their pH: HEPES 
(pH 7.0), PBS (pH 7.5) and PIPES (pH 6.5). They were used throughout for VLP extraction 
including the final purification steps. In this experiment the same amount of infiltrated 
leaf material expressing wt PV1 VLPs was separated into three parts and purification and 
extraction was conducted according to the standard protocol (see Figure 4.4-3); with a 
sucrose cushion followed by a Nycodenz gradient but using the three different buffers.  
 
Figure 4.4-4: TEM images of wt PV1 VLPs in different buffers. In order to optimise sample purity 
and to investigate the influence of buffers on PV VLP stability they were extracted and purified in 
three different buffers: A, B, C) HEPES (pH 7.0), D, E, F) PBS (pH 7.5) and G, H, I) PIPES (pH 6.5). 
The VLPs were visualised by TEM using negative staining. White arrows show correctly assembled 
VLPs and black arrows show contamination.  
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In the figure above, TEM images are presented of wt PV1 VLPs extracted and purified in 
three different buffers. There are clear differences in purity and appearance of the VLPs. 
Figure 4.4-4 A, B and C show obvious contamination of the sample which has been 
extracted and purified using HEPES buffer (black arrows). One can see particulate 
structures of uneven size and form between the characteristic-looking VLPs. These 
unwanted contaminants are thought to be RuBisCo or other plant-derived proteins with 
higher-order structures. By contrast the wt PV1 VLP sample extracted using PBS buffer 
looks very clean and pure with almost no visible contamination (Figure 4.4-4 D, E, F). 
Particles are even in shape and of high abundance; however, for unknown reasons the 
VLPs appear larger than typical PV VLPs being approximately 30-38 nm in diameter. They 
appear swollen and very round without the typical icosahedral form (Figure 4.4-4 F). 
Furthermore, the stain did not penetrate the particles, which is a sign that their centre is 
occupied or the particles are impermeable to stain. When PIPES buffer was used, a pure 
sample with correctly sized PV VLPs of characteristic shape and appearance was 
obtained (white arrows Figure 4.4-4 G, H, I). The variations in purity are most likely down 
to the pH of the respective buffer. It influences protein extraction and can have a 
negative impact on the sample`s clarity (Vardakou et al., 2012).  
Overall the best result was achieved using PIPES buffer which had the lowest pH (6.5) of 
the buffers tested. With the aim of further increasing the quality of the plant-made PV 
VLPs, the use of a different buffer for the initial extraction was investigated. Leaves 
expressing wt PV1 VLPs were homogenized using P-buffer and the VLPs were then 
transferred into PIPES during the sucrose cushion. The P-buffer has already successfully 
been utilised for NNV VLP extraction. In order to remove plant-derived contaminations 
the sample was run through a Nycodenz gradient and then visualised by the TEM (Figure 
4.4-5).   
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Figure 4.4-5: TEM images of wt PV1 VLPs extracted with P-buffer. VLPs were extracted using 
P-buffer followed by gentle transfer of the VLPs into PIPES buffer.  
The above electron micrograph shows an improvement in purity of the wt PV1 VLP 
sample when P-buffer was used for the initial protein extraction compared to Figure 
4.4-4. Almost no contamination appears in this TEM image and most importantly, the 
particles seem correctly shaped.  
Summary of section 4.4.3: In summary the best results can be achieved when using 
P-buffer for the initial protein extraction but then for further purification and long term 
storage PIPES buffer is the best option.  
 EMPTY? 
Encapsulation of host DNA or RNA is common in recombinantly expressed VLPs. Usually 
empty capsids allow stain to penetrate which makes them appear with a dark centre in 
TEM images. So far no consistent pattern could be observed when expressing wt PV1 
VLPs. Stain penetration seems to depend on the buffer (Figure 4.4-4) but this may not be 
the only reason. In order to check if the plant produced PV VLPs encapsulate host 
nucleic acid, native agarose gel electrophoresis was carried out.  
Native gel electrophoresis of virus particles or VLPs in an agarose matrix is a technique 
routinely used to assess the protein and RNA contents of particles. The method has 
already been described in section 3.5.2. In this experiment approximately 5 µg and 10 µg 
of purified wt PV1 particles were analysed.     
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Figure 4.5-1: Native gel electrophoresis of wt PV1 VLPs to analyse encapsidation of nucleic acid. 
Approximately 10 µg of CPMV and eVLPs and 5-10 µg purified wt PV1 VLPs were loaded per lane. 
The particles were separated on 1% agarose gels and stained with Coomassie blue or ethidium 
bromide.  
Native gel electrophoresis is an effective method to find out if the VLPs encapsulate 
nucleic acid during assembly. RNA containing CPMV can be stained with both ethidium 
bromide and Coomassie blue, whereas eVLPs do not contain any genomic material and 
can therefore only be stained with Coomassie blue. The same was found to be true for 
wt PV1 VLPs (Figure 4.5-1); the capsids stained strongly with Coomassie blue but there is 
no signal in the ethidium bromide stained gel under conditions which clearly revealed 
the RNA in the CPMV control. This indicates that the PV1 VLPs contain little or no nucleic 
acids. 
Summary of section 4.5: The plant made wt PV1 VLPs appear free of nucleic acid. 
 CHARACTERISATION OF PLANT PRODUCED WT PV1, 2 AND 3 
In the chapters above optimisation of expression, extraction and purification of plant-
made PV VLPs has been described using wt PV1 as an example. However, the aim of this 
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project is to express all three PV serotypes in plants. The following sections will mainly 
focus on the expression and characterisation of type 2 and 3 but will also compare the 
differences between all three serotypes.  
 ANALYSING THE EFFECT OF WT PV1, 2, 3 EXPRESSION ON PLANTS 
Figure 4.6-1 presents the effect of the expression of P1 from the three PV serotypes on 
plants when co-expressed with the same non-HT 3CD construct. Agrobacteria solutions 
carrying the respective P1 were prepared to an OD600 of 0.8 and co-infiltrated with 
agrobacteria harbouring pEAQ-3CD with an OD600 of 0.4. A picture was taken of the 
same infiltrated leaf for 10 days and compared to the control where pEAQ-HT-EV (empty 
vector) was expressed.   
 
Figure 4.6-1: Effect of wt PV VLP expression over time on infiltrated N. benthamiana leaves. A) 
As a control agrobacteria harbouring pEAQ-HT-EV were infiltrated with an OD600 of 0.4. Equal 
amounts of agrobacteria solutions containing B) pEAQ-HT-wt-PV1-P1 (OD600 = 0.8) C) 
pEAQ-HT-wt-PV2-P1 (OD600 = 0.8) D) pEAQ-HT-wt-PV3-P1 (OD600 = 0.8) were mixed with 
pEAQ-3CD (OD600 = 0.4) and co-infiltrated into leaves. A picture of the same infiltrated leave was 
taken every day for 10 days.  
Overall the assembly of pictures illustrates slight yellowing of the infiltrated leaf areas 
over time in all three serotypes though wt PV2 and wt PV3 show as stronger change of 
colour compared to wt PV1. However, also the control wears similar symptoms. 
Yellowing of agroinfiltrated leaves are a common sight and not to be mistaken for 
necrosis.  
Summary of section 4.6: This section shows how the appearance of infiltrated leaves 
change over time when expressing wt PV1, 2 or 3 together with low levels of non-HT 
3CD.  
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 EXPRESSION OVER TIME 
In order to obtain the highest possible yield of wt PV VLPs their expression over time 
was monitored and compared between the three serotypes. One plant each was 
agoinfiltrated with the respective P1 together with non-HT 3CD and leaf discs were 
sampled over a period of 10 days. The change in VP1 expression was analysed on a 
Western blot using anti-VP1 MAB8566 antibody which cross reacts with all three 
serotypes equally (Figure 4.6-2).   
 
Figure 4.6-2: Expression of wt PV1, 2 and 3 VLPs over time in plants. A plant each was 
agoinfiltrated with the respective P1 together with non-HT 3CD and leave discs were sampled for 
10 days. The change in VP1 expression was analysed on a Western blot. The Western blots were 
probed with anti-VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights indicated. 
C+ = PV1. Red arrows indicate position of VP1.  
The expression of wt PV1 VP1 was already presented earlier but here it is used to 
emphasise the differences in expression between the three PV serotypes. Wt PV1 
expresses very well in plants, with detectable levels of VP1 already 1 dpi. It then 
accumulates to the highest levels on 5-6 dpi after which it slowly decreases but even on 
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day 10 after infiltration VP1 is still detectable. In contrast wt PV2 shows the lowest 
expression levels of the three. In order to detect VP1 on the above Western blot the 
exposure time had to be 3-4-times longer than wt PV1 and wt PV3. The best yield of wt 
PV2 was achieved 4 dpi but afterwards the expression level dropped dramatically. 
Generally, wt PV3 expresses better than wt PV2 (confirmed in Figure 4.6-4) but it shows 
a similar pattern with the peak at 4 dpi followed by a striking decline in VP1.  
Summary of section 4.6.2: Overall a striking difference in expression can be observed 
between the three PV serotypes with wt PV1 showing the highest levels of VP1 and it 
also accumulates for the longest period in plants. In direct contrast is wt PV2 which 
expresses the worst of the three, whereas wt PV3 ranges between wt PV1 and wt PV2.  
 EXPRESSING WT PV2 AND WT PV3 VLPS  
As the expression of wt PV1 VLPs has been described earlier in this chapter, this section 
will focus on the characterisation of plant-made wt PV2 and PV3 VLPs. For this reason 
plants were infiltrated with either wt PV2 P1 or wt PV3 P1 together with non-HT 3CD 
and harvested 4 dpi. Because of the low expression level of these serotypes the crude 
plant extract was run through a sucrose gradient instead of a step gradient and each 
fraction was analysed for PV VLP content (Figure 4.6-3 A). The sucrose fraction 
containing the VLPs were combined, dialysed and then for further purification 
centrifuged through a Nycodenz gradient (Figure 4.6-3).  
 
Figure 4.6-3: Purification of wt PV2 and wt PV3 VLPs. A) Plant extract harbouring either wt PV2 
or wt PV3 VLPs was centrifuged through a sucrose gradient and the fractions were analysed for 
PV VP1 content using anti-VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights 
indicated. SN= Supernatant. C+ = PV1. Black arrow indicates VP1. B) For further purification the 
samples were centrifuged through a Nycodenz gradient and the red arrow indicates the band 
containing the VLPs.  
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Figure 4.6-3 A shows the Western blot analysing each of the sucrose fraction for VP1 
content. Most striking is the difference in VP1 expression: wt PV2 shows very small 
amounts compared to wt PV3. Also wt PV3 shows a signal for VP1 across many fractions 
and also in the SN, which indicates the presence of unassembled VP1, broken or 
incorrectly assembled particles. However, the strongest signal can be found in the 30% 
(w/v) and 40% (w/v) fraction where correctly assembled VLPs usually accumulate. The 
same is true for wt PV2 VLPs. Therefore, those fractions were combined and after 
dialysis centrifuged through a Nycodenz gradient after which two grey bands had 
formed as expected. The top band (indicated with a red arrow) contained the VLPs 
which was confirmed via immunodetection (data not shown) and visualised by TEM 
(Figure 4.6-4).   
 
Figure 4.6-4: A) TEM image of wt PV2 VLPs. B) TEM image of wt PV3 VLPs. 
On the left of Figure 4.6-4 wt PV2 VLPs are illustrated and on the right wt PV3 VLPs. In 
both images properly shaped and sized VLPs are visualised by TEM. Consistent with the 
results of the Western blot analysis (Figure 4.6-2, Figure 4.6-3) there appear to be fewer 
particles in the PV2 sample. 
 Quantitative analysis of wt PV1, 2 and 3 VLP expression 
A quantitative comparison of the expression levels of wt PV1, 2 and 3 VLP obtained from 
plants was carried out using the Modified Lowry Assay (Thermo Fischer Scientific), 
following the manufacturer’s instructions. The results are listed below: 
 wt PV1 VLPs: ~70 mg/kg fresh weight 
 wt PV2 VLPs: no data 
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 wt PV3 VLPs: ~60 mg/kg fresh weight 
Of the three serotypes wt PV1 VLPs can be produced to the highest level in plants, with 
yields of up to 70 mg of purified particles/kg infiltrated plant tissue being obtained. This 
was closely followed by wt PV3 VLPs with yields of approximately 60 mg/kg infiltrated 
plant material. The analysis with wt PV2 was inaccurate presumably because the 
concentration was below the level of detection which reinforces the low yield to which 
wt PV2 accumulates in plants. The reasons behind this are not clear and one can only 
presume unstable mRNA or intrinsic problems leading to its degradation.  
Summary of section 4.6.3: This section completes the aim of expressing all three PV 
serotypes in plants. Striking differences in yield were observed between the serotypes 
with wt PV2 showing the lowest concentration.  
 INSTABILITY OF WT PV VLPS 
Figure 4.6-5 shows two electron micrographs that illustrate the problems which 
occurred when purifying the wt PV VLPs.  
 
Figure 4.6-5: Example of structural instability of wt PV VLPs. A) TEM image of wt PV1 VLPs. B) 
TEM image of wt PV3 VLP. White arrows indicate correctly shaped VLPs, red arrows indicate 
broken, irregular particles.  
In general, all three serotypes show signs of instability and when visualised by TEM as 
demonstrated by the presence of broken and irregularly shaped particles in 
preparations of plant-produced and purified wt PV1 and wt PV3 VLPs (see red arrows 
Figure 4.6-5). During this project no method could be developed to stabilise the wt 
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particles during extraction and purification. It is also possible that the VLPs deteriorate 
when they are still inside the plant cell cytoplasm. 
These observations are in line with the findings of Guttman and Baltimore who clearly 
showed that particles in which VPO is uncleaved are much less stable than mature 
virions to a variety of conditions, including elevated temperature, detergents, high salt, 
and extremes of pH (Guttman and Baltimore, 1977a). Empty particles, similar to the 
VLPs, naturally occur during particle assembly and their outer surface and the protein 
shell are virtually indistinguishable compared to the virion but their role is not totally 
understood. Their N-terminal extension of VP1, as well as portions corresponding to VP4 
and the N-terminal extension of VP2 are disordered, and many stabilising interactions 
that are present in the mature virion are missing (Basavappa et al., 1994). The disruption 
of the network eliminates extensive contacts between VP1, VP2, and VP3 within a 
protomer and between protomers in the pentamer (Hogle, 2002). The lack of these 
critical interactions may explain the decreased stability of the plant-made wt VLPs.  
Two distinct antigenic forms of poliovirus exist, named D and C antigen. The D antigen is 
found on infectious virus whereas the C antigen is expressed on non-infectious particles. 
C particles do not display the antigens responsible for eliciting protective immune 
responses and are ineffective as vaccines. Although empty capsids are initially in the 
desirable D conformation they are easily converted to the C form during extraction and 
purification (Marongiu et al., 1981). A non-competitive sandwich ELISA assay was 
conducted by Helen Fox at NIBSC in order to measure the D antigen content of plant-
produced wt PV VLPs type 1 and type 3 (Singer et al., 1989). Briefly, dilutions of antigen 
were captured with a serotype-specific polyclonal antibody, and then detected using 
serotype-specific, D antigen or C antigen-specific monoclonal antibodies followed by 
anti-mouse peroxidase conjugate. As a reference the European Pharmacopeia Standard 
for IPV was applied, which is a mixture of all three types (formulation for type 1, 2 and 3 
is 320, 67 and 282 DAgU (Antigen Units) per ml respectively).  
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Figure 4.6-6: Non-competitive sandwich ELISA assay for the measurement of D antigen content 
A) wt PV1 VLPs analysed for D/C antigen content using Mab 234 (D antigen) and Mab 1588 (C 
antigen). B) wt PV3 VLPs analysed for D/C content using MAb 520 (D antigen) and MAb 517 (C 
antigen). IPV = European Pharmacopeia Standard for IPV.  
Part A of Figure 4.6-6 shows that no D antigen could be detected in the preparation of 
plant-made wt PV1 VLPs; only C antigen was identified. In Figure 4.6-6 B very high levels 
of C antigen were found in this sample of wt PV3 VLPs whereas the amount of D antigen 
is negligible. This confirms previous studies where PV VLPs were expressed in a different 
system (Saccharomyces cerevisiae) but also showed C antigenicity (Rombaut et al., 
1994), meaning that they underwent the conformational change and are therefore 
unlikely to induce neutralizing and protective antibodies.  
This was verified by Helen Fox at NIBSC who tested the ability of plant-produced wt PV3 
VLPs to elicit the production of neutralising antibodies in rats. For immunogenicity 
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experiments in rats the European Pharmacopeia standard test for IPV batch release was 
followed. This involves immunising each rat intramuscular twice with 0.25 ml of the VLP 
sample. There are 4 serial dilutions, starting with the equivalent of a single human dose 
(here 32 DAgU for type 3) and 10 rats in each group. After 21 days the rats were bled, 
the serum collected and tested using a standard neutralising antibody assay for IPV 
batch release (European Pharmacopeia standard test). The serum sample from each rat 
was plated out in duplicate and titrated down the plate. The titrated serum samples 
were incubated with 100 TCID50 of the appropriate serotype of Sabin virus per well for 3 
hours. HEp2C (HeLa derivative) cells were added to the wells and incubated at 35 °C for 
6 days. The endpoint dilution constitutes the neutralising antibody titre and is calculated 
using the Spearman Karber method. Across a group of 10 rats, the average geomean 
titre was obtained from the individual neutralisation titres. As a reference the European 
Pharmacopeia Standard for IPV was applied, which is a mixture of all three types 
(formulation for Type 1, 2 and 3 is 320, 67 and 282 DAgU/ml respectively).  
 
Figure 4.6-7: Neutralising antibody titre in rats after immunisation with wt PV3 VLPs. Each rat 
was immunised twice with wt PV3 VLPs. In total the sample was tested in 40 rats and the same 
number of rats was used for the control material IPV. After 21 days the rats were bled, the serum 
collected and tested using a standard neutralising antibody assay for IPV batch release (European 
Pharmacopeia standard test). IPV = European Pharmacopeia Standard for IPV.  
They estimated the CAgU to an equivalent dose of DAgU for immunisation in rats but 
the immunogenicity was negligible compared to IPV.  
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Summary of section 4.6.4: Many of the plant-produced wt PV VLPs are irregular and not 
of icosahedral shape; they appear broken or incorrectly assembled. Empty PV particles 
are known to be labile due to the lack of critical interactions between the capsid 
proteins. When analysing the antigenicity, wt PV1 and wt PV3 VLPs show negligible to no 
D antigenicity but strong C antigenicity, confirming their structural instability. Wt PV3 
VLPs do not induce neutralising antibodies in rats.  
 DO PV VLPS ENCAPSULATE REPLICATING RNA? 
Instability of empty PV capsids is a well-known issue (Basavappa et al., 1994; Guttman 
and Baltimore, 1977b; Marongiu et al., 1981). The lack of critical internal interactions 
between the capsid proteins is most likely the main reason for the lability of the plant-
made wt VLPs. Encapsulated genomic material can act as a stabilising force which VLPs 
lack (Da Poian et al., 1994). With the aim of increasing the stability of the PV VLPs their 
ability to take up foreign, harmless genomic material was investigated. This would also 
help to gain insight into the encapsulation procedure. Little is known about the genome 
encapsulation in PV and the process has been the subject of some controversy. Two 
possible models have been proposed: pentamers condense around the viral RNA during 
particle assembly to form a provirion. The alternate model proposes that pentamers first 
form an empty capsid, into which the viral RNA is inserted to yield the provirion; 
however more evidence supports the first model (Jiang et al., 2014; Putnak and Phillips, 
1981; Verlinden et al., 2000).  
So far the results of this work suggest that PV VLPs do not encapsidate plant RNA or DNA 
during assembly (Figure 4.5-1). However, the idea was to use replicating RNA from a 
distantly related virus to investigate if active replication might lead to encapsidation 
because encapsidation and replication is believed to be linked in PV (Saxena and 
Lomonossoff, 2014). For this purpose, CPMV was chosen; an extensively studied plant 
virus with a ss (+) RNA genome of two segments which is a member of the same order 
(the Picornavirales) as poliovirus. RNA-1 encodes the virus replication machinery and 
RNA-2 encodes two capsid proteins and the viral movement protein (Sainsbury et al., 
2010a). RNA-1 is capable of replicating independently (Goldbach et al., 1980). Therefore, 
by deploying only RNA-1, replication takes place without the formation of CPMV 
particles. This was exploited in this experiment, where the constructs shown in Figure 
Expression of polio VLPs in plants 
98 
 
4.6-8 were co-expressed in N. benthamiana with the aim of producing wt PV VLPs that 
encapsulate CPMV RNA-1 and which would thereby be stabilised:   
 
Figure 4.6-8: Schematic diagrams of constructs expressing RNA-1, wt PV1 P1 and 3CD. Relevant 
sections of pEAQ-HT-RNA-1, pEAQ-HT-wt-PV1-P1 and pEAQ-3CD are illustrated. RNA-1 encodes a 
32 kDa proteinase co-factor (ProC); a 58 kDa helicase; a 2 kDa genome-linked viral protein (VPg); 
a 24 kDa viral proteinase (Pro) and a 87 kDa RNA-dependent RNA polymerase. The green arrow 
and red circle represent the CaMV 35S promoter and nos terminator respectively.  
As a control VP60, which contains the large (L) and small (S) coat protein of CPMV, was 
co-expressed with RNA-1 to provide a positive control for encapsidation (Figure 4.6-9):  
 
Figure 4.6-9: Schematic diagram of constructs expressed as control to demonstrate 
encapsulation of RNA-1. VP60 encodes the L and S coat proteins. The green arrow and red circle 
represent the CaMV 35S promoter and nos terminator respectively.  
Furthermore, wt PV1 VLPs were expressed in the absence of CPMV RNA-1 as described 
earlier in this chapter as a negative control. The plants were harvested 6 dpi and purified 
over a sucrose cushion. In order to accommodate the needs of CPMV and PV, PBS buffer 
was used in this experiment. After dialysis the samples were visualised by TEM in order 
to assess particle appearance. The images are presented in Figure 4.6-10.  
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Figure 4.6-10: Monitoring particle assembly and appearance when co-expressing RNA-1 and wt 
PV1 VLPs. A), B) TEM image of wt PV1 VLPs co-exoressed in plants with replicating CMPV RNA-1. 
C) Assembled CPMV particles visualised by TEM when VP60 was co-expressed (containing the L + 
S coat protein) with RNA-1. D) TEM image of standard wt PV1 VLPs.  
Co-expressing RNA-1 with wt PV1 results in very evenly shaped particles with a slightly 
larger diameter than usual (Figure 4.6-10 A, B), but this could be explained by the buffer 
they are in (PBS) as already observed and described earlier in this chapter. However, the 
standard wt PV1 VLPs are of correct size (Figure 4.6-10 D) and in the same buffer. CPMV 
particles produced from co-expressing VP60 (L + S coat protein) are depicted in Figure 
4.6-10 C. The TEM image show authentic particles of 28-30 nm in diameter. All particles 
in Figure 4.6-10 appear full because no stain has entered the capsid. Though, it has 
already been proven that wt PV VLPs do not always get penetrated by the negative stain 
even though they do not contain nucleic acid. Most CPMV particles are expected to 
show a full core as they will have encapsulated the co-expressed RNA-1. 
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From all samples RNA was extracted and analysed by NanoDrop spectrometer. As an 
additional control a sample of CPMV eVLPs was analysed. After adjusting the particle 
concentration, the same protocol for RNA extraction was followed, even though eVLPs 
do not contain RNA. The RNA was dissolved in exactly the same volume of sterile water 
and in the following table the RNA concentration of each sample is listed:   
Table 4.6.1: RNA concentration of purified particles. RNA was extracted from purified particles 
and the concentration measured using the NanoDrop spectrophotometer.  
Sample RNA concentration 
VP60 + RNA-1 173.4 ng/µl 
Wt PV1 VLPs + RNA-1 118.7 ng/µl 
Wt PV1 VLPs 39.1 ng/µl 
eVLPs  55.0 ng/µl 
   
Table 4.6.1 the measured RNA concentrations of all samples are listed and the highest 
amount of RNA was detected in the CPMV sample (VP60 + RNA-1). This was expected as 
CPMV is known to encapsidate its cognate RNA and thus serves as a positive control. 
The negative control in this experiment is the eVLP sample; as the name suggests eVLPs 
are empty and do not contain RNA. However, the NanoDrop apparently measured 
55 ng/µl of RNA.  This can be explained by the presence of impurities in the sample like 
phenol residues which can affect the reading of the machine. Interestingly PV VLPs that 
have been co-expressed in the presence of replicating RNA-1 show a higher RNA content 
than those produced in its absence. All together these results hint at the possible 
encapsulation of replicating CPMV RNA-1 by co-expressed wt PV1 VLPs.  
To definitely demonstrate RNA-1 encapsidation by PV capsids it would be necessary to 
demonstrate the presence of full-length RNA-1 in RNA extracted from wt PV1 
VLPs + RNA-1 by agarose gel electrophoresis. Unfortunately, all attempts at 
demonstrating this failed. Several reasons, such as low RNA concentration and RNA 
degradation, may account for this. However, the results obtained were tantalising and 
demand further investigation. Larger scale infiltrations are needed to produce more 
material for further experiments. In order to get a more definitive result it is worth 
considering northern blot or reverse-transcription (RT)-PCR analysis. 
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Summary of section 4.6.5: The preliminary data presented in this chapter suggest that 
wt PV1 VLPs may encpasidate replicating RNA-1 of CPMV when co-expressed in plants. 
However, the final proof is still to be made.  
 DISCUSSION 
PV VLPs have been produced in various recombinant expression systems (e.g. vaccinia 
virus, baculovirus, Saccharomyces cerevisiae) (Ansardi, 1991; Brautigam et al., 1993; Jore 
et al., 1994), however, this work reports the first successful expression of wt PV 1, 2 and 
3 VLPs in plants.  
This chapter presents experiments that have been undertaken to optimise expression 
and purification of PV VLPs. For the synthesis of PV VLPs not only the polyprotein P1, 
which contains the sequences of the coat proteins, but also the proteinase 3CD are 
necessary; without the cleavage of P1 by the proteinase the  mature capsid proteins do 
not form and VLPs do not assemble (Jore et al., 1988). Protein analyses showed that 
when only the P1 region is expressed, an antibody specific for VP1 reacts with a ~96 kDa 
product that is presumably the precursor to the capsid proteins. No evidence was 
obtained for the presence of mature VP1 in these extracts, indicating that, as predicted 
from other published reports, the poliovirus protease is required for capsid production 
(Hanecak et al., 1982; Toyoda et al., 1986). When co-expressing P1 and 3CD only mature 
VP1, and not the precursor molecule P1, was detected indicating that processing is 
highly efficient in plants. A very important step was reducing the level of 3CD expression 
as it causes severe necrosis in the infiltrated plant tissue. Reversal of the HT-mutation 
(AUG 161) on the 3CD construct and adjusting the P1 to 3CD ratio, the infiltrated tissue 
suffered less from necrosis leading to higher yields of PV VLPs.  
Reversal of the HT-mutation (AUG 161) on the 3CD construct and adjustment of the P1 
to 3CD ratio, resulted in the infiltrated tissue suffering less necrosis which, in turn led to 
higher yields of PV VLPs. The reduced 3CD levels proved to be adequate to achieve 100% 
processing of P1 and thus this lower level expression method was adopted for all 
subsequent work.  
The first samples of PV VLPs contained large amounts of plant contaminants. Alternative 
extraction and purification techniques were therefore investigated to improve the purity 
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and concentration of the VLPs. Here, most beneficial proved to be increasing the 
duration of the Nycodenz ultracentrifugation step; longer spins separated the VLPs from 
plant contaminants with very similar densities. Furthermore, the effect of different 
buffers on the sample purity was tested. A combination of P-buffer for extraction and 
PIPES for the following purification steps had the most favourable outcome. However, 
more time could be invested in trying a buffer with an even lower pH, as PV naturally is 
acid stable and a lower pH could facilitate removal of more plant contaminants. 
It was noted that in TEM images the wt PV VLPs looked full, which means their core does 
not allow stain penetration. This could indicate the presence of nucleic acid within the 
VLPs. However, analysis on non-denaturing agarose gels showed no evidence of nucleic 
acid within the particles as judged by ethidium bromide staining. This result is similar to 
that found with CPMV, a plant-infecting member of the order Picornavirales and may 
reflect similarity in the genome packaging mechanisms.  
High yields of PV VLPs were achieved with approximately 70 mg/kg infiltrated leaf tissue 
for wt PV1. However, this could probably be even further improved with specific codon-
optimisation or improvements to the protocol for extraction and purification. In 
comparison to other systems that successfully express PV VLPs the yield of ~70 mg/kg 
fresh weight is very good. In yeast for example, a yield of 0.1-1 mg of particles was 
obtained from 1 l of yeast culture (Jore et al., 1994).  
The results also revealed differences in yield between the serotypes, especially type 2 
proved difficult to be expressed in plants to the same concentration as the other two 
serotypes. Reasons behind these observations are only assumptions as generally the 
serotypes are structurally very similar. However, no known cases of wt PV2 have been 
reported since 1999 and therefore type 2 was declared eradicated by the WHO in 
September 2015. Intrinsic problems within the type 2 mRNA might lead to its fast 
degradation of the host cell defence mechanisms.  
In the TEM images it became apparent that the plant-produced wt PV VLPs are unstable 
and undergo distortion and/or degradation during purification. Many broken particles 
are visible in the images even though the purification process was kept as gentle as 
possible. More importantly the antigenicity of the plant-produced wt PV1 and 3 VLPs 
was almost entirely of the C conformation. The same is true for PV VLPs generated in 
Saccharomyces cerevisiae, which were also shown to be C antigenic (Rombaut and Jore, 
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1997), implying that these particles are denatured. Empty capsids are known to be very 
unstable and that they readily switch antigenicity from the native form (D) to the non-
native or heated form (C) (Basavappa et al., 1994). Thus, it came as no surprise that the 
plant-made VLPs could not induce neutralizing antibodies when tested in rats (Helen 
Fox, NIBSC). Again, the yeast-produced VLPs showed the same result. With the aim of 
stabilising their VLPs Rombaut and colleagues added pocket-binding compounds to the 
sample (Rombaut and Jore, 1997). The binding of `pocket factors` to the canyon in the 
virus capsid has been shown to positively influence stability of the virions and empty 
capsids (Grant et al., 1994; Rombaut et al., 1991). When Rombaut et al. added the 
compound prodavir they obtained D antigenic empty capsids which have the same 
immunogenicity as poliovirus virions (Rombaut and Jore, 1997). However, the use of 
such compounds is incompatible with commercial vaccine production (Katpally and 
Smith, 2007; Kelly et al., 2015). PV VLPs expressed in the baculovirus system induced 
only a very weak neutralizing response in mice (Urakawa, 1989); no data on the 
immunological response of the empty capsids isolated from the vaccinia virus expression 
system are available (Ansardi, 1991). 
With the aim to stabilise the plant-made PV capsids and at the same time shed light into 
the encapsulation of nucleic acid it was investigated if replicating RNA would be taken 
up by the assembling PV VLPs. Very little is known about how Picornavirales encapsulate 
their genome and how they are able to distinguish foreign nucleic acid from their own 
genomic material. In this chapter I already discussed that plant-produced PV VLPs do not 
contain random host nucleic acid but potentially a replicating RNA from a related virus 
would be taken up. Hence CPMV was chosen; a plant virus with structural and genetic 
similarities with picornaviruses (Franssen et al., 1984). When only RNA-1 from its 
bipartite genome is deployed, replication takes place without the formation of CPMV 
particles (Goldbach et al., 1980; Van Bokhoven et al., 1993). Using a replicating RNA 
molecule was the key in this experiment as there is believed to be a linkage of 
enacapsidation and replication for PV (Saxena and Lomonossoff, 2014). Preliminary data 
suggest that the RNA content of VLPs increases when VLPs are co-expressed with 
replicating RNA-1. Certainly, this experiment needs more thorough enquiry using more 
sensitive techniques to clarify if the RNA isolated from the PV VLPs actually is CPMV`s 
RNA-1.  
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Overall this chapter demonstrates the first report of plant-made PV VLPs. However, 
these wt PV VLPs are labile and readily undergo the conformational change from D to C 
antigenicity, rendering them unsuitable as vaccines. Finding a way to improve their 
stability and to stop the conformational change from taking place without impacting 
their immunogenicity would create an inexpensive and safe vaccine candidate for the 
eradication and also post-eradication era. In the next chapter of this thesis I will 
introduce stabilised mutants developed by our collaborators at NIBSC and the University 
of Leeds that have increased thermostability and express to high levels in plants. 
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Chapter 5: STABILISED PV VLP MUTANTS 
 INTRODUCTION 
The previous chapter describes the stability issues encountered with wt PV VLPs 
transiently expressed in plants. The purified VLPs do not induce neutralising antibodies 
when tested in animals, making them inappropriate as vaccines. The overall aim of the 
poliovirus work reported in this thesis was the generation of non-infectious PV VLPs that 
have the capability of eliciting a protective immune response against polio. Together 
with the WHO-funded consortium we developed stabilised mutant versions of the 
poliovirus gene P1, which keep the correct antigenicity during expression and 
purification. We showed that plant-based transient expression is an efficient method of 
producing these stabilised capsids. This work was built up on capsid stabilisation 
experiments on foot-and-mouth disease virus (FMDV) (Porta et al., 2013a; Porta et al., 
2013b). In this chapter I describe the expression of the stabilised mutants in plants, 
analyse their characteristics and show their properties and potential.  
As already mentioned in the earlier chapter, two distinct antigenic conformations of 
poliovirus exist, D and C, (Hummeler and Hamparian, 1958; Le Bouvier, 1955; Mayer et 
al., 1957) where D is the required conformation for the VLPs if they are to elicit an 
appropriate immune response. The virus undergoes the conformational change during 
cell infection, ending up as non-infectious C particles (see Figure 4.1-2) (Le Bouvier, 
1955; Schwerdt and Fogh, 1957). C particles do not display the antigens responsible for 
eliciting protective immune responses and are therefore ineffective as vaccines. The D 
to C change is induced by binding the receptor CD155 where the N-terminal extension of 
VP1 and the myristoylated VP4 get externalised proposedly to anchor the virus in the 
cell membrane to facilitate the transport of viral components into the host cytoplasm 
(Danthi et al., 2003; De Sena and Mandel, 1977; Fricks and Hogle, 1990; Ren et al., 2013; 
Tosteson and Chow, 1997; Tosteson et al., 2004); an irreversible restructuring (Hogle, 
2002).  
Particles, like VLPs, with uncleaved V0 are less stable than mature virions (Guttman and 
Baltimore, 1977a) and readily undergo the switch from D to C. They are also more 
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sensitive to elevated temperature, detergents, high salt and extremes of pH (Guttman 
and Baltimore, 1977a). Infectious PV has a complex internal protein network formed by 
VP4 and the N-terminal extensions of the other capsid proteins (Basavappa et al., 1994; 
Hogle, 2002). The failure of VLPs to form such a network interferes with critical internal 
interactions and may explain their decreased stability. Another element influences 
stability of PV capsids: the pocket factor (Grant et al., 1994).  
On the surface of PV a prominent depression circumscribes the star-shaped mesa at the 
fivefold axes known as the canyon (see Figure 1.5-1). It is the site of receptor 
attachment (Belnap et al., 2000b; He et al., 2000). At the bottom of the canyon is an 
opening into a hydrophobic pocket between the two beta sheets of the VP1 capsid 
protein where the pocket factor binds (Filman et al., 1989). The pocket factor has been 
modelled as fatty acids (e.g. sphingosine, palmitate) based on the hydrophobic 
environment in the pocket and crystallographic studies (Hogle, 2002). The binding sites 
of the pocket factor and the CD155 receptor overlap and therefore it has been 
suggested that the pocket factor stabilises the capsid until a viable receptor competes 
for the binding site. Then the pocket factor is released which destabilises the virus and 
initiates uncoating (Grant et al., 1994; Rossmann, 1994; Rossmann et al., 2002). When 
antiviral drugs bind the pocket factor the PV particle becomes non-infectious 
(Rossmann, 1989). The reason behind this is thought to be overly strong stabilisation of 
the capsids which makes them resistant to uncoating. The binding of such drugs has also 
been shown to stabilise PV capsids against transitions from the native (D antigenic) state 
to the heated (C antigenic) state, changes that are required for productive cell entry 
(Grant et al., 1994; Hiremath et al., 1995; Rombaut et al., 1991). Hence, the presence of 
a ligand in the pocket plays a critical role in regulating particle stability. One pocket 
factor analogue which has been shown to bind polioviruses is termed GPP3 (De Colibus 
et al., 2015).  
There are two differing approaches that could be used to produce stabilised VLPs: the 
use of structural information to identify mutations that could theoretically stabilised 
capsids, an approach used successfully with FMDV (Porta et al., 2013a) or the use of 
“forced evolution” to select for stabilising mutations by propagating the virus under 
restrictive conditions. Poliovirus, as well as other RNA viruses, is prone to mutations due 
to the non-proofreading RNA-dependent RNA polymerase (RdRp), which allows rapid 
evolution under selection pressure (Elde, 2012; Karakasiliotis et al., 2005). This property 
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can be exploited as a means of forced evolution to select for thermostable capsid 
mutants. Using both these approaches, our collaborators at the University of Leeds have 
attempted to generate stabilised empty PV capsids of PV1, while our collaborators at 
NIBSC worked on producing and identifying stabilised PV1, PV2 and PV3 empty capsids 
by forced evolution. 
 STABILISED PV1 VLPS 
 SELECTION AND CHARACTERISATION OF PV1 Q94C 
As a first attempt in generating stabilised PV1 VLPs, our collaborators at the University 
of Leeds purposely changed amino acids in the capsid protein VP2 aiming towards 
stabilising the pocket. This was based on the work of Porta et al. who engineered a 
disulfide bond by mutating a single histidine residue at position 93 of VP2 located at the 
icosahedral 2-fold axis between adjacent pentamers in FMDV (Porta et al., 2013a). A 
number of mutant viruses have been constructed with substitutions designed to 
introduce side chains into the VP1 pocket – the location of the pocket factor present in 
infectious wt PV and the binding site of a number of compounds which increase the 
thermal stability of the particles. Some of the mutations prevented particle assembly but 
a single mutation allowed the formation of D antigenic empty PV1 particles with 
apparent enhanced stability.  
In order to exchange Glutamine at position 94 with Cysteine, plasmid 
pEAQ-HT-wt-PV1-P1 was subjected to SDM using primer pair PV1 Q94C_F and 
PV1 Q94C_R (listed in Appendix 1) generating pEAQ-HT-PV1 Q94C. After verification of 
the incorporation of the mutation, pEAQ-HT-PV1 Q94C was co-expressed with 3CD in 
plants. Particles were purified following the standard protocol of a sucrose cushion 
followed by a Nycodenz gradient. The results are illustrated in Figure 5.2-1.  
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Figure 5.2-1: Purification of PV1 Q94C VLPs. A) The sample was purified through a Nycodenz 
gradient. Three bands formed within the gradient. B) The Nycodenz fractions were analysed on a 
Western blot for VP1 content using anti-VP1 MAB8566 antibody. Red arrow indicates VP1. 
M = SeeBlue Plus 2 with molecular weights indicated. C+ = PV3 SktSC8 VLPs. C) TEM picture of 
PV1 Q94C VLPs.  
Expression and purification was simple because of the high expression level of this 
mutant. Figure 5.2-1 A shows the Nycodenz gradient which was used to purify the 
sample. Three bands formed within the gradient and band 1 was verified to contain the 
VLPs (Figure 5.2-1 B) which were visualised by TEM. The sample was send to our 
collaborators at NIBSC who tested the VLPs for D/C antigen content using Mab 234 (D 
antigen) and Mab 1588 (C antigen) in a non-competitive sandwich ELISA (Singer et al., 
1989). Briefly, two-fold dilutions of antigen were captured with a serotype-specific 
polyclonal antibody, then detected using serotype-specific, D antigen (Mab 234) or C 
antigen (Mab 1588) specific monoclonal antibodies followed by anti-mouse peroxidase 
conjugate.  
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Figure 5.2-2: Potency of PV1 Q94C VLPs. PV1 Q94C analysed for D/C antigen content using Mab 
234 (D antigen) and Mab 1588 (C antigen).  
Unfortunately, the VLPs revealed only C antigenicity. At this point other data collected 
by my collaborators from thermostability experiments supported the evidence that the 
designed mutant PV1 Q94C does not fulfil the expected stability.  
 SELECTION OF THERMALLY-STABLE PV1 M2DELTA AND PV1 M3DELTA  
Because the designed mutant PV1 Q94C did not appear to have enhanced stability, 
Oluwapelumi Adeyemi of the University of Leeds selected thermally-stable empty 
capsids of PV1. He identified mutations on the capsid surface and internal networks that 
are responsible for the stability (submitted for publication Adeyemi et al., 2016) . His 
strategy is briefly described in the following paragraph.  
Virus derived from an infectious cDNA clone (Mahoney strain) was passaged through 
rounds of thermal selection at increasing temperatures of 51 °C, 53 °C and 57 °C until 
there was a severe fitness cost. To identify the capsid mutations in thermally-selected 
virus pools, genomic RNA was extracted and the P1 coding region amplified by reverse 
transcription PCR and purified amplicons sequenced. Nucleotide sequence alignment of 
the thermally-selected viruses against wt PV-1 (Mahoney) reference sequence (NCBI 
GenBank locus V01149.1) revealed induced mutations. The wt PV1 empty capsids do not 
retain D antigenicity above 10 °C (Basavappa et al., 1994), however, the thermally-
selected viruses were shown to have D antigenic empty capsids, with the switch to C 
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antigenicity occurring at 37 °C or higher. Together, these data demonstrate that both full 
virions and empty capsids of the thermally-selected viruses had an increased native 
antigenic tolerance for elevated temperatures. Two mutants were selected based on 
their performance in antigenic and particle stability tests, PV1 M2delta and PV1 
M3delta, for recombinant expression in plants.  
When aligned against wt PV1 (Mahoney), three changes could be detected in the P1 
sequence PV1 M2delta. They are specified in Table 5.2.1. 
Table 5.2.1: PV1 M2delta mutations and their location.  
Mutation Location 
V1087A B strand of the VP1 β-barrel; outer surface of the virus pocket 
A1026T Internal surface of the virus capsid; close to the N-terminus of VP1 
F4046L VP0 
PV1 M3delta was aligned against wt PV1 (Mahoney) and five mutations were detected. 
They are listed in Table 5.2.2. 
Table 5.2.2: PV1 M3delta mutations their location.  
Mutation Location 
V1087A B strand of the VP1 β-barrel; outer surface of the virus pocket 
S1097P Resides on B-C loop of the VP1 β-barrel 
C3175A Capsid surface residue, located between monomers within a pentamer 
R4034S VP0 
D4045V VP0 
The following section characterises these stabilised mutants when expressed as VLPs in 
plants.  
 Expression of PV1 M2delta and PV1 M3delta in plants 
The sequences for PV1 M2delta-P1 and M3delta-P1 were codon-optimised for the 
expression in N. benthamiana and cloned into pEAQ-HT via restriction digest. Plants 
were infiltrated with pEAQ-HT-PV1 M2delta-P1 or M3delta-P1 plus pEAQ-3CD and 
harvested 6 dpi. Due to time limitations only a sucrose cushion was carried out without 
further purification steps.  
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Figure 5.2-3: PV1 M2delta VLPs and PV1 M3 delta VLPs roughly purified through a sucrose 
cushion. A) Sucrose fractions analysed for VP1 content on a Western blot with anti-VP1 
MAB8566 antibody. B) TEM image of PV1M2delta VLPs. C) Sucrose fractions analysed for VP1 
content via immunodetection on a Western blot using anti-VP1 MAB8566 antibody. D) TEM 
image of PV1M3delta VLPs. M = SeeBlue Plus 2 with molecular weights indicated. SN = 
Supernatant. C+ = PV3 SktSC8 VLPs. Red arrows indicate VP1. White arrows indicate VLPs and 
black arrows show contamination.  
The 70% (w/v) sucrose fraction together with the interface (IF) contained the capsid 
protein VP1 as confirmed on the Western blots in Figure 5.2-3 A, C using the anti-VP1 
MAB8566 antibody. After dialysis the samples were visualised by TEM (Figure 5.2-3 B, 
D). As expected both samples were still heavily contaminated with plant cell debris 
however; they also contained large amounts of correctly sized and apparently properly 
assembled VLPs.  
For stability analyses both samples were sent to our collaborator at the University of 
Leeds who generated the mutants. The following results are preliminary data which 
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were gathered by Oluwapelumi Adeyemi at the University of Leeds and are presented 
here with his permission.  
 Thermostability analyses 
For the purpose of determining the capsid integrity of the plant-made VLPs they were 
heat-treated at a range of temperatures for 30 minutes. Particle antigenicity was 
assayed by capture ELISA, using a purified polyclonal antibody (Rab 1A) as capture. 
Monoclonal PV1 antibodies Mab 234 and Mab 1588 were applied as primary antibodies 
to identify native and non-native particles, respectively (Osterhaus et al., 1983). An anti-
mouse conjugated to HRP was applied as secondary antibody. ELISA was carried out 
according to standard protocols (Gan and Patel, 2013). 
 
Figure 5.2-4: Thermal stability of plant-expressed PV1 M2delta and PV1 M3delta VLPs. VLPs 
were incubated at a range of temperature (from 25 oC to 60 oC) for 30 minutes. ELISA was carried 
using polyclonal (Rab 1A) antibody as capture. Monoclonal PV-1 antibodies Mab 234 and Mab 
1588 were applied as primary antibodies to identify native and non-native particles. An anti-
mouse conjugated to HRP was applied as secondary antibody. BRP = European Pharmacopeia 
Standard for IPV (Fuchs et al., 2003). (This figure was produced by Oluwapelumi Adeyemi and 
presented with his permission).  
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In comparison to wt empty capsids produced by Oluwapelumi Adeyemi in L-cells, the 
plant-made stabilised mutant VLPs (their purification is presented in 5.2.2.1) showed 
increased heat tolerance in this experiment. Both mutants lost their D antigenicity 
rapidly when 40 °C was reached. The antigenic shift for the corresponding mutant empty 
capsids occurred at 42 oC for PV1 M2delta and 45 oC for PV1 M3delta (submitted for 
publication Adeyemi et al., 2016); differences between the expression systems could 
explain the small variations in stability.  
Oluwapelumi Adeyemi of the University of Leeds also conducted an 
immunoprecipitation experiment using single domain antibody fragments of camelid 
origin (nanobodies, or VHH). Purified plant-made VLPs and BRP, an inactivated polio 
vaccine control (Fuchs et al., 2003), were heat-treated at range of temperatures for 30 
minutes and immunoprecipitated using anti-PV-1 D-specific and C-specific VHH 
nanobodies. Magnetic beads were added and incubated for 10 minutes at room 
temperature, under continuous shaking. Using a magnet, the beads were separated 
from the supernatant which was boiled in SDS-loading buffer (Schotte et al., 2012). 
Immunoprecipitated particles were immunoblotted against anti-VP0 rabbit polyclonal 
and anti-VP1 MAb antibodies (Figure 5.2-5). 
 
Figure 5.2-5: Immunoprecipitation using D antigenic VHH. VLP samples were incubated 
temperature range for 30 minutes, then cool to 4 oC. D antigenic VLPs were precipitated using 
specific VHH nanobodies (specific for D antigen). Western blots were incubated with anti-VP1 or 
anti-VP0 antibodies. (This figure was prepared by Oluwapelumi Adeyemi and presented with his 
permission).  
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In Figure 5.2-5 the samples were analysed for D antigen after incubation at a range of 
temperatures; testing the thermostability of the particles. Both plant-made mutant 
samples still contained D antigenic VLPs at 50 °C, whereas the vaccine control had lost 
most of the D antigenicity already at 45 °C. In the wt empty capsid sample D antigen was 
detected at 50 °C; an unexpected result because the wt is known to be highly instable.  
Summary of section 5.2: Overall these preliminary results indicate successful capsid 
stabilisation in PV1 M2delta and PV1 M3delta. When expressed in plants both mutants 
showed increased thermostability compared to L-cell produced wt empty capsids 
however, the experiments need to be repeated and a more detailed analysis performed. 
The purposely designed mutant PV1 Q94C did not fulfil the expectations of increased 
capsid stability and was therefore not analysed further. The results suggest that forced 
evolution and selection of stable mutants is likely to be the most effective way of 
identifying stabilising mutations which can then be incorporated into VLPs. 
 SELECTION OF THERMOSTABLE MUTANTS 
Our collaborators at NIBSC, Helen Fox and Dr. Andrew Macadam worked on the 
identification of mutations in the capsids of all 3 PV serotypes. This led to the 
identification of 3 stabilised mutants: PV1 MahSC6b, PV2 MEFSC6b and PV3 SktSC8. The 
P1 regions from these 3 mutants were expressed in plants in the presence of 3CD. The 
resulting VLPs were characterised as described in the following sections of this chapter.  
The NIBSC group followed a slightly altered method for the generation of stabilised PV 
mutants compared to the method used by Oluwapelumi Adeyemi at the University of 
Leeds (Section 5.2.1). Their method is described in more detail in their most recent 
publication (submitted for publication Fox et al., 2016) . Briefly, for the development of 
PV1 MahSC6b, a mutation known to make Sabin type 3 vaccine strain temperature 
sensitive was introduced into the P1 region of a PV type 1 Mahoney strain. HEp2c cells 
were transfected with RNA transcripts from this construct, incubated at the non-
permissive temperature of 39 °C and the resulting progeny examined by deep 
sequencing to identify stabilised mutants. They selected for the best mutants with 
thermostability and antigenicity tests, one of which was PV1 MahSC6b. The amino acid 
changes in this mutant are listed in the following table.  
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Table 5.3.1: PV1 MahSC6b mutations and locations. 
Mutation Location 
R4018G Internal network 
T2025A Pentamer interface 
D2057E Pentamer interface 
L3119M Internal 
Q3178L Promoter interface 
H1248P Promoter interface 
For the development of PV2 MEFSC6b they followed the same strategy as they did with 
the type 1 mutant. Briefly, they inserted a destabilising mutation into MEF-2 and 
transfected HEp2c cells with the RNA transcripts from this construct, incubated at the 
non-permissive temperature of 39 °C and the resulting progeny was examined by deep 
sequencing to identify stabilised mutants. They selected for the best mutants with 
thermostability and antigenicity tests. PV2 MEFSC6b proved to be most stable. The 
amino acid changes in this mutant are listed in the following table.  
Table 5.3.2: PV2 MEFSC6b mutations and locations. 
Mutation Location 
I4057V Internal network 3-fold 
D2057A Pentamer interface 
Q3178L Protomer interface 
V1107I Protomer interface 
F1134L Pocket 
V1183L Pocket 
To generate stabilised type 3 mutants they started by growing type 3 Sabin vaccine 
strain in Hep2C cells at semi-permissive temperatures and identified eight mutations 
that supress one of the main attenuating mutations which makes the virus temperature 
sensitive. Mutations identified as candidate capsid stabilising changes were introduced 
into Leon, the virulent precursor of the Sabin vaccine strain of type 3 in different 
combinations. Those mutants were grown at increasing temperature and further 
mutations emerged that have stabilising effects. The strain that is used for production of 
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inactivated serotype 3 polio vaccine, hence the appropriate target for VLP design, is the 
wt virus Saukett. Constructs were made in which amino acids were exchanged for the 
stabilising forms, resulting in PV3 SktSC8, with eight amino acid differences from the IPV 
Saukett sequence as shown in Table 5.3.3. 
Table 5.3.3: PV3 SktSC6b mutations and their location. 
Mutation Location 
T4067A Internal network near three fold axis 
L2018I Beta sheet at pentamer interface 
L2215M Protomer interface 
D2241E VP2/VP3 interface, buried 
H3019Y Internal network, tube below 5 fold axis 
L3085F Beta sheet at pentamer interface 
T1105M North wall of canyon 
F1132L Pocket 
Thermostability assays, D/C antigenicity tests and animal studies for these three 
mutants described in this section, were performed by Helen Fox and Dr. Andrew 
Macadam at NIBSC. The results are presented with their permission. 
 EXPRESSION AND PURIFICATION OF THERMOSTABLE MUTANTS  
 PV1 MahSC6b VLPs  
To produce VLPs of mutant PV1 MahSC6b in plants, the P1 region of this mutant was 
inserted into pEAQ-HT and co-expressed with the 3CD proteinase. After 6 days the 
infiltrated tissue was harvested and any VLPs present were purified as described above. 
The results are summarised in Figure 5.3-1.  
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Figure 5.3-1: PV1 MahSC6b VLP purification from plants. A) The different fractions of the 
sucrose cushion were analysed on a Western blot using anti-VP1 MAB8566 antibody. B) The 
Nycodenz gradient after ultracentrifugation with an unusually wide and blurry grey band, 
indicated with the number 1. C) The Nycodenz fractions were retrieved and checked for VP1 
content. First the grey band (1) was removed and then the gradient was fractionated from the 
bottom (2-6). Anti-VP1 MAB8566 antibody was used in both Western blots. SN = Supernatant. 
M = SeeBlue Plus 2 with molecular weights indicated. C+ = PV3 SktSC8 VLPs. Red arrows indicate 
position of VP1.  
The Western blot probed with the anti-VP1 antibody showed strong signals in all three 
fractions retrieved from the sucrose cushion also the 25% (w/v) sucrose fraction and the 
SN contained VP1 (Figure 5.3-2 A). When the sample was purified through a Nycodenz 
gradient an unusually wide and blurry band appeared, which was extracted separately 
by piercing the side of the tube. Afterwards the gradient fractionated from the bottom 
(fractions 2-6). All were analysed for VP1 content via immunodetection (Figure 5.3-1 C). 
The grey band did contain VLPs but according to the Western blot the VLPs were spread 
across most of the gradient. Both results indicate that the sample contained particles of 
various sizes but it could also suggest instabilities in the capsid which caused the 
particles to break during purification. 
Obtaining a pure sample of homogenous PV1 MahSC6b VLPs proved difficult as 
described above. However, the image below illustrates a clean sample of this plant-
produced mutant received from a Nycodenz gradient after dialysis. 
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Figure 5.3-2: TEM images from PV1 MahSC6b VLPs. Visualised in negative stain.  
The TEM images above visualise PV1 MahSC6b VLPs of typical PV size and shape. The 
yield of highly purified VLPs is negatively affected by the heterogeneity of this mutant 
but approximately 40 mg of purified particles/kg infiltrated plant tissue was achieved.  
 PV2 MEFSC6b VLPs  
PV2 MEFSC6b was routinely co-expressed in plants with the necessary proteinase. From 
previous time course experiments I am aware of the early peak in protein expression of 
all type 2 VLPs and therefore harvest this mutant 4 dpi. Also, generally all type 2 VLPs 
have lower expression levels compared to the other serotypes when produced in plants. 
Therefore, a considerably larger number of plants had to be infiltrated in order to obtain 
sufficient amount of VLPs for subsequent analysis. In the following Figure 5.3-3 shows 
the last purification steps of PV2 MEFSC6b VLPs from plant material.  
 
Figure 5.3-3: Purification of PV2 MEFSC6b VLPS. A) In the Nycodenz gradient the typical grey 
band formed during ultracentrifugation, labelled with 1. This band was extracted and then the 
gradient was fractionated by piercing the bottom of the tube (fractions 2-5). B) Each fraction was 
tested for VP1 content via immunodetection using anti-VP1 MAB8566 antibody. M = SeeBlue Plus 
2 with molecular weights indicated. C+ = PV3 SktSC8 VLPs. Red arrow indicates VP1. C) VLPs were 
visualised in negative stain by TEM.  
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PV2 MEFSC6b VLPs were purified first through a sucrose cushion and then through a 
Nycodenz gradient as depicted in Figure 5.3-3 A. The grey band labelled with 1 was 
separately removed from the tube as it was expected to contain the VLPs. Afterwards 
the bottom of the tube was pierced and fractions 2-5 retrieved. Also fraction 4 tested 
positive for VP1 on the Western blot shown in part B; possibly material that was missed 
when the grey band 1 was retrieved. Fraction 1 and 4 were combined and visualised by 
TEM as presented in Figure 5.3-3 C. Approximately 5-8 mg purified PV2 MEFSC6b VLPs 
were prepared from 1 kg infiltrated plant material.   
 PV3 SktSC8 VLPs 
With the aim to optimise VLP yield a time course experiment with PV3 SkSC8 was carried 
out. A leaf was infiltrated with the respective P1 and the proteinase 3CD and leaf discs 
were samples every day for 10 days. At the end of the experiment the samples were run 
on a PAGE gel before the protein got transferred on a nitrocellulose membrane. An anti-
VP1 (MAB8566) was applied to detect the highest expression level of VP1 in the 10 
samples (Figure 5.3-4).  
 
Figure 5.3-4: Expression of PV3 SktSC6b VLPs in plants over time. Equal amounts of agrobacteria 
solutions harbouring pEAQ-HT-PV3 SktSC8-P1 (OD600 = 0.8) or pEAQ-3CD (OD600 = 0.4) were 
mixed and infiltrated into leaves. A small scale protein extraction was conducted 1-10 dpi. Anti-
VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights indicated. C+ = PV3 SktSC8 
VLPs. Red arrow indicates position of VP1.  
The Western blot revealed detectable amounts of protein already 2 dpi and the highest 
yield at 6 dpi. Following this results, PV3 SktSC8 VLPs were always harvested on day 6 
after infiltration.  
PV3 SktSC8 VLPs were produced in plants by co-expressing the P1 region together with 
the proteinase. The infiltrated leaf tissue was harvested and the VLPs extracted and 
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purified as previously described. Below plant-made PV3 SktSC8 VLPs are visualised in 
negative stain.  
 
Figure 5.3-5: TEM images of PV3 SktSC8 VLPs. 
The stabilised mutant PV3SktSC8 accumulates to very high levels in plants, with 
estimated concentration of 50-70 mg/kg infiltrated plant material. It is also a very 
durable and stable VLP which makes purification relatively simple. In the TEM images 
above one can see very evenly shaped particles of perfect size and form (Figure 5.3-5). 
Most particles appear empty with stain that has penetrated their core.  
Summary of section 5.3.1: PV1 MahSC6b expresses well in plants, however its 
heterogeneity complicates the preparation of uniform VLP samples. PV2 MEFSC6b VLPs 
accumulate to very low concentration in plants, however up-scaling of the experiment 
produced sufficient material for further analyses. PV3 SktSC8 VLPs are very stable and 
highly expressed in plants.   
 IMMUNOLOGICAL DATA 
 D AND C ANTIGEN ELISA 
Non-competitive sandwich ELISA assays were conducted by Helen Fox to measure the D 
antigen content of the plant-produced stabilised mutants (Singer et al., 1989). The 
analysed VLP samples were prepared following the routine protocol described in (see 
Figure 4.4-3); however, based on results obtained by collaborators, a new buffer was 
introduced which contains 20 mM EDTA (PBS + EDTA). Briefly, two-fold dilutions of 
antigen were captured with a serotype-specific polyclonal antibody, then detected using 
serotype-specific, D antigen or C antigen specific monoclonal antibodies followed by 
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anti-mouse peroxidase conjugate. The D antigen content of each test sample was 
evaluated against a reference of assigned D antigen content (Fuchs et al., 2003) by 
parallel line analysis (Combistats).  
In the following Figure 5.4-1, plant-produced PV1 MahSC6b VLP samples were analysed, 
using D antigen (Mab 234) and C antigen (Mab 1588) specific monoclonal antibodies.  
 
Figure 5.4-1: Non-competitive sandwich ELISA assay for the measurement of D antigen content 
in plant-produced PV1 MahSC6b VLP samples A) PV1 MahSC6b VLPs in PIPES buffer analysed for 
D/C antigen content using Mab 234 (D antigen) and Mab 1588 (C antigen). B) PV1 MahSC6b VLPs 
in PBS + EDTA buffer analysed for D/C content using MAb 234 (D antigen) and MAb 1588 (C 
antigen). IPV = European Pharmacopeia Standard for IPV.  
The left graph in Figure 5.4-1 shows the D antigen content in the sample purified in 
PIPES buffer; a total of 140 DAgU/ml were detected in this sample. C antigen could also 
be detected but in very low amounts. Part B of Figure 5.4-1 illustrates that higher C than 
D antigen levels were obtained in the sample purified in PBS + EDTA buffer, though the 
total amount D antigen (530 DAgU/ml) was also higher. Both samples derived from very 
similar amounts of infiltrated plant tissue (90 leaves/ ~60 g) and were prepared the 
same way apart from the different buffers (see above). 
In the following ELISA assay, two samples of PV2 MEFSC6b VLPs in either PIPES or PBS + 
EDTA buffer were analysed and compared (Figure 5.4-2). D antigen (Mab 1050) specific 
monoclonal antibody was utilised. 
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Figure 5.4-2: Non-competitive sandwich ELISA assay for the measurement of D antigen content 
in two PV2 MEFSC6b VLP samples. PV2 MahSC6b VLPs in PIPES buffer or PBS + EDTA buffer 
analysed for D antigen content using Mab 1050. IPV = European Pharmacopeia Standard for IPV.  
In this ELISA the sample prepared in PIPES buffer contained slightly higher levels of D 
antigen with 45 DAgU/ml than the sample in PBS+EDTA buffer with 29 DAgU/ml. Both 
samples derived from very similar amounts of infiltrated plant material (150 infiltrated 
leaves/ approximately 300 g) and were prepared following the same routine protocol. 
However, these small differences can be due to the plants growing at varying speeds 
depending on the time of the year, changes in temperature or lighting conditions in the 
glasshouse. The C antigen was not tested because there is currently no C specific 
antibody available for type 2. Therefore, it is difficult to conclude which buffer stabilises 
the VLPs best and produces the sample with the favourable D to C antigen ratio. This 
result is in strong contrast to the findings with PV1 MahSC6b, where the PBS + EDTA 
buffer produced a sample with significantly more DAgU than PIPES buffer.  
The following graph shows a non-competitive sandwich ELISA assay analysing a 
PV3 SktSC8 VLP sample prepared from plant material, using D antigen (Mab 520) or C 
antigen (Mab 517) specific monoclonal antibodies.  
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Figure 5.4-3: Potency plant-made PV3 SktSC8 VLPs. Non-competitive sandwich ELISA assay for 
the measurement of D/C antigen content using Mab 520 (D antigen) and Mab 517 (C antigen). 
IPV = European Pharmacopeia Standard for IPV.  
An estimate of 2200 DAgU was measured in this sample derived from 90 infiltrated 
leaves (~60 g plant tissue). It represents the high potency of this specific type 3 mutant.   
Summary of section 5.4.1: PV1 MahSC6b VLPs show great amounts of D antigen when 
using EDTA enriched buffer, but also high levels of C antigen. As already mentioned 
PV2 MEFSC6b expresses comparably weak in plants, however useful amounts of DAgU 
could be obtained. PV3 SktSC8 VLPs produces very large amounts of DAgU.  
 THERMOSTABILITY ASSAY 
The plant-expressed stabilised VLPs (produced following the routine protocol described 
in Figure 4.4-3) were exposed to a range of temperatures for ten minutes and assayed 
for D antigen and C antigen content in order to test their thermostability. As a control 
empty capsids of the same mutant produced by infection in mouse L cells, were 
analysed in parallel. IPV`s maximum heat tolerance is known and used here as a 
performance comparison.  
In Figure 5.4-4, plant-made PV1 MahSC6b VLPs prepared in two different buffers were 
analysed using D antigen (Mab 234) and C antigen (Mab 1588) specific monoclonal 
antibodies.  
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Figure 5.4-4: Thermostability PV1 MahSC6b VLPs. Reactivity of plant-produced VLPs compared 
to empty capsids and IPV with Mab 234 (D specific) in ELISA after incubation at different 
temperatures for 10 minutes.  
In this experiment two samples of plant-made PV1 MahSC6b VLPs were analysed; these 
are the same samples that were tested for their D/C antigenicity above (Figure 5.4-1). 
The VLPs kept in PIPES were least tolerant to the temperature increase and changed D 
to C antigenicity at 30-35 °C. In direct comparison the VLPs in PBS + EDTA had slightly 
increased thermostability. Overall it is apparent that the plant-produced PV1 MahSC6b 
VLPs are less stable than the empty capsids made in L cells. The empty capsids produced 
by infection of L cells were more tolerant to the increased temperature than the 
currently marketed IPV, which converts from D to C antigen at 49-52 °C. 
In order to determine their thermostability, two samples of PV2 MEFSC6b VLPs in either 
PIPES or PBS + EDTA buffer were assayed for D antigen (Mab 1058) content (Figure 
5.4-5).  
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Figure 5.4-5: Thermostability of PV2 MEFSC6b VLPs. Reactivity of plant-produced VLPs 
compared to empty capsids and IPV with Mab 1050 (D specific) in ELISA after incubation at 
different temperatures for 10 minutes.  
The outcome of this experiment is very similar to the one of PV1 MahSC6b VLPs shown 
in Figure 5.4-4. VLPs made in PBS + EDTA buffer were more thermostable than VLPs kept 
in PIPES. And again VLPs produced in plants seem less thermostable as those produced 
in L cells.  
 Influence of EDTA on particle stability 
This experiment was conducted after differences in stability were observed in samples 
of the same mutant that was kept in different buffers (see Section 5.4.2). We were able 
to identify the chelating agent EDTA to play a key role in the stability of VLPs. Here, a 
non-competitive sandwich ELISA assay was used to observe the D to C antigen switch 
under the influence of EDTA. A sample of PV3 SktSC8 VLPs in PBS buffer was split in half 
and to one part EDTA was added to a final concentration of 20 mM. The samples were 
slowly heated from 4 °C to 60 °C and serotype-specific polyclonal antibody was utilised 
to capture antigen, then detected using serotype-specific, D antigen (Mab 520) or C 
antigen (Mab 517) specific monoclonal antibodies followed by anti-mouse peroxidase 
conjugate.  
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Figure 5.4-6: Influence of EDTA on VLP integrity. Non-competitive sandwich ELISA assay for the 
measurement of D to C antigen conversion in PV3 SktSC8 VLPs using Mab 520 (D antigen) and 
Mab 517 (C antigen) when heated. A) PV3 SktSC8 VLPs in PBS buffer. B) PV3 SktSC8 VLPs in PBS 
and 20 mM EDTA. IPV = European Pharmacopeia Standard for IPV.  
This ELISA illustrates a clear role of EDTA in keeping the VLPs in the desired D 
conformation at elevated temperatures. Without the added EDTA the switch from D to C 
started at 35 °C, whereas with added EDTA the change in conformation was slower and 
did not start until 40°C was reached. In order to analyse if a lower concentration of EDTA 
would also affect the stability of the VLPs several concentrations were tested and the 
results presented in the following graph (Figure 5.4-7).  
 
Figure 5.4-7: Effect of different EDTA concentrations on VLP thermostability. Non-competitive 
sandwich ELISA assay for the measurement of D in PV3 SktSC8 VLPs using Mab 520 when heated 
under the influence of increasing EDTA concentrations. IPV = European Pharmacopeia Standard 
for IPV.  
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Several concentrations were tested in order to determine if a lower amount than 20 mM 
EDTA would also stabilise the VLPs. However, the concentration of 20 mM EDTA 
achieved the best result in this experiment; the higher the concentration of EDTA the 
later the shift from D to C antigenicity occurred. Based on these results 20 mM EDTA 
was added to all stabilised mutant VLPs produced in plants. It was also investigated if 
removing divalent cations from the buffer would increase the thermostability of 
PV3 SktSC8 VLPs (data not shown). The routinely used PBS + EDTA buffer contains 
0.9 mM Ca2+ and 0.5 mM Mg2+. Therefore, the VLPs were transferred into a PBS buffer 
without divalent cations present but no difference was found (loss of 50% DAgU at 
40 °C). In future experiments it should be investigated if even higher concentrations of 
EDTA in the buffer can increase particle stability.  
Summary of section 5.4.2: All mutant VLPs retain their D antigenicity better when 
20 mM EDTA is added. Though, when the mutants are expressed as VLPs in plants they 
are less thermostable than the empty capsid version of themselves made in L cells.  
 NEUTRALISING ANTIBODY RESPONSE AND PROTECTION IN ANIMALS 
The neutralising antibody response of plant-produced PV1 MahSC6b VLPs and PV3 
SktSC8 VLPs was analysed in either mice or rats by ELISA. Furthermore, their potency to 
elicit a neutralising antibody response was compared to empty capsids produced in L 
cells. As a reference the European Pharmacopeia Standard for IPV was applied and the 
animals were also immunised with PBS as a negative control. The animals were 
immunised intramuscular and after 21 days they were bled, the serum collected and 
tested using a standard neutralising antibody assay for IPV batch release (European 
Pharmacopeia standard test). The overall outcome of these experiments was that the 
plant-produced mutant PV VLPs do elicit neutralising antibodies but less than IPV and 
the empty capsids produced in L cells. However, comparing an immune response of 
either L cell produced empty capsids with plant-produced VLPs is not very meaningful. 
The empty capsids were produced by infection which is very different to the 
recombinant expression of VLPs. Other factors that are necessary for virus infection 
could be present in the sample and influence the antibody response in the animals.  
Transgenic mice carrying the human receptor for poliovirus are susceptible to infection 
and paralysis. Groups of eight animals were immunised with one dose of PV1MahSC6b 
VLPs either produced at NIBSC in L cells or in plants, PBS as a negative control or the 
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European reference IPV (Fuchs et al., 2003). The mice were then challenged with 
infectious wt poliovirus and monitored for any signs of paralysis for 14 days. This 
experiment was also carried out with PV3 SktSC8 VLPs. Both plant-made stabilised 
mutants (PV1 MahSC6b and PV3 SktSC8) gave 100% protection against wt virus in mice. 
No difference was detectable between the empty capsids produced in L cells or the 
plant produced VLPs.  
Summary of section 5.4.3: Both plant-expressed mutants, PV1 MahSC6 VLPs and PV3 
SktSC8 VLPs elicit 100% protection in transgenic mice against infectious virus; even 
though their immune response in rats or mice is comparably weak.  
 STRUCTURAL ANALYSIS OF PV3 SKTSC8 VLPS 
The structural analysis was carried out by our collaborators at the University of Oxford 
using samples provided by myself. The data in this thesis are presented with the kind 
permission of Dr. Mohammad Bahar, Prof. David Stuart and Dr. Elizabeth Fry.  
Cryo-EM analysis demands highly concentrated and pure samples. The mutant 
PV3 SktSC8 was selected because of its stability and high expression levels in plants. In 
order to obtain a suitable sample for cryo-EM analysis, PV3 SktSC8 VLPs were purified 
from approximately 200 g infiltrated leaf tissue. Expression and purification was carried 
out following the routine protocol of two successive density gradients (see Figure 4.4-3). 
For this analysis the stabilised VLPs were extracted using P-buffer and further purified in 
PIPES buffer. Structures of the stabilised plant-expressed PV3 SktSC8 VLP were 
determined by cryo-EM in the absence and presence of the GPP3 (3-(4-pyridyl)-2-
imidazolidinone) pocket-binding compound (De Colibus et al., 2015). 4046 particles of 
PV3 SC8 and 2060 particles of PV3 SktSC8 + GPP3 yielded structures at 3.6 Å and 4.1 Å 
resolution respectively (Figure 5.5-1). The models were refined (Afonine et al., 2012) and 
structure validation was performed. The polypeptide main chain and side chains were 
well resolved for most of the capsid (Figure 5.5-2), allowing an atomic model for the 
majority of the three capsid proteins (VP0, VP1 and VP3) to be manually built into the 
cryo-EM density maps.  
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Figure 5.5-1: Cryo-EM structure of PV3 SktSC8 VLP at 3.6 Å. A) Cryo-EM image of PV3 SktSC8 
VLPs in vitreous ice. Examples of some VLPs are highlighted with black arrows. B) 3D 
reconstruction of PV3 SktSC8 VLP at 3.6 Å resolution, viewed along the 2-fold axis. The surface is 
coloured by radius from the centre of VLP from blue through green to red from the highest to the 
lowest radius. C) A central slice through the VLP to show the empty internal surface, viewed 
along the 2-fold axis and coloured as in (B).  
The overall architecture of the plant expressed PV3 SC8 VLP preserves structural 
features characteristic of native conformation (D form) particles such as the canyon 
depression around the fivefold vertex of the capsid (Figure 5.5-1 B). It revealed that the 
atomic structure of PV3 SktSC8 VLPs closely resemble the native wild-type poliovirus 
(see Figure 1.5-1) (Hogle et al., 1985).  
 
Figure 5.5-2: Cryo-EM density for PV3 SktSC8 and PV3 SktSC8 + GPP3 VLPs. A) Cryo-EM density 
map at 3.6 Å resolution of PV3 SktSC8 VLP looking at the VP1 protein pocket. VP1 is shown as 
sticks with carbon atoms coloured yellow, nitrogen atoms in blue and oxygen in red. B) Cryo-EM 
density map at 4.1 Å resolution of the PV3 SktSC8 VLP with GPP3 pocket factor compound bound 
to the VP1 protein pocket. VP1 is shown as sticks and coloured as in (A). The GPP3 molecule is 
coloured in green. Cryo-EM density maps are contoured at 1.0 σ.  
Cryo-EM density is not observed for a pocket factor molecule in the VP1 protein for the 
PV3 SktSC8 structure at 3.6 Å resolution (Figure 5.5-2). However, the structure of the 
PV3 SktSC8 VLP mixed with the GPP3 pocket binding molecule determined at 4.1 Å 
resolution shows unambiguous density for GPP3 bound to the VP1 protein pocket 
(Figure 5.5-2 B). The binding mode of GPP3 to VP1 is very similar to structures of other D 
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conformation polio capsids, suggesting that the plant-expressed PV3 SktSC8 VLP 
assembles in an authentic D form competent to bind pocket factor molecules. 
Summary of section 5.5: Cryo-EM analysis revealed that the atomic structure of 
stabilised PV3 SktSC8 VLPs closely resemble the native wt poliovirus.  
 DISCUSSION  
This chapter presents the results for potential vaccine candidates. It reflects the ultimate 
aim in generating stabilised PV VLPs that could potentially displace the currently 
available vaccines. In this chapter results were illustrated of those stabilised VLPs 
produced in plants and I will discuss their outcome.  
Initial work with the PV1 Q94C mutant quickly suggested that the deliberate design of 
PV mutants did not result in the desired increase in capsid stability. Therefore, an 
alternative strategy of applying selection pressure during propagation of the virus was 
adopted with the aim of obtaining empty capsids with enhanced stability. Directed 
evolution is a classical approach in virology and generated a vast amount of mutants 
with potentially great vaccine characteristics (submitted for publication Fox et al., 2016). 
However, the aim of the consortium is to develop a recombinantly expressed VLP 
vaccine, which would have the advantage of not requiring the growth of infectious virus, 
as is necessary for current vaccines. This would be a major advantage for the final 
eradication of poliovirus. For this reason, several expression systems have been 
proposed for the production of stabilised VLPs: insect cells, yeast and E. coli. Plants 
however, have so far proved to be the most successful and it was possible to express 
mutant PV VLPs from all three serotypes. These have been characterised as described in 
this chapter. 
The type 1 mutants produced by forced evolution, developed at the University of Leeds, 
have not been deeply analysed yet due to time limitations. The data presented in this 
work are preliminary and only give an indication towards their potential. So far PV1 
M2delta and PV1 M3delta VLPs produced in plants seem to have slightly increased 
capsid stability but further tests have to be carried out to confirm this. Both are very 
well expressed in plants, so such analyses should be possible. 
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The third type 1 mutant that was expressed and analysed was PV1 MahSC6b developed 
at NIBSC. Time allowed more complete analysis of this stabilised VLP expressed in plants 
and promising data were collected. In particular, it fully protected mice carrying the 
human PV receptor against challenge with a paralysing dose of infectious virus. This is a 
very positive result and certainly the most important one. The mice were also bled 
before the challenge and the serum tested for the presence of neutralising antibodies. It 
was noticeable that the plant-made VLPs triggered a significantly lower neutralising 
response than empty capsids made in mouse L cells. This discrepancy between L cell 
produced empty capsids and plant-produced VLPs has been observed with every 
stabilised VLP so far. The empty capsids were produced by electroporating L cells, which 
lack the receptor for poliovirus, with full-length RNA transcripts encoding the stabilised 
mutants to give a single cycle of infection. The particles produced were purified on 
sucrose gradients (submitted for publication Fox et al., 2016). Obviously there are 
differences between generating empty capsids in L cells via infection compared to the 
recombinant expression of VLPs in plants. During infection non-structural proteins are 
also expressed and these could play a role in the immune response in animals if they co-
purify with the empty particles. These proteins are not present in the plant-made 
samples. This could be an explanation for the weaker antibody response in animals. 
Furthermore, the uncharacteristic pocket factor of the plant-made VLPs could also have 
an influence on the antibody response in animals.  
The D/C antigen ELISA assay of PV1 MahSC6b VLPs revealed high D antigen levels in a 
sample that was purified in PIPES buffer. When PBS + EDTA buffer was utilised much 
more DAgU could be purified from the plant material; however, increased amounts of C 
antigen were also present. There could be plenty of reasons behind these discrepancies, 
one of which could be variations in the plant growth conditions or accidental changes in 
the purification. Generally, purification of this mutant caused trouble as it seemed to 
produce heterogeneous VLPs which could be a reflection of stability issues. This was 
noticed during the density gradients where the PV1 MahSC6b VLPs were spread over 
several fractions. Also cryo-EM revealed flexibility or heterogeneity in this VLP (Dr. 
Mohammad Bahar, University of Oxford, personal communication). Therefore, this 
mutant needs careful evaluation and further studies to finalise a verdict about its 
suitability as a vaccine candidate.  
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Working with type 2 has been most challenging as its expression or accumulation levels 
are very low in plants. PV2 has also proved to be the most difficult to express in other 
heterologous systems (Prof. Ian Jones, University of Reading, personal communication). 
One can only assume unstable mRNA or intrinsic instabilities of the capsid proteins lead 
to its early degradation. However, PV2 MEFSC6b was the most successful type 2 
stabilised mutant and therefore chosen to be represented in this thesis. The results so 
far indicate that the VLPs purified from plants are in the desired D conformation. As 
already mentioned above they are less thermostable than IPV or the empty capsids 
produced in L cells even with added EDTA. No protection studies have been carried out 
with the type 2 VLPs yet, because of the recent change in the composition of OPV 
vaccine. In April 2016 the WHO switched from trivalent OPV (tOPV) to bivalent OPV 
(bOPV) by removing the type 2 component (OPV2) from immunisation programmes. The 
absence of a type 2 vaccine means that any research using virulent type 2 requires 
higher containment facilities than the other serotypes with consequences for challenge 
experiments. As soon as those facilities are available the type 2 mutant will be tested in 
animals.  
PV3 SktSC8 has been the most reliable and successful sVLP so far with very positive and 
promising results. It accumulates to high concentrations in plants, is very robust and 
therefore easy to purify. It keeps its D antigenicity very well during purification and from 
90 infiltrated leaves ~2200 DAgU could be extracted. Even though the neutralising 
antibody response in rats was weak it provided complete protected for transgenic mice 
against infectious virus.  
We noticed variations not only in the antibody response in animals but also in the 
thermostability between L cell produced empty capsids and the plant-made VLPs in our 
studies. There are several reasons behind this which I already discussed above. Another 
factor however, was quickly identified. My collaborators at NIBSC used a PBS based 
buffer containing 20 mM of the chelating agent EDTA when purifying their empty 
capsids. A rather unusual addition as magnesium chloride is known to stabilise Sabin 
polio vaccine (Mirchamsy et al., 1978). We analysed its effect on the antigenic switch 
during increased temperature and it became clear that EDTA supports the PV3 SktSC8 
VLPs in their D form but concentrations less than 20 mM did not increase capsid 
stability. Also type 1 and type 2 mutants showed increased thermostability when 20 mM 
EDTA was present. Preliminary data, which are not presented in this thesis, showed that 
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EDTA has a stabilising effect only on the mutants but not on the wt VLPs. It is therefore 
hard to say what exactly the key stabilising factor is. We assumed the removal of Ca2+ by 
EDTA could possibly have a positive effect on the stabilised VLPs but when they were 
transferred into a buffer without divalent cations no increased stability was observed. 
Possibly useful could be adjusting the concentration of divalent cations in the buffer, 
especially Ca2+, which might result in even more resistant particles. Also I would like to 
experiment with even higher concentrations of EDTA and see if that would further 
increase capsid integrity.  
High resolution cryo-EM resolved the structure of the PV3 SktSC8 VLPs to 3.6 Å 
resolution illustrating its similarity to wild-type polio 3 Sabin strain and demonstrating 
that recombinant plant-expression of polio VLPs produces authentic particles with the 
correct antigenic features. The PV3 SktSC8 structure does not show strong density for a 
pocket factor in the VP1 pocket. However, it is unlikely that the VP1 pocket is empty; 
because the pocket has not collapsed (structure is native antigenicity). Weak density is 
observed at very low cryo-EM density map contour levels. This suggests that the VP1 
pocket is occupied with a heterogeneous mixture of pocket factors, acquired from the 
plant cell expression system. Indeed, when the PV3 SktSC8 VLP is mixed with a well-
known pocket binding compound (GPP3), a complex can be formed. The structure of 
PV3 SktSC8 + GPP3 shows clear, unambiguous density for the pocket-binding molecule 
in the VP1 pocket. The structure of PV3 SktSC8 + GPP3 is unchanged in other aspects 
compared to PV3 SktSC8 without GPP3, and both structures display a native antigenic 
conformation. It is possible to soak pocket factor compounds into the VP1 pocket of 
recombinant plant expressed polio VLPs. This suggests an additional method for further, 
enhanced stabilisation of synthetic polio vaccines.  
In summary, plants successfully express stabilised mutants VLPs of all three serotypes of 
PV. The presented data suggest effective production of stabilised VLPs in plants which 
demonstrate promising results. However, more work has to be invested in generating 
uniform samples. Furthermore, the reasons behind the difference between L cell 
produced empty capsids and the plant-produced VLPs have to be further examined.  
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Chapter 6: AN ALTERNATIVE PRODUCTION SYSTEM 
 INTRODUCTION 
The previous chapter described the successful synthesis and purification of 
immunogenic, stabilised PV VLPs in whole N. benthamiana plants using transient 
expression, underlining the great potential of this expression platform. However, critics 
complain about the need of large greenhouses and unusual techniques and methods 
when using whole plants as a production system, despite the fact that companies like 
Medicago or Kentucky BioProcessing, Inc. (KBP) have proved the feasibility of industrial 
production of pharmaceuticals using this approach. The currently used systems for 
large-scale manufacturing like mammalian cells, yeast or bacteria cell cultures grow in 
bioreactors and their handling is backed by years of cumulative experience and process 
optimisation. Yet working with plant-based systems does not necessarily demand big 
investment in greenhouses or adopting completely new strategies if plant cell 
suspension cultures are used. The handling of plant cell suspension cultures is very 
similar to the other more established systems and therefore possibly more attractive to 
industry. With the licensed PMT Protalix’s Elelyso, plant suspension cultures have 
proven their capability of producing a commercially available pharmaceutical.  
Plant suspension cultures combine the advantages of whole plants with those of 
traditional fermenter systems. They grow in contained, controlled and sterile 
environment with medium costs (as defined in Table 6.1.1). The cultivation strategies 
are versatile with almost no limitation for mass culture (Santos et al., 2016). For a 
comparison between whole plants, plant cell suspension cultures and mammalian cell 
cultures see Table 6.1.1 below.  
Table 6.1.1: Comparison among the available systems for biopharmaceutical production. Cost: 
Low, $20–100/g; Medium, $50–1000/g; High, $1000–10,000/g (Santos et al., 2016). 
System Contamination risk Scalability Cost 
Whole plant systems Low Very high Low 
Plant cell suspension Very low High Medium 
Mammalian cells High Medium High 
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Bright Yellow-2 (BY-2) is a widely used tobacco cultivar which was developed in 1968 by 
the Japan Tobacco Company. It can multiply up to 100-fold within 7 days with a doubling 
time of 16-24 h under ideal conditions (Santos et al., 2016). They are grown in the dark 
which reduces energy costs for production. Transformation with A. tumefaciens has 
proven to be highly efficient (Nagata et al., 1992); allowing the synthesis of several 
biopharmaceuticals. Some are listed in the following Table 6.1.2: 
Table 6.1.2: Biopharmaceuticals produced in BY-2 cell suspension culture. FW = fresh weight, 
TSP = total soluble protein (Santos et al., 2016). 
Protein Indication Yield 
Hepatitis B Surface Antigen (HBsAg) Hepatitis B vaccine 6.5 µg/g FW 
Human Growth Hormone Growth hormone Up to 35 mg/l 
EPO Tissue protective function Low 
Granulocyte-Macrophage Colony 
Stimulating Factor (GM-CSF) 
Production of white cells Up to 250 µg/l 
IL-4 Immunoregulation 0.18 µg/l 
IL-12 Immunoregulation Up to 160 µg/l 
α -HBsAg Mab Hepatitis B antibody Up to 15 mg/ l 
Norwalk virus capsid protein Acute gastroenteritis vaccine 
Up to 1.2% 
TSP 
The Table above demonstrates the versatility of this expression system and its potential. 
All these positive factors attracted my attention looking for an alternative production 
platform for the PV VLPs. Furthermore, BY-2 cells had already been successfully 
transformed with the pEAQ system and used to produce human serum albumin (Sun et 
al., 2011). At the VTT Technical Research Centre of Finland, Dr. Anneli Ritala and Jaana 
Rikkinen introduced me to the stable expression of recombinant proteins in BY-2 cells. 
With their help I tested the system with the relatively simple NNV and successfully 
expressed NNV VLPs in a transgenic line of BY-2 cells. To my knowledge this was the first 
time assembled VLPs were expressed in a plant suspension culture. The results are 
presented in detail later in this chapter. However, the main aim was the expression of 
PV VLPs in these cells. In a workshop run by the Fraunhofer IME (Aachen, Germany) in 
Cape Town, South Africa (2015) I was taught by Markus Sack and his colleagues how to 
transiently express proteins in BY-2 cells; a technique developed and patented by 
Dr. Thomas Rademacher (WO2013113504). The fast and simple technique of casting BY-
2 cell packs or “cookies” seemed to address some of the problems critics have with 
whole plants as expression hosts and therefore appeared worth investigating as a means 
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for the production of PV VLPs. The following Figure 6.1-1 illustrates the simplicity of the 
technique. 
 
Figure 6.1-1: Making a cookie. BY-2 cells are poured into a Büchnerfunnel, which is laid out with 
sterile filter paper, and a vacuum is applied to remove the media. When a solid cell pack has 
formed it gets transferred with the filter paper into a petri dish where agroinfiltration takes 
place. The cell packs are incubated in a lightproof box at 28 °C with a water reservoir to keep the 
humidity high.  
The cells are grown in Erlenmayer flasks on a shaker at 28 °C in the dark. However, 
cultivation strategies are versatile and range from stirred tank reactors (Doran, 1999), 
wave reactors (Eibl et al., 2010) to bubble columns (Terrier et al., 2007). After 3-4 days 
the cells have grown and multiplied and are ready to be used. Under sterile conditions 
the cells are poured into a Büchner funnel, which is laid out with sterile filter paper, and 
a vacuum is applied. When the liquid media is completely removed and the cell pack has 
formed it gets transferred into a petri dish. Agrobacteria harbouring the gene of interest 
are carefully dropped onto the cell pack until it is saturated. The cell packs are stored in 
a lightproof box at 28 °C with a water reservoir for the purpose of keeping the humidity 
high.  
This chapter is about the exploration of BY-2 cells and their potential as a suitable 
alternative production platform for whole plants. VLPs were expressed in a transgenic 
BY-2 cell line but also via transient expression. Characterisation of expression is 
presented in the following sections as well as properties of the BY-2 cell made VLPs.  
 STABLE EXPRESSION OF NNV VLPS IN BY-2 CELLS 
For the generation of stable transgenic BY-2 cells the same construct used for transient 
expression of NNV VLPs in plants (pEAQ-HT-NNV) was sent to Jaana Rikkinen, VTT 
Finland.  She prepared 2-3 days old BY-2 cell cultures with 0.25 mM acetosyringone and 
set up agrobacteria solution carrying pEAQ-HT-NNV to an OD600 of 1.0. Both were mixed 
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together and left to incubate at 28 °C for 2-3 days. Afterwards the BY-2 cells were 
transferred onto solid MS media with appropriate antibiotics (25 ppm kanamycin, 500 
ppm carbenicillin and 500 ppm vancomycin) and left in the darkness at 28 °C. After 2-3 
weeks small calli had grown which were tested via PCR using the primer pair C1/C3 
(listed in Appendix 1) for the gene of interest. When I arrived at VTT we tested in total 
15 calli positive for the NNV coat protein gene and therefore further analysed them for 
protein expression. Small scale protein extraction was carried and analysed on a 
Western blot using anti-NNV antibody.  
 
Figure 6.2-1: Analysing BY-2 cell lines for NNV coat protein expression. Small scale protein 
extraction was carried out on 15 BY-2 cell lines and checked for NNV coat protein content via 
immunodetection using anti-NNV (ab26812) antibody. C- = BY-2 cells. C+ = plant-made NNV VLPs. 
Red arrow indicates position of the coat protein.  
All but cell line 1 and 5 showed detectable levels of NNV coat protein in the Western 
blot above (Figure 6.2-1). The cell lines showed differences in expression level of the 
desired protein. BY-2 cell line 16 displayed the highest concentration of NNV coat 
protein and thus was chosen for larger scale VLP production.  
To check for assembled NNV VLPs, 500 ml of MS media was inoculated with BY-2 cell 
line 16 and after 3.5 days the cells were harvested. They were homogenised using a 
mortar and pestle and after a clarification spin the VLPs were purified through a 
discontinuous sucrose cushion. Each sucrose fraction was retrieved after 
ultracentrifugation and analysed on a Western blot using anti-NNV (ab26812) antibody. 
The Western blot is displayed in Figure 6.2-2 A. 
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Figure 6.2-2: NNV VLP purification from transgenic BY-2 cell line. A) The VLPs were purified 
through a discontinuous sucrose gradient of 20%-60% (w/v), each fraction was retrieved and 
analysed on a Western blot. SN = Supernatant. C+ = plant-made NNV-VLPs. Anti-NNV (ab26812) 
antibody. M = Protein ladder, molecular weights indicated. C+ = plant-made PV3 SktSC8 VLPs. 
Red arrow indicates NNV coat protein alpha. Black arrow indicates mature NNV coat protein 
beta. B) TEM image of NNV VLPs purified from transgenic BY-2 cells. Yellow arrows indicate NNV 
VLPs.  
The Western blot showed a weak signal for the NNV coat protein in the 40% (w/v) and 
50% (w/v) sucrose fractions. Specifically, two bands could be seen (indicated by a red 
and black arrow in Figure 6.2-2 A), an observation I made occasionally when expressing 
NNV VLPs transiently in plants; a possible explanation for this has been discussed earlier 
in this thesis (see section 3.4). There was also a strong signal in the SN, which suggests 
the presence of non-assembled coat protein. The 40% (w/v) and 50% (w/v) sucrose 
fractions were combined and dialysed overnight. TEM analysis showed the first NNV 
VLPs made in transgenic BY-2 cells (Figure 6.2-2 B).  
Summary of section 6.2: Generating a transgenic BY-2 cell line is relatively simple, but 
nonetheless time-consuming technique compared to transient expression. A transgenic 
BY-2 cell line successfully produced NNV VLPs.   
 PROOF OF EXPRESSION FOR PV VLPS 
In order to express all three wild-types and mutants, agrobacteria were prepared exactly 
the same way as for the infiltration of plants (see section 2.3.2). Agrobacteria 
harbouring the respective P1 gene were diluted to an OD600 of 0.8 and agrobacteria 
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carrying the gene for the proteinase were diluted to an OD600 of 0.4 in MMA buffer. Both 
solutions were mixed at equal ratios and dropped onto the cell pack. After 5 days 
incubation at 28 °C a small scale protein extraction was carried out and after separation 
on a SDS-PAGE gel the protein was transferred onto a nitrocellulose membrane.  
 
Figure 6.3-1: Proof of VP1 expression in BY-2 cells. Agrobacteria carrying the respective P1 gene 
were mixed with agrobacteria containing the proteinase. They were dropped onto the cell pack 
and incubated for 5 days at 28 °C in a lightproof box. Small scale protein extraction was carried 
out and the results were analysed via immunodetection. Anti-VP1 MAB8566 antibody. 
M = SeeBlue Plus 2 with molecular weights indicated. C- = pEAQ-HT-EV. C+ = plant-made PV3 
SktSC8 VLPs. Red arrow indicates VP1.  
The Western blot above (Figure 6.3-1) demonstrates the successful expression and 
proteolytic processing of the P1 regions of all the wt PV serotypes and their respective 
stabilised mutants. VP1 appeared equally strong expressed in all six samples.  
With the aim of identifying the time of peak PV protein expression in the cells and to 
compare it to plants, a time course experiment was carried out with all three serotypes 
and their respective stabilised mutant. A BY-2 cell pack was formed and suspension of 
Agrobacterium containing plasmids encoding P1 and 3CD added. Equal amounts of cells 
were sampled every day using a cork borer. As a negative control Agrobacteria 
containing pEAQ-HT-EV (empty vector control) were added to the BY-2 cells while the 
positive control was a sample of PV3 SktSC8 VLPs purified from plants. The protein 
content was analysed on a Western blot using anti-VP1 MAB8566 antibody.  
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Figure 6.3-2: Expression of PV VLPs in BY-2 cell packs over time. All three serotypes and the 
respective mutants were expressed in BY-2 cell packs. With a cork borer the same amount of cells 
was sampled for 10 days and the protein content analysed for VP1 via immunodetection. Anti-
VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights indicated. C- = pEAQ-HT-EV. 
C+ = plant-made PV3 SktSC8 VLPs. Red arrows indicate position of VP1.  
The Western blots showed VP1 expression starting at 5 dpi, only wt PV1 and wt PV3 
displayed detectable levels of VP1 2-3 days after infiltration. In the wt PV1 sample the 
level of VP1 increased during the time of incubation whereas with the other types the 
amount of VP1 stayed relatively constant (after day 2). Based on these results it is 
difficult to determine if longer incubation times would increase the protein/VLP amount 
in the cells. It would be worth repeating this time course experiment and also increase 
the time over which sampling took place to confirm these results. In most types the 
concentration of protein stayed constant from day 5 to day 10 after infiltration which is 
in contrast to the expression pattern in whole plants, where the protein level reduces on 
day 7-8 after infiltration.    
In order to see if VLPs are able to assemble in BY-2 cells the experiment was scaled up 
and a VLP-purification was carried out. So far only the three stabilised mutants below 
have been analysed for VLP assembly. 
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Figure 6.3-3: TEM images of stabilised VLPs made in BY-2 cells. PV1 MahSC6b VLPs, PV2 
MEFSC6b VLPs and PV3 SktSC8 VLPs visualised by TEM in negative stain.   
The TEM images above show that correctly assembled VLPs of PV1 MahSC6b, 
PV2 MEFSC6b and PV3 SktSC8 can be produced using the cell pack technology. The VLPs 
were of expected size and shape; no obvious differences were visible compared to plant-
produced particles. However, in the following section plant-made VLPs are compared in 
more detail to those produced in BY-2 cells and the differences are highlighted.   
Summary of section 6.3: Transient expression of PV VLPs in BY-2 cells is successful and 
correct assembly was proven.  
 WHOLE PLANTS VS. BY-2 CELLS 
During extraction and purification abnormalities in sedimentation behaviour were 
identified in the cell pack produced VLPs which triggered a direct comparison between 
the PV VLPs produced in N. benthamiana leaves and those expressed in BY-2 cell packs. 
As an example PV3 SktSC8 was chosen because of its stability and reliability. For the 
purpose of this experiment BY-2 cell packs were formed and infiltrated with 
pEAQ-HT-PV3 SktSC8-P1 and pEAQ-3CD; the same constructs were co-infiltrated into 
N. benthamiana leaves. The cell packs and plants were harvested 6 dpi and 
homogenised using either a mortar and pastel for the BY-2 cells or a blender for the 
infiltrated leaf material. For the purification an identical protocol was followed. The 
samples were either purified over a sucrose cushion made up out of 5 ml 25% (w/v) 
sucrose and a 1 ml bottom fraction containing 70% (w/v) sucrose or through a 
discontinuous sucrose gradient (20-60% w/v) as shown in Figure 3.2-1. Each fraction was 
analysed for VP1 on a Western blot using anti-VP1 MAB8566 antibody.   
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Figure 6.4-1: Comparison of plant-produced- with BY-2 produced PV VLPs. PV3 SktSC8 VLPs 
were extracted from plants or BY-2 cells and separately purified. On the left a schematic drawing 
represents the make-up of the gradient and where the VLPs were located; either produced in 
plants (represented by the leaf) or expressed in BY-2 cell packs (illustrated by the coloured petri 
dish). A) The VLPs were purified through a sucrose cushion, the fractions retrieved and analysed 
on a Western blot: the bottom 500 µl fraction (B), the 70% and interface (IF), the 25% and the 
supernatant (SN). B) The VLPs were purified through a discontinuous sucrose gradient of 20%-
60% (w/v), each fraction was retrieved and analysed on a Western blot. SN = Supernatant. Anti-
VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights indicated. C+ = plant-made 
PV3 SktSC8 VLPs. Red arrows indicate VP1.  
The results above illustrate slight differences in the sedimentation behaviour between 
plant-made and BY-2 cell-made PV VLPs (Figure 6.4-1). The sketch of the gradients show 
where most VLPs were located, either expressed in plants (represented by a leaf) or in 
BY-2 cells (represented by a petri dish). In both the sucrose cushion and the sucrose 
gradient, the VLPs expressed in BY-2 cells sedimented further in the gradients than 
those produced in whole plants. Additionally, when expressed in cell packs, the VLPs 
were of higher consistency: the signal of VP1 detected in Western blots was spread over 
fewer fractions in the sucrose gradient (Figure 6.4-1 B). It is also noticeable that in the 
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sucrose gradient analysis of the BY-2 cell-made VLPs (Figure 6.4-1 B), no signal could be 
detected in the SN. Signal in this fraction can be an indication of non-assembled protein 
or broken particles. In order to check particle shape and size they were visualised by 
TEM. No yield comparison has been carried out yet. 
 
Figure 6.4-2: TEM images of PV3 SktSC8b VLPs made in either BY-2 cells or whole plants. A+B) 
VLPs were purified by sucrose cushion. C+D) VLPs were purified by sucrose gradient. On the left 
the VLPs were produced in BY-2 cells (represented by the petri dish) and on the right in plants 
(represented by the leaf).  
Even though the VLPs produced in the two systems showed differences in sedimentation 
behaviour, they appeared even and identical under the TEM. The VLPs were of the right 
size (27-30 nm in diameter) and the usual shape. Again, it is hard to tell if the VLPs were 
empty or if they encapsulated host nucleic acid.  
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Summary of section 6.4: PV VLPs expressed in BY-2 cells sediment more quickly than 
those produced in whole plants and they are also more uniform. When visualised by 
TEM, no differences in shape and size could be detected implying the BY-2 cell-produced 
particles are denser. 
 IMMUNOLOGICAL PROPERTIES OF BY-2 CELL PRODUCED PV2 MEFSC6B VLPS 
For a slightly larger scale production, cell packs were formed out of 300 ml of BY-2 cells 
and inoculated with PV2 MEFSC6b and the 3CD proteinase. After 9 days incubation at 
28 °C the cells were homogenised and purified through a sucrose cushion followed by a 
Nycodenz gradient. Based on previous experiments and the high density of BY-2 cell-
made VLPs (section 6.4), the sucrose cushion was slightly altered to start with a 35% 
(w/v) sucrose layer instead of 25% (w/v) with the aim to improve sample purity.    
 
Figure 6.5-1: Purification of PV2 MEFSC6b VLPs from BY-2 cells. A) The clarified cell extract was 
purified through a sucrose cushion made out of 5 ml of a 35% (w/v) sucrose solution and a 1 ml 
70% (w/v) sucrose bottom fraction. Each fraction was analysed for VP1 content on a Western blot 
using anti-VP1 MAB8566 antibody. M = SeeBlue Plus 2 with molecular weights indicated. C+ = 
plant-made PV3 SktSC8 VLPs. Red arrow indicates VP1. B) PV2 MEFSC6b VLPs made in BY-2 cells 
visualised by TEM in negative stain. 
The Western blot showed a strong signal in the bottom part of the sucrose cushion. This 
fraction was dialysed and further purified through a standard Nycodenz gradient (as 
described in section 2.6.3). The PV2 MEFSC6b VLPs were visualised by TEM in negative 
stain (Figure 6.5-1 B). The sample was still contaminated even though the VLPs have 
been through two purifying gradients. Obtaining a clean sample of BY-2 cell-made VLPs 
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will clearly require alterations and improvements to the extraction and purification 
strategy.  
Helen Fox (NIBSC) used a non-competitive sandwich ELISA assay to measure the D-
antigen content of the BY-2 cell made PV2 MEFSC6b VLPs (Singer et al., 1989). Briefly, 
two-fold dilutions of antigen were captured with a serotype-specific polyclonal antibody, 
then detected using serotype-specific, D antigen (Mab 1050)-specific monoclonal 
antibody followed by anti-mouse peroxidase conjugate. No C specific type 2 antibody 
was available. The D antigen content of each test sample was evaluated against a 
reference of assigned D antigen content (Fuchs et al., 2003) by parallel line analysis 
(Combistats).  
 
Figure 6.5-2: Potency of PV2 MEFSC6b VLPs made in BY-2 CELLS. Non-competitive sandwich 
ELISA assay for the measurement of D antigen content in PV2 MEFSC6b VLP sample made in BY-2 
cell packs using Mab 1050 (D antigen). IPV = European Pharmacopeia Standard for IPV.  
In the ELISA a small amount of D antigen was measured. The sample, which derived 
from 300 ml BY-2 cell culture, contained approximately 4 DAgU/ml. A satisfying result 
especially because type 2 expresses to only a very low level in comparison to the other 
types but still a small amount of D antigen could be produced.  
Summary of section 6.5: D antigenic PV2 MEFSC6b VLPs can be produced in BY-2 cells.   
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 DISCUSSION 
The results presented in this chapter are still preliminary but point towards the 
possibilities that BY-2 cells offer as an alternative expression system for pharmaceuticals 
including, in this specific case, for VLP-based vaccines. This chapter demonstrates the 
successful expression of all PV serotypes and correct particle assembly of the stabilised 
mutants PV1 MahSC6b, PV2 MEFSC6b and PV3 SktSC8 in BY-2 cells. The PV VLPs are 
expressed over a long period of time at a constant level, compared to transient 
expression in plants where the concentration decreases after 7-8 days: possibly an 
advantage of BY-2 cells over whole plants.  
A larger scale production has only been attempted with PV2 MEFSC6b VLPs and the 
sample tested positive for D antigen. In this experiment 300 ml of MS media was 
inoculated with BY-cells, a volume that could easily be increased. There is almost no 
limitation for mass culture with BY-2 cells. Also casting the cell packs can be scaled up 
and experiments are currently ongoing at the Fraunhofer IME Aachen on improving this 
large scale technique. Quite simply with the use of bigger cookie casting equipment 
larger cell packs could be formed.  
In case the cell pack technique appears too elaborate one could generate a transgenic 
BY-2 cell line which constantly expresses the desired protein or VLP. Once a stable line 
has been established the workflow is simple, quick and easily scalable. Working with 
transgenic BY-2 cells is very similar to other commonly used tissue cultures and for that 
reason referred to as the “HeLa-cells in the biology of higher plants” (Nagata et al., 
1992). In this chapter successful expression of NNV VLPs in transgenic BY-2 cells is 
demonstrated. Future work will include larger scale expression in order to do in depth 
analysis of these transgenically produced VLPs, comparison to plant-produced NNV VLPs 
and for animal studies. A transgenic BY-2 cell line could also be generated for PV VLPs. 
Combining the polyprotein P1 with the proteinase in a single expression cassette would 
facilitate the successful creation of a line expression both proteins.  
Interestingly, differences in density could be observed between BY-2 cell-produced VLPs 
and plant-made VLPs. When purified through density gradients the VLPs, made in the 
BY-2 cell culture, sedimented much further down the gradient than those expressed in 
plants. Their density appeared of higher consistency whereas plant-expressed PV VLPs 
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usually spread over several fractions in the density gradients. The reason behind this is 
still not understood but possibly encapsulation of host nucleic acid could lead to 
increased density. Previous experiments showed that plant-made PV VLPs do not take 
up host RNA or DNA, however in TEM images mixtures of empty and full looking 
particles can be seen. Also high resolution microscopy revealed that the plant-made 
particles are loaded to various degrees with unknown material. The environment in BY-2 
cells might promote uptake of random host nucleic acid or even protein by the PV VLPs. 
High resolution microscopy could help solving this uncertainty. It would also be 
interesting to see in high resolution images if BY-2 cell-made PV VLPs carry pocket 
factors. The existence of a pocket factor could have an impact on density.   
In order to promote BY-2 cell suspension cultures, improvements to the extraction and 
purification methods will have to be undertaken. The BY-2 cells are surprisingly tough 
and therefore breaking them open is a challenge. Using mortar and pestle is suitable 
only to a limited extend but alternatives like cell disruptors could facilitate the extraction 
of VLPs from the cells. Experiments involving freezing the cells with liquid nitrogen prior 
to attempting extraction have been conducted and this approach improved the VLP 
yield slightly. The stabilised PV VLPs withstood the harsh treatment of liquid nitrogen 
(data not shown). Purification has also been an issue and more work has to be invested 
in this area in the future.  
When aiming for commercial production of pharmaceuticals the yield of the product is 
of course of very high importance. The BY-2 cell line has been utilised as an expression 
host for numerous recombinant proteins mostly because of its exceptional growth rate. 
However, the yields in the BY-2 cells are still generally low (see Table 6.1.2), especially 
when compared to mammalian cell cultures which produce yields of 5 g/l (Walsh, 2010). 
Low protein productivity remains a major obstacle that limits extensive 
commercialisation of plant cell suspension cultures as production platforms. High levels 
of contaminants in the samples have hindered credible measurements of VLP 
concentration and therefore no VLP yield has been determined yet. Further 
development of plant cell cultures is needed in order to meet the general industrial 
demand of grams per litre product titre.  
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Chapter 7: FINAL DISCUSSION  
Overall, the work presented in this thesis demonstrates the potential of plant-based 
production of VLP vaccine candidates. First, the comparatively simple NNV VLP was 
expressed, which has never been done in plants before. The capsid of this virus consists 
of a single type of coat protein that self-assembles into a stable T = 3 icosahedral capsid 
when expressed in a variety of heterologous systems, including, as demonstrated by the 
work reported in this thesis, plants. Structural studies carried out by Daniel Hurdiss at 
the University of Leeds, revealed authentic looking plant-made particles when compared 
to wild-type NNV. Currently ongoing are further improvements of the structure to 
resolve the P-domains. Immunological studies of this VLP vaccine candidate are 
currently in preparation in collaboration with Dr. Richard Paley at CEFAS, Weymouth, 
UK. A positive outcome of the immunological studies would be a step towards the final 
aim of developing an oral vaccine against VNN. Possibilities like pressing plant material 
harbouring NNV VLPs into pellets and feeding it to the animals should be investigated in 
the future. This basic NNV VLP was a great starting point for the expression of the more 
complex PV VLPs in plants. Correct particle assembly of PV requires processing of the 
capsid precursor polyprotein, which was provided by the co-expression of the 
proteinase. The work in this thesis represents the first report of the production of 
immunologically effective non-infectious poliovirus-like particles in plants. The 
expression level of the plant-produced stabilised VLPs vary between the serotypes but 
levels of up to 70 mg purified VLPs per kg infiltrated plant tissue were obtained. All 
analysed plant-expressed stabilised mutants showed improved capsid stability and those 
that were tested protected transgenic mice from infectious virus. The approach of 
stabilised VLP-based vaccines could be adopted for related picornaviruses e.g. foot-and-
mouth disease virus (FMDV) or hepatitis A virus (HAV). In summary, this work 
demonstrates the potential of plants as a production platform for various VLP-based 
vaccines. Furthermore, I could show the successful expression of all wild-types and three 
stabilised PV VLPs, as well as stable expression of NNV VLPs in BY-2 cells, an alternative 
expression system to whole plants.  
Despite the many advantages of plants as expression systems (discussed in section 
1.1.1) they are still overshadowed by other production platforms like mammalian cell 
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cultures, yeast or E. coli; mostly because these systems are backed by decades of 
experience and their simple growth conditions compared to the demands of plants. 
However, whole plants compared with traditional biomanufacturing platforms that grow 
in bioreactors, demand significant less capital investment and show >50% reduction in 
cost of goods compared with published values at similar production scales (Nandi et al., 
2016). Slowly change is happening and companies realise the potential lying within 
plants as production hosts for pharmaceuticals (Lomonossoff and D'Aoust, 2016).  
Plant suspension cultures are a potentially attractive alternative to whole plants or even 
traditional microbial or animal cell cultures as production platforms for pharmaceutical 
production. In comparison with whole plants grown in greenhouses, cell suspension 
cultures offer tighter control over the growth conditions in standardised bioreactors, 
therewith enabling higher batch to batch consistency and a greater opportunity of 
adhering to cGMP. Also, they do not require light which reduces the cost of growing the 
cultures. In contrast to mammalian cells, the plant cell cultures grow at lower 
temperatures (20-28 °C vs. 37 °C), yet another cost reducing factor. Important also is the 
feasibility of downstream processing which is simplified in plant cell suspension cultures 
by the lack of waxes in plant cell cultures (Reuter et al., 2014).  
Plant cell suspension cultures have been utilised as an expression host for numerous 
recombinant proteins (listed in Table 6.1.2). I have already mentioned Protalix’s Elelyso, 
the first PMT protein approved by the FDA for human use (see section 1.1.2). Yet 
another great example for successful commercial production of pharmaceuticals in 
plant-cell culture is Phyton Biotech, utilising the Plant Cell Fermentation (PCF®) platform 
technology. Phyton is the largest supplier of high quality Paclitaxel and Docetaxel 
(chemotherapy medication) in the world, producing nearly 500 kg Paclitaxel annually 
under strict GMP conditions. They propagate their plant cell cultures in reactors that can 
hold between 80 and 7500 litres with a total capacity of 220 000 litres, especially 
designed for large scale plant cell cultivation (Phyton, 2016).  
The feasibility of large scale plant-cell culture cultivation has been confirmed by the 
success of Phyton Biotech`s Paclitaxel and Docetaxel. In order to estimate costs of this 
production system and to compare it to whole plants I contacted Dr. Tanja Holland (IME 
Fraunhofer Aachen, Germany) who is an expert in the plant-cell pack technology. The 
MS media used for the propagation of BY-2 cells costs 0.50-1.00 € per litre. When 
utilising a 30 litre continuous fermentation reactor, which needs daily addition of 15 
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litres fresh media, for the propagation of plant suspension cells the costs for media 
come to approximately 450 € per month and it takes 16 h per month of man power to 
keep the process going. From this reactor 200 litres or 22 kg cell culture wet weight can 
be harvested per month; this correlates with 250-500 N. benthamiana plants. However, 
for the growth of 250-500 plants an estimate of 25-50 m2 are needed, whereas the 
fermenter requires only a base of 3-4 m2. Furthermore, getting plants from seed to a 
mature plant ready to be infiltrated takes 5-6 weeks (2 weeks germination and 3-4 
weeks growing), whereas  BY-2 cells  multiplying 80- to 100-fold over 1 week in optimal 
conditions (Nagata et al., 1992). In summary plant cell cultures are inexpensive to grow 
and need less space and time than whole plants. However, comparing costs of whole 
plants and plant cell suspension cultures is not straight-forward because the yields of 
recombinantly produced proteins differ between both systems. In general, the 
obtainable yield of proteins produced in the BY-2 cell line is low (see Table 6.1.2). Thus, 
further development is needed in order to meet the general industrial demand of grams 
per litre product titre.  
In conclusion, plants, whole or as cell suspension culture, are a promising platform for 
the production of VLP-based vaccines. The work presented in this thesis provides 
evidence for the potential of the plant-expressed stabilised PV mutants. However, more 
work has to be invested in getting 3 potent and reliable stabilised PV VLPs. Especially 
type 1 and type 2 have to be further analysed and optimised. Getting this project 
towards commercial production is the main future goal. It would be a great achievement 
to replace the current polio vaccines with plant-produced stabilised VLPs. It would also 
be a big step forwards for plant-based production of biologics and a great advertisement 
for this platform. The production of this VLP-based polio vaccine would be a non-profit 
venture, but nevertheless a big honour. Unfortunately, traditional expression hosts are 
still dominating the pharmaceutical market but I hope that in future plants will convince 
big pharmaceutical industries to invest into this technique. The results presented in this 
thesis are certainly a step into the right direction.  
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APPENDIX 1: LIST OF PRIMERS 
Details of the primers used for amplification of inserts, verification of clones and 
introduction of mutations in the work described in this thesis are presented below.  
For verification of inserts cloned in between the 5`UTR and 3`UTR of pEAQ-HT: 
C1 AACGTTGTCAGATCGTGCTTCGGCACC 
C3 CTGAAGGGACGACCTGCTAAACAGGAG 
5`UTR GTTTTCCCGTGGTTTTCGAACTTG 
3`UTR GCACACCGAATAACAGTAAATTCAAACTAAAG 
For SDM of P19 to generate P19m: 
P19-R43W-SDM-F CGAGTTGGACTGAGTGGTGGCTACATAACGATGAG 
P19-R43W-SDM-R CTCATCGTTATGTAGCCACCACTCAGTCCAACTCG 
For SDM of AUG 161 to generate non-HT pEAQ: 
Rev AUG161_F GCTTCGGCACCAGTACAATGTTTTCTTTCACTG 
Rev AUG161_R CAGTGAAAGAAAACATTGTACTGGTGCCGAAGC 
For SDM of PV1-P1 to generate pEAQ-HT-PV1 Q94C: 
PV1 Q94C_F CTCTACCATCACCACTTGCGAGGCTGCTAACTCTGTTG 
PV1 Q94C_R CAACAGAGTTAGCAGCCTCGCAAGTGGTGATGGTAGAG 
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APPENDIX 2: SEQUENCES  
Sequences utilised in this work, codon-optimised for the expression in N. benthamiana 
and synthesised by GeneArt, are listed below. Start codons are highlighted in green, stop 
codons are highlighted in red. The restriction sites used for cloning into pEAQ-HT, 
namely AgeI and XhoI, are underlined in orange and blue, respectively. 
3CD 
TCAAGGCCGCATACCGGTAACAATGGGTCCTGGTTTCGATTACGCTGTTGCTATGGCTAAGAGG
AACATCGTGACTGCTACCACCTCTAAGGGAGAGTTCACTATGCTTGGTGTGCACGATAACGTGG
CAATTCTTCCTACTCACGCTAGCCCTGGTGAGAGCATTGTGATCGATGGTAAAGAGGTTGAGAT
CCTGGATGCTAAGGCTCTTGAAGATCAGGCTGGTACTAACCTTGAGATCACCATCATCACCCTGA
AGAGGAACGAGAAGTTCAGGGATATCAGGCCTCACATCCCTACCCAGATTACCGAGACTAACG
ATGGTGTGCTGATCGTGAACACCAGCAAGTACCCTAACATGTACGTTCCAGTGGGTGCTGTTAC
TGAGCAGGGTTACCTTAATCTTGGTGGTAGGCAGACTGCTAGGACCCTGATGTACAATTTCCCT
ACTAGAGCTGGTCAGTGCGGTGGTGTGATTACCTGCACTGGTAAGGTGATCGGTATGCACGTT
GGTGGTAATGGTTCTCACGGTTTCGCTGCTGCTCTGAAGAGGTCTTACTTCACCCAATCTAGCCA
GGGTGAGATCCAATGGATGAGGCCTTCTAAAGAGGTGGGATACCCTATCATCAACGCTCCATCT
AAGACCAAGCTTGAGCCTAGCGCTTTCCACTACGTTTTCGAGGGTGTGAAAGAGCCTGCTGTTC
TGACCAAGAACGATCCTAGGCTTAAGACCGATTTCGAAGAGGCTATCTTCTCCAAGTACGTGGG
TAACAAGATCACCGAAGTGGATGAGTACATGAAGGAAGCTGTGGATCACTACGCTGGTCAGCT
GATGTCTCTGGATATTAACACCGAGCAGATGTGCCTTGAGGATGCTATGTACGGAACCGATGGT
CTTGAGGCTCTGGATCTTTCTACCTCTGCTGGTTACCCTTATGTGGCTATGGGTAAGAAGAAGAG
GGATATCCTGAACAAGCAGACCAGGGATACCAAAGAGATGCAAAAGCTGCTGGATACCTACGG
TATCAACCTTCCTCTTGTGACCTACGTGAAGGATGAGCTGAGGTCAAAGACCAAGGTGGAACAG
GGAAAGTCTAGGCTGATCGAGGCTAGCTCTCTGAACGATTCAGTGGCTATGAGGATGGCTTTCG
GTAACCTGTACGCTGCTTTCCACAAGAACCCTGGTGTGATCACTGGTTCTGCTGTTGGTTGCGAT
CCTGATCTGTTCTGGTCTAAGATCCCTGTGCTGATGGAAGAGAAGCTGTTCGCATTCGATTACAC
CGGATACGATGCTAGCCTTAGCCCTGCTTGGTTTGAGGCACTTAAGATGGTGCTTGAGAAGATC
GGTTTCGGTGATAGAGTGGATTACATCGATTACCTGAACCACAGCCACCACCTGTACAAGAACA
AGACCTACTGCGTGAAGGGTGGTATGCCTTCTGGTTGCTCTGGAACCAGCATCTTCAACAGCAT
GATCAACAACCTGATTATCAGGACCCTGCTGCTGAAAACCTACAAGGGTATCGATCTGGATCAC
CTGAAGATGATCGCTTACGGTGATGATGTTATCGCTAGCTACCCTCACGAAGTTGATGCTTCTCT
GCTTGCTCAGAGCGGTAAGGATTACGGTCTTACTATGACCCCTGCTGATAAGAGCGCTACCTTC
GAGACTGTGACTTGGGAGAATGTGACCTTCCTGAAGAGATTTTTCAGGGCAGATGAGAAGTAC
CCTTTCCTGATCCATCCTGTGATGCCTATGAAGGAAATCCACGAGTCTATCAGGTGGACCAAGG
ATCCTAGGAATACCCAGGATCACGTGAGATCTCTGTGCCTTCTTGCTTGGCATAACGGTGAGGA
AGAGTACAACAAGTTCCTGGCTAAGATCAGATCCGTGCCTATTGGTAGGGCTCTGCTTTTGCCT
GAGTACAGCACCCTTTACAGAAGATGGCTGGATAGCTTCTAGCTCGAGCTGGGCCTCATGGGCC
TTCCGCTCACTGCCCGCTTTCCAG 
 
 
Appendix 2: Sequences 
174 
 
PV1 MahSC6b 
AGGCCGCATACCGGTAACAATGGGTGCTCAGGTGTCATCTCAGAAGGTTGGAGCACACGAGAA
CAGCAATGGTGCTTACGGTGGTAGCACCATCAACTACACCACCATTAACTACTACAGGGATAGC
GCTAGCAACGCTGCTTCCAAGCAGGATTTTAGCCAGGATCCTAGCAAGTTCACCGAGCCTATTA
AGGATGTGCTGATCAAGACCGCTCCTATGCTGAACTCTCCTAACATTGAGGCTTGCGGTTACAG
CGATAGGGTGTTGCAACTTACCCTGGGAAACTCTACCATCACCGCTCAAGAGGCTGCTAATTCT
GTTGTGGCTTATGGTAGGTGGCCTGAGTACCTTAGAGATAGCGAGGCTAATCCTGTGGATCAGC
CTACTGAACCTGAAGTTGCTGCTTGCAGGTTCTACACCCTTGATACTGTGAGCTGGACCAAAGA
AAGCAGAGGATGGTGGTGGAAGCTGCCTGATGCTTTGAGAGATATGGGACTGTTCGGTCAGAA
CATGTACTACCACTACCTGGGAAGGTCTGGTTACACTGTTCATGTGCAGTGCAACGCTTCCAAGT
TCCATCAAGGTGCTCTTGGTGTTTTCGCTGTGCCTGAGATGTGTCTGGCTGGTGATTCTAACACT
ACCACCATGCACACCAGCTACCAGAATGCTAATCCAGGTGAGAAGGGTGGAACCTTTACTGGAA
CTTTCACCCCTGATAACAACCAGACCAGTCCTGCTAGAAGGTTCTGCCCTGTGGATTACCTTCTT
GGTAACGGAACCCTTCTGGGAAACGCTTTCGTGTTCCCTCACCAGATTATCAACCTGAGGACCA
ACAACTGCGCTACCCTTGTGCTTCCTTACGTGAACAGCCTGAGCATCGATAGCATGGTGAAGCA
CAACAACTGGGGTATCGCTATTCTTCCTCTGGCTCCTCTGAACTTCGCTTCCGAATCTTCTCCAGA
GATCCCTATCACCCTGACCATTGCTCCTATGTGCTGCGAGTTCAACGGTCTGAGGAACATTACCT
TGCCTAGGCTTCAGGGTCTGCCTGTGATGAATACCCCTGGTTCTAACCAGTACCTGACCGCTGAT
AACTTCCAGTCTCCATGTGCTCTGCCTGAGTTCGATGTGACCCCTCCTATTGATATCCCTGGTGA
GGTGAAGAACATGATGGAATTGGCTGAGATTGATACCATGATCCCTTTCGATCTGAGCGCTACC
AAGAAAAACACCATGGAAATGTACAGGGTGAGGCTGAGCGATAAGCCTCATACCGATGATCCT
ATCCTGTGCCTGTCTCTGTCTCCTGCTTCTGATCCTAGGCTTTCTCACACCATGCTTGGTGAGATC
CTGAATTACTACACCCACTGGGCTGGTAGCCTGAAGTTCACTTTTATGTTCTGCGGTAGCATGAT
GGCTACCGGAAAGCTTCTTGTGTCTTACGCTCCTCCTGGTGCTGATCCTCCTAAAAAAAGAAAAG
AAGCTATGCTGGGAACCCACGTGATCTGGGATATTGGTCTGCAGTCAAGCTGCACTATGGTGGT
GCCTTGGATTTCCAATACCACCTACAGGCTGACCATCGATGATAGCTTTACCGAGGGAGGTTAC
ATCAGCGTGTTCTACCAGACTAGGATTGTGGTGCCACTTAGCACCCCTAGAGAGATGGATATTC
TGGGTTTCGTGAGCGCTTGCAACGATTTCTCTGTGAGGCTTCTTAGGGATACCACCCACATTGAG
CAGAAGGCTCTTGCTCAAGGTCTTGGTCAGATGCTTGAGAGCATGATCGATAACACCGTGAGG
GAAACTGTGGGTGCTGCTACTTCTAGAGATGCTCTGCCAAATACCGAGGCTTCTGGTCCTACTCA
CAGCAAAGAGATTCCAGCTCTTACCGCTGTTGAGACTGGTGCTACTAATCCTCTGGTGCCTTCTG
ATACTGTTCAGACTAGGCATGTTGTGCAGCACAGGTCTAGGTCCGAGTCCTCTATTGAGTCATTC
TTCGCTAGAGGAGCTTGCGTGACCATCATGACTGTGGATAACCCTGCTAGCACCACCAACAAGG
ATAAGTTGTTCGCTGTGTGGAAGATCACTTACAAGGATACCGTGCAGCTGAGAAGAAAGCTTGA
GTTCTTCACTTACAGCAGGTTCGATATGGAACTGACCTTCGTGGTGACCGCTAACTTCACCGAGA
CTAACAACGGTCACGCTCTGAATCAGGTGTACCAAATCATGTATGTGCCTCCAGGTGCTCCTGTT
CCTGAGAAGTGGGATGATTACACTTGGCAGACCAGCAGCAACCCTAGCATCTTCTATACCTACG
GTACTGCTCCAGCTAGGATCTCCGTTCCATACGTGGGAATCAGCAACGCTTACAGCCACTTCTAC
GATGGTTTCAGCAAGGTGCCACTGAAGGATCAGTCTGCTGCTCTTGGAGATTCTCTGTACGGTG
CTGCTTCCCTGAACGATTTCGGTATTTTGGCTGTGAGGGTGGTGAACGATCCTAACCCTACTAAG
GTGACCAGCAAGATCAGGGTGTACCTGAAGCCAAAGCACATTAGGGTTTGGTGCCCTAGACCTC
CTAGGGCTGTTGCTTATTATGGTCCTGGTGTGGATTATAAGGATGGAACCCTTACCCCTCTGAGC
ACCAAGGATCTTACTACCTACTAGCTCGAGCTGGGCCTC 
 
 
 
 
Appendix 2: Sequences 
175 
 
PV1 M3delta: 
TCAAGGCCGCATACCGGTAACAATGGGTGCTCAGGTGTCATCTCAGAAGGTTGGAGCACACGA
GAACAGCAATAGGGCTTACGGTGGTAGCACCATCAACTACACCACCATTAACTACTACAGGGAT
AGCGCTAGCAACGCTGCTTCCAAGCAAGATTTTGCTCAGGATCCTTCCAAGTTCACCGAGCCTGT
TAAGGATGTGCTGATCAAGACTGCTCCTACCCTGAACTCTCCTAACATTGAGGCTTGCGGTTACA
GCGATAGGGTGATGCAACTTACCCTGGGAAACTCTACCATCACCACTCAAGAGGCTGCTAACTC
TGTGGTTGCTTATGGTAGGTGGCCTGAGTACATCAAGGATAGCGAGGCTAATCCTGTGGATCA
GCCTACTGAACCTGCTGTTGCTGCTTGCAGGTTCTACACTCTTGATACCGTGACTTGGAGGAAAG
AATCCAGAGGATGGTGGTGGAAGCTGCCTGATGCTCTTAAGGATATGGGACTGTTCGGTCAGA
ATATGTTCTACCACTACCTGGGTAGGGCTGGTTACACTGTTCATGTGCAGTGCAACGCTAGCAA
GTTCCATCAAGGTGCTCTTGGTGTTTTCGCTGTGCCTGAGATGTGTCTGGCTGGTGATTCTACTA
CCCACATGTTCACCAAGTACGAGAACGCTAACCCTGGTGAAAAGGGTGGTGAGTTCAAGGGAT
CTTTCACCCTGGATACCAACGCTACTAACCCTGCTAGGAATTTCTGCCCTGTGGATTACCTGTTCG
GTTCTGGTGTGCTTGCTGGTAACGCTTTCGTTTACCCTCACCAGATCATCAACCTGAGGACCAAC
AATTGCGCTACCCTTGTGCTTCCTTACGTGAACAGCCTGAGCATCGATAGCATGACCAAGCACAA
CAACTGGGGTATCGCTATTCTTCCTCTGGCTCCACTTGATTTCGCTACCGAGTCATCTACCGAGAT
CCCTATCACCCTTACCATTGCTCCTATGTGCTGCGAGTTCAACGGTCTGAGGAATATTACTGTGC
CTAGGACCCAGGGTCTGCCTGTGCTTAATACTCCTGGTTCTAACCAGTACCTGACCGCTGATAAC
TACCAGTCTCCTTGCGCTATTCCTGAGTTCGATGTGACCCCTCCTATCGATATTCCTGGTGAGGT
GAGGAACATGATGGAATTGGCTGAGATTGATACCATGATCCCTCTGAACCTGACCAACCAGAGA
AAGAACACCATGGATATGTACAGGGTTGAGCTGAACGATGCTGCTCACTCTGATACCCCTATTCT
GTGCCTTAGCCTGAGCCCTGCTTCTGATCCTAGACTTGCTCATACCATGCTGGGTGAGATCCTGA
ATTACTACACTCACTGGGCTGGTAGCCTGAAGTTCACCTTTCTTTTCTGCGGTTCCATGATGGCTA
CCGGAAAGCTTCTTGTGTCTTACGCTCCTCCTGGTGCTGAAGCTCCTAAGTCTAGAAAAGAAGCT
ATGCTGGGAACCCACGTGATCTGGGATATTGGTCTGCAGTCAAGCTGCACTATGGTGGTGCCTT
GGATTAGCAATACCACCTACAGGCTGACCATCAACGATAGCTTTACCGAGGGAGGTTACATCAG
CATGTTTTACCAGACTAGGGTTGTGGTGCCTCTGTCTACTCCTAGGAAGATGGATATCCTGGGTT
TCGTGAGCGCTTGCAACGATTTCTCTGTGAGGCTTCTTAGGGATACCACCCACATCTCACAAGAG
GCTATGCCTCAAGGTCTGGGTGATCTTATTGAGGGTGTTGTGGAAGGTGTGACTAGGAACGCTC
TTACTCCTCTTACCCCTGCTAACAACCTGCCTGATACTCAGTCATCTGGTCCAGCTCACAGCAAAG
AGACTCCAGCTCTTACTGCTGTTGAGACTGGTGCTACAAACCCTCTGGTGCCTTCTGATACTGTG
CAGACCAGGCATGTGATTCAGAAGAGGACTAGGTCTGAGAGCACCGTTGAGTCATTCTTCGCTA
GAGGAGCTTGCGTGGCAATCATCGAAGTGGATAACGATGCACCTACCAAGAGGGCTAGCAAGC
TGTTCTCTATCTGGAAGATCACCTACAAGGATACCGTGCAGCTGAGAAGAAAGCTTGAGTTCTT
CACCTACTCCAGGTTCGATATGGAACTGACCTTCGTGGTGACCTCTAACTACACCGATGCAAACA
ACGGTCACGCTCTGAATCAGGTGTACCAGATTATGTACATCCCTCCAGGTGCTCCAATCCCTGGT
AAGTGGAATGATTACACCTGGCAGACCAGCAGCAACCCTTCTCTGTTCTATACTTACGGTGCTCC
TCCAGCTAGGATCTCTGTTCCTTATGTGGGAATCGCTAACGCTTACAGCCACTTCTACGATGGTT
TCGCTAAGGTGCCACTTGCTGGTCAGGCTTCTACTGAAGGTGATAGCCTTTACGGTGCAGCTAG
CCTGAACGATTTCGGTTCTCTTGCTGTTAGAGTGGTGAACGATCATAACCCTACCAAGCTGACCT
CCAAGATCAGGGTGTACATGAAGCCTAAGCACGTGAGAGTTTGGTGCCCTAGACCTCCTAGAGC
TGTGCCATATTATGGTCCTGGTGTTGATTACAAGGATGGTCTGGCTCCTTTGCCTGAGAAGGGT
CTTACTACCTACTAGCTCGAGCTGGGCCTCATGGGCCTTCCGCTCACTGCCCGCTTTCCAG 
 
 
 
 
Appendix 2: Sequences 
176 
 
PV1 M2delta: 
CGCGGTACCACCGGTAACAATGGGTGCTCAGGTGTCATCTCAAAAAGTTGGTGCTCACGAGAAC
AGCAACAGGGCTTATGGTGGTAGCACCATCAACTACACCACCATTAACTACTACAGGGATAGCG
CTAGCAACGCTGCTTCTAAGCAGGATCTTAGCCAGGATCCTAGCAAGTTCACCGAGCCTATTAA
GGATGTGCTGATCAAGACCGCTCCTATGCTGAACTCTCCTAACATTGAGGCTTGCGGTTACAGC
GATAGGGTGTTGCAACTTACCCTGGGAAACTCTACCATCACCACTCAAGAGGCTGCTAACTCTGT
TGTGGCTTACGGTAGATGGCCTGAGTACCTTAGAGATAGCGAGGCTAATCCTGTGGATCAGCCT
ACTGAACCTGATGTTGCTGCTTGCAGGTTCTACACCCTTGATACTGTGAGCTGGACCAAAGAAA
GCAGAGGATGGTGGTGGAAGCTGCCTGATGCTTTGAGAGATATGGGACTGTTCGGTCAGAACA
TGTACTACCACTACCTGGGAAGGTCTGGTTACACTGTTCATGTGCAGTGCAACGCTTCCAAGTTC
CATCAAGGTGCTCTTGGTGTTTTCGCTGTGCCTGAGATGTGTCTGGCTGGTGATTCTAACACTAC
TACCATGCACACCAGCTACCAGAACGCTAATCCAGGTGAAAAGGGTGGAACCTTTACCGGAACT
TTCACCCCTGATAACAACCAGACCAGTCCTGCTAGAAGGTTCTGCCCTGTGGATTACCTTCTTGG
TAACGGAACCCTTCTGGGAAACGCTTTCGTGTTCCCTCACCAGATTATCAACCTGAGGACCAACA
ACTGCGCTACCCTTGTGCTTCCTTACGTGAACAGCCTGAGCATCGATAGCATGGTGAAGCACAA
CAACTGGGGTATCGCTATTCTTCCTCTGGCTCCTCTGAACTTCGCTTCCGAATCTTCTCCAGAGAT
CCCTATCACCCTGACCATTGCTCCTATGTGCTGCGAGTTCAACGGTCTGAGGAACATTACCTTGC
CTAGGCTTCAGGGTCTGCCTGTGATGAATACCCCTGGTTCTAACCAGTACCTGACCGCTGATAAC
TTCCAGTCTCCATGTGCTCTGCCTGAGTTCGATGTGACCCCTCCTATTGATATTCCAGGTGAGGT
GAAGAACATGATGGAATTGGCTGAGATTGATACCATGATCCCTTTCGATCTGAGCGCTACCAAG
AAAAACACCATGGAAATGTACAGGGTGAGGCTGAGCGATAAGCCTCATACCGATGATCCTATCC
TGTGCCTGTCTCTGTCTCCTGCTTCTGATCCTAGGCTTTCTCACACCATGCTTGGTGAGATCCTGA
ATTACTACACCCACTGGGCTGGTAGCCTGAAGTTCACTTTTCTGTTCTGCGGTAGCATGATGGCT
ACCGGAAAGCTTCTTGTGTCTTACGCTCCTCCTGGTGCTGATCCTCCTAAAAAAAGAAAAGAAGC
TATGCTGGGAACCCACGTGATCTGGGATATTGGTCTGCAGTCAAGCTGCACTATGGTGGTGCCT
TGGATTAGCAATACCACCTATAGGCAGACCATCGATGATAGCTTCACCGAGGGAGGTTACATCA
GCGTGTTCTACCAGACTAGGATTGTGGTGCCACTTAGCACCCCTAGAGAGATGGATATTCTGGG
TTTCGTGAGCGCTTGCAACGATTTCTCTGTGAGGCTTCTTAGGGATACCACCCACATTGAGCAGA
AGGCTCTTGCTCAAGGTCTTGGTCAGATGCTTGAGAGCATGATCGATAACACCGTGAGGGAAAC
TGTGGGTGCTGCTACTTCAAGGGATACCCTTCCTAATACCGAGGCTTCTGGTCCTACCCACTCTA
AAGAGATTCCAGCTCTTACCGCTGTTGAGACTGGTGCTACTAATCCTCTGGTGCCTTCTGATACT
GTTCAGACTAGGCATGTTGTGCAGCACAGGTCTAGGTCCGAGTCCTCTATTGAGTCATTCTTCGC
TAGAGGAGCTTGCGCTACCATCATGACTGTGGATAACCCTGCTAGCACCACCAACAAGGATAAG
TTGTTCGCTGTGTGGAAGATCACTTACAAGGATACCGTGCAGCTGAGAAGAAAGCTTGAGTTCT
TCACTTACAGCAGGTTCGATATGGAACTGACCTTCGTGGTGACCGCTAATTTCACCGAGACTAAC
AACGGTCACGCTCTGAATCAGGTGTACCAAATCATGTATGTGCCTCCAGGTGCTCCTGTTCCTGA
GAAGTGGGATGATTACACTTGGCAGACCAGCAGCAACCCTAGCATCTTCTATACCTACGGTACT
GCTCCAGCTAGGATCTCCGTTCCATACGTGGGAATCAGCAACGCTTACAGCCACTTCTACGATG
GTTTCAGCAAGGTGCCACTGAAGGATCAGTCTGCTGCTCTTGGAGATTCTCTGTACGGTGCTGC
TTCCCTGAACGATTTCGGTATTCTTGCTGTGAGGGTGGTGAACGATCACAACCCTACTAAGGTG
ACCAGCAAGATCAGGGTGTACCTGAAGCCAAAGCACATTAGGGTTTGGTGCCCTAGACCTCCTA
GGGCTGTTGCTTATTATGGTCCTGGTGTGGATTATAAGGATGGAACCCTGACCCCTCTGTCCACC
AAGGATCTTACTACTTACTAGCTCGAGGAGCTCG 
 
 
 
 
Appendix 2: Sequences 
177 
 
PV1 M3delta: 
ACCGGTAACAATGGGTGCTCAGGTGTCATCTCAAAAAGTTGGTGCTCACGAGAACAGCAACAG
GGCTTATGGTGGTGCACCATCAACTACACCACCATTAACTACTACAGCGATAGCGCTAGCAACG
CTGCTTCCAAGCAGGTTTTTAGCCAGGATCCTAGCAAGTTCACCGAGCCTATTAAGGATGTGCTG
ATCAAGACCGCTCCTATGCTGAACTCTCCTAACATTGAGGCTTGCGGTTACAGCGATAGGGTGTT
GCAACTTACCCTGGGAAACTCTACCATCACCACTCAAGAGGCTGCTAACTCTGTTGTGGCTTACG
GTAGATGGCCTGAGTACCTTAGAGATAGCGAGGCTAATCCTGTGGATCAGCCTACTGAACCTGA
TGTTGCTGCTTGCAGGTTCTACACCCTTGATACTGTGAGCTGGACCAAAGAAAGCAGAGGATGG
TGGTGGAAGCTGCCTGATGCTTTGAGAGATATGGGACTGTTCGGTCAGAACATGTACTACCACT
ACCTGGGAAGGTCTGGTTACACTGTTCATGTGCAGTGCAACGCTTCCAAGTTCCATCAAGGTGC
TCTTGGTGTTTTCGCTGTGCCTGAGATGTGTCTGGCTGGTGATTCTAACACTACTACCATGCACA
CCAGCTACCAGAACGCTAATCCAGGTGAAAAGGGTGGAACCTTTACCGGAACTTTCACCCCTGA
TAACAACCAGACCAGTCCTGCTAGAAGGTTCTGCCCTGTGGATTACCTTCTTGGTAACGGAACCC
TTCTGGGAAACGCTTTCGTGTTCCCTCACCAGATTATCAACCTGAGGACCAACAACTGCGCTACC
CTTGTGCTTCCTTACGTGAACAGCCTGAGCATCGATAGCATGGTGAAGCACAACAACTGGGGTA
TCGCTATTCTTCCTCTGGCTCCTCTGAACTTCGCTTCCGAATCTTCTCCAGAGATCCCTATCACCCT
GACCATTGCTCCTATGTGCTGCGAGTTCAACGGTCTGAGGAACATTACCTTGCCTAGGCTTCAG
GGTCTGCCTGTGATGAATACCCCTGGTTCTAACCAGTACCTGACCGCTGATAACTTCCAGTCTCC
ATGTGCTCTGCCTGAGTTCGATGTGACCCCTCCTATTGATATTCCAGGTGAGGTGAAGAACATG
ATGGAATTGGCTGAGATTGATACCATGATCCCTTTCGATCTGAGCGCTACCAAGAAAAACACCA
TGGAAATGTACAGGGTGAGGCTGAGCGATAAGCCTCATACCGATGATCCTATCCTGTGCCTGTC
TCTGTCTCCTGCTTCTGATCCTAGGCTTTCTCACACCATGCTTGGTGAGATCCTGAATTACTACAC
CCACTGGGCTGGTAGCCTGAAGTTCACTTTTCTGTTCTGCGGTAGCATGATGGCTACCGGAAAG
CTTCTTGTGTCTTACGCTCCTCCTGGTGCTGATCCTCCTAAAAAAAGAAAAGAAGCTATGCTGGG
AACCCACGTGATCTGGGATATTGGTCTGCAGTCAAGCTGCACTATGGTGGTGCCTTGGATTAGC
AATACCGCTTATAGGCAGACCATCGATGATAGCTTCACCGAGGGAGGTTACATCAGCGTGTTCT
ACCAGACTAGGATTGTGGTGCCACTTAGCACCCCTAGAGAGATGGATATTCTGGGTTTCGTGAG
CGCTTGCAACGATTTCTCTGTGAGGCTTCTTAGGGATACCACCCACATTGAGCAGAAGGCTCTTG
CTCAAGGTCTTGGTCAGATGCTTGAGAGCATGATCGATAACACCGTGAGGGAAACTGTGGGTG
CTGCTACTTCTAGAGATGCTCTGCCAAATACCGAGGCTTCTGGTCCTACTCACAGCAAAGAGATT
CCAGCTCTTACCGCTGTTGAGACTGGTGCTACTAATCCTCTGGTGCCTTCTGATACTGTTCAGACT
AGGCATGTTGTGCAGCACAGGTCTAGGTCCGAGTCCTCTATTGAGTCATTCTTCGCTAGAGGAG
CTTGCGCTACCATCATGACTGTGGATAACCCTGCTCCAACCACCAACAAGGATAAGTTGTTCGCT
GTGTGGAAGATCACTTACAAGGATACCGTGCAGCTGAGAAGAAAGCTTGAGTTCTTCACTTACA
GCAGGTTCGATATGGAACTGACCTTCGTGGTGACCGCTAATTTCACCGAGACTAACAACGGTCA
CGCTCTGAATCAGGTGTACCAAATCATGTATGTGCCTCCAGGTGCTCCTGTTCCTGAGAAGTGG
GATGATTACACTTGGCAGACCAGCAGCAACCCTAGCATCTTCTATACCTACGGTACTGCTCCAGC
TAGGATCTCCGTTCCATACGTGGGAATCAGCAACGCTTACAGCCACTTCTACGATGGTTTCAGCA
AGGTGCCACTGAAGGATCAGTCTGCTGCTCTTGGAGATTCTCTGTACGGTGCTGCTTCCCTGAAC
GATTTCGGTATTTTGGCTGTGAGGGTGGTGAACGATCACAACCCTACTAAGGTGACCAGCAAGA
TCAGGGTGTACCTGAAGCCAAAGCACATTAGGGTTTGGTGCCCTAGACCTCCTAGGGCTGTTGC
TTATTATGGTCCTGGTGTGGATTATAAGGATGGAACCCTGACCCCTCTGTCCACCAAGGATCTTA
CTACCTACTAGCTCGAG 
 
 
 
 
Appendix 2: Sequences 
178 
 
PV2 MEFSC6b: 
AAGGCCGCATACCGGTAACAATGGGTGCTCAGGTGTCATCTCAGAAGGTTGGAGCACACGAGA
ACAGCAATAGGGCTTACGGTGGTAGCACCATCAACTACACCACCATTAACTACTACAGGGATAG
CGCTAGCAACGCTGCTTCCAAGCAAGATTTTGCTCAGGATCCTTCCAAGTTCACCGAGCCTGTTA
AGGATGTGCTGATCAAGACTGCTCCTACCCTGAACTCTCCTAACATTGAGGCTTGCGGTTACAGC
GATAGGGTGATGCAACTTACCCTGGGAAACTCTACCATCACCACTCAAGAGGCTGCTAACTCTG
TGGTTGCTTATGGTAGGTGGCCTGAGTACATCAAGGATAGCGAGGCTAATCCTGTGGATCAGCC
TACTGAACCTGCTGTTGCTGCTTGCAGGTTCTACACTCTTGATACCGTGACTTGGAGGAAAGAAT
CCAGAGGATGGTGGTGGAAGCTGCCTGATGCTCTTAAGGATATGGGACTGTTCGGTCAGAATA
TGTTCTACCACTACCTGGGTAGGGCTGGTTACACTGTTCATGTGCAGTGCAACGCTAGCAAGTTC
CATCAAGGTGCTCTTGGTGTTTTCGCTGTGCCTGAGATGTGTCTGGCTGGTGATTCTACTACCCA
CATGTTCACCAAGTACGAGAACGCTAACCCTGGTGAAAAGGGTGGTGAGTTCAAGGGATCTTTC
ACCCTGGATACCAACGCTACTAACCCTGCTAGGAATTTCTGCCCTGTGGATTACCTGTTCGGTTC
TGGTGTGCTTGCTGGTAACGCTTTCGTTTACCCTCACCAGATCATCAACCTGAGGACCAACAATT
GCGCTACCCTTGTGCTTCCTTACGTGAACAGCCTGAGCATCGATAGCATGACCAAGCACAACAA
CTGGGGTATCGCTATTCTTCCTCTGGCTCCACTTGATTTCGCTACCGAGTCATCTACCGAGATCCC
TATCACCCTTACCATTGCTCCTATGTGCTGCGAGTTCAACGGTCTGAGGAATATTACTGTGCCTA
GGACCCAGGGTCTGCCTGTGCTTAATACTCCTGGTTCTAACCAGTACCTGACCGCTGATAACTAC
CAGTCTCCTTGCGCTATTCCTGAGTTCGATGTGACCCCTCCTATCGATATTCCTGGTGAGGTGAG
GAACATGATGGAATTGGCTGAGATTGATACCATGATCCCTCTGAACCTGACCAACCAGAGAAAG
AACACCATGGATATGTACAGGGTTGAGCTGAACGATGCTGCTCACTCTGATACCCCTATTCTGTG
CCTTAGCCTGAGCCCTGCTTCTGATCCTAGACTTGCTCATACCATGCTGGGTGAGATCCTGAATT
ACTACACTCACTGGGCTGGTAGCCTGAAGTTCACCTTTCTTTTCTGCGGTTCCATGATGGCTACC
GGAAAGCTTCTTGTGTCTTACGCTCCTCCTGGTGCTGAAGCTCCTAAGTCTAGAAAAGAAGCTAT
GCTGGGAACCCACGTGATCTGGGATATTGGTCTGCAGTCAAGCTGCACTATGGTGGTGCCTTGG
ATTAGCAATACCACCTACAGGCTGACCATCAACGATAGCTTTACCGAGGGAGGTTACATCAGCA
TGTTTTACCAGACTAGGGTTGTGGTGCCTCTGTCTACTCCTAGGAAGATGGATATCCTGGGTTTC
GTGAGCGCTTGCAACGATTTCTCTGTGAGGCTTCTTAGGGATACCACCCACATCTCACAAGAGG
CTATGCCTCAAGGTCTGGGTGATCTTATTGAGGGTGTTGTGGAAGGTGTGACTAGGAACGCTCT
TACTCCTCTTACCCCTGCTAACAACCTGCCTGATACTCAGTCATCTGGTCCAGCTCACAGCAAAG
AGACTCCAGCTCTTACTGCTGTTGAGACTGGTGCTACAAACCCTCTGGTGCCTTCTGATACTGTG
CAGACCAGGCATGTGATTCAGAAGAGGACTAGGTCTGAGAGCACCGTTGAGTCATTCTTCGCTA
GAGGAGCTTGCGTGGCAATCATCGAAGTGGATAACGATGCACCTACCAAGAGGGCTAGCAAGC
TGTTCTCTATCTGGAAGATCACCTACAAGGATACCGTGCAGCTGAGAAGAAAGCTTGAGTTCTT
CACCTACTCCAGGTTCGATATGGAACTGACCTTCGTGGTGACCTCTAACTACACCGATGCAAACA
ACGGTCACGCTCTGAATCAGGTGTACCAGATTATGTACATCCCTCCAGGTGCTCCAATCCCTGGT
AAGTGGAATGATTACACCTGGCAGACCAGCAGCAACCCTTCTCTGTTCTATACTTACGGTGCTCC
TCCAGCTAGGATCTCTGTTCCTTATGTGGGAATCGCTAACGCTTACAGCCACTTCTACGATGGTT
TCGCTAAGGTGCCACTTGCTGGTCAGGCTTCTACTGAAGGTGATAGCCTTTACGGTGCAGCTAG
CCTGAACGATTTCGGTTCTCTTGCTGTTAGAGTGGTGAACGATCATAACCCTACCAAGCTGACCT
CCAAGATCAGGGTGTACATGAAGCCTAAGCACGTGAGAGTTTGGTGCCCTAGACCTCCTAGAGC
TGTGCCATATTATGGTCCTGGTGTTGATTACAAGGATGGTCTGGCTCCTTTGCCTGAGAAGGGT
CTTACTACCTACTAGCTCGAGCTGGGC 
 
 
 
 
Appendix 2: Sequences 
179 
 
PV3 SktSC8: 
TCAAGGCCGCATACCGGTAACAATGGGTGCTCAGGTGTCATCTCAGAAGGTTGGAGCACACGA
GAACAGCAATAGGGCTTACGGTGGTAGCACCATCAACTACACCACCATTAACTACTACAAGGAT
AGCGCTAGCAACGCTGCTTCCAAGCAGGATTATAGCCAGGATCCTAGCAAGTTCACCGAGCCTC
TTAAGGATGTGCTGATCAAGACTGCTCCTGCTCTGAACTCTCCTAACGTTGAGGCTTGCGGTTAC
TCTGATAGGGTGCTGCAGCTTACCATCGGTAACTCTACCATTACCACCCAAGAGGCTGCTAACTC
TGTGGTTGCTTATGGTAGGTGGCCTGAGTTCATCAGGGATGATGAGGCTAATCCTGTGGATCAG
CCTACTGAGCCTGATGTTGCTACTTGCAGGTTCTACACCCTGGATACTGTGATGTGGGGTAAAG
AAAGCAAGGGATGGTGGTGGAAGCTGCCTGATGCTCTTAGAGATATGGGACTGTTCGGTCAGA
ACATGTACTACCACTACCTGGGAAGGTCTGGTTACACTGTTCATGTGCAGTGCAACGCTTCCAAG
TTCCATCAAGGTGCTCTTGGTGTGTTCGCTATCCCTGAGTATTGCCTGGCTGGTGATTCTGATAA
GCAGAGGTACACCAGCTACGCTAACGCTAATCCAGGTGAGAAGGGTGGTAAGTTCTACAGCCA
GTTCAATAGGGATACCGCTGTGACCTCTCCTAAGAGAGAGTTCTGCCCTGTTGATTACCTTCTGG
GTTGCGGTGTGCTTCTGGGTAATGCTTTTGTGTACCCTCACCAGATCATCAACCTGAGGACCAAC
AACAGCGCTACCATCGTGTTGCCTTACGTGAACGCTATGGCTATCGATTCCATGGTGAAGCACA
ACAACTGGGGTATCGCTATCCTGCCTCTGTCTCCTCTTGATTTCGCTCAAGAGTCCAGCGTTGAG
ATCCCTATCACTGTGACCATTGCTCCTATGTGCAGCGAGTTCAACGGTCTTAGGAATGTGACCGC
TCCAAAGTTCCAGGGTTTGCCTGTGCTTAATACCCCTGGTTCTAACCAGTACCTGACCAGCGATA
ACTACCAGTCTCCTTGCGCTATTCCAGAGTTCGATGTGACTCCTCCTATCGATATTCCTGGTGAG
GTGAAGAACATGATGGAATTGGCTGAGATCGATACCATGATCCCTCTGAACCTTGAGAATACCA
AGAGGAACACCATGGATATGTACAGGGTGACCCTGAGCGATAGCGCTGATCTTTCTCAGCCTAT
CCTGTGCTTCAGCCTGTCTCCTGCTTCTGATCCTAGGCTTTCTCACACCATGCTTGGAGAGGTGCT
GAATTACTACACTCACTGGGCTGGTAGCCTGAAGTTCACCTTTCTTTTCTGCGGTTCCATGATGG
CTACCGGAAAGATTCTTGTGGCTTACGCTCCTCCTGGTGCTCAACCTCCTACCTCTAGAAAAGAA
GCTATGCTGGGAACCCACGTGATCTGGGATCTTGGACTTCAGTCAAGCTGCACTATGGTGGTGC
CTTGGATTAGCAACGTTACCTACAGGCAGACCACCCAGGATTCTTTTACTGAGGGAGGTTACAT
CAGCATGTTCTACCAGACCAGGATTGTGGTGCCACTGTCTACCCCTAAGTCCATGTCTATGCTTG
GTTTCGTGAGCGCTTGCAACGATTTCTCTGTGAGGCTTTTGAGGGATACCACCCATATCAGCCAG
TCTGCTTTGCCTCAGGGTATCGAGGATCTTATTACCGAGGTTGCACAGGGTGCTCTTACCCTGTC
TTTGCCTAAGCAGCAGGATTCTCTGCCTGATACCAAGGCTTCTGGTCCTGCTCACTCTAAAGAGG
TGCCAGCTCTTACTGCTGTTGAGACTGGTGCTACTAACCCTCTGGTGCCTTCTGATACTGTGCAG
ACCAGGCATGTGATCCAGAGAAGATCTAGGTCCGAGAGCACCATCGAGTCATTCTTCGCTAGAG
GAGCTTGCGTGGCAATCATCGAAGTGGATAATGAGGAACCTACCACCAGGGCTCAAAAGCTGT
TTGCTATGTGGAGGATCACCTATAAGGATACCGTGCAGCTGAGAAGAAAGCTGGAATTCTTCAC
TTACAGCAGGTTCGATATGGAACTGACCTTCGTGGTGACCGCTAACTTCACCAATACCAACAAC
GGTCACGCTCTGAACCAGGTGTACCAGATTATGTACATCCCTCCAGGTGCTCCTACCCCAAAGTC
TTGGGATGATTACACTTGGCAGACCAGCAGCAACCCTAGCATCTTCTATACTTACGGTGCTGCTC
CAGCTAGGATCTCTGTTCCTTATGTGGGTCTGGCTAACGCTTACAGCCACTTCTACGATGGTTTC
GCTAAGGTGCCACTTAAGACCGATGCTAACGATCAGATCGGTGATAGCCTGTACTCTGCTATGA
CCGTGGATGATTTCGGTGTGCTGGCTATTAGGGTGGTGAACGATCATAACCCTACCAAGGTGAC
CAGCAAGGTGAGGATCTACATGAAGCCTAAGCACGTTAGGGTTTGGTGCCCTAGACCTCCTAGA
GCTGTTCCATATTACGGTCCTGGTGTGGATTACAAAGATAACCTGAACCCTCTGAGCGAGAAGG
GTCTTACTACCTACTAGCTCGAGCT 
Appendix 3: Publications 
180 
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